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ABSTRACT 
Xin Long 
 
ROLE OF ADENOSINE A1 RECEPTORS IN NATIVE CORONARY 
ATHEROSCLEROSIS, IN-STENT STENOSIS, AND CORONARY BLOOD 
FLOW REGULATION IN METABOLIC SYNDROME AND EXERCISE 
 
 Adenosine is widely thought to elicit coronary vasodilation and attenuate 
smooth muscle cell (SMC) proliferation, thereby providing cardioprotection. We 
cloned the porcine adenosine A1 receptor (A1R) subtype and found that it 
paradoxically stimulated proliferation of cultured coronary SMC by the 
extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) signaling 
pathways, thus suggesting A1R dysregulation could play a role in coronary artery 
disease (CAD), restenosis, and regulation of coronary blood flow (CBF). We 
utilized the Ossabaw swine model of metabolic syndrome (MetS) to test the 
hypothesis that A1R activation contributes to development of CAD, in-stent 
stenosis, and CBF regulation. Swine were fed standard chow (Lean) or excess 
calorie atherogenic diet for over 20 weeks, which elicited MetS characteristics 
and coronary atherosclerosis compared to Lean. We observed increased A1R in 
native CAD in MetS, which was reversed by exercise training, and upregulation 
of A1R expression and A1R-ERK1/2 activation in an in vitro organ culture model 
of CAD. Intracoronary stent deployment followed by different durations of 
recovery showed A1R upregulation occurred before maximal in-stent stenosis in 
 vi  
vivo. More importantly, selective A1R antagonism with 8-cyclopentyl-1, 3-
dipropylxanthine (DPCPX)-eluting stents decreased coronary ERK1/2 activation 
and reduced in-stent stenosis comparable to Taxus® (paclitaxel-eluting stents). 
A1R antagonism potentiated vasodilatory effects of some vasodilators other than 
adenosine in porcine coronary microcirculation under basal conditions. Short-
term exercise training around stenting prevented stent-induced microvascular 
dysfunction and attenuated native atheroma in the genetically lean Yucatan 
swine. Conclusions: A1R upregulation and activation contributes to coronary in-
stent stenosis in vivo in MetS, plays a role in the development of coronary 
atherosclerosis in vitro, and might involve in CBF dysregulation in dyslipidemia 
and stenting. Exercise training decreased A1R expression in atherosclerosis, 
reduced native atheroma, and prevented stent-induced microvascular 
dysfunction. Selective pharmacological antagonism of A1R holds promise for 
treatment of CAD. 
 
 Michael S. Sturek, PhD, Chair 
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CHAPTER 1. INTRODUCTION 
 
1.1. 
The left main, circumflex, left anterior descending, and right coronary 
arteries are the main epicardial coronary arteries branching from aortic ostium 
(Figure 1.1A). The coronary vascular wall is divided by internal and external 
elastic laminae into three different layers: intima, media, and adventitia (Figure 
1.1B). The intima is lumenal to the internal elastic lamina and includes the inner 
cellular lining of the vascular wall, i.e. endothelium. Media is bounded by internal 
and external elastic lamina and mainly composed of smooth muscle cells (SMCs) 
often separated by collagen and elastin fibers in the large epicardial conduit 
arteries. Outside of the external elastic lamina is adventitia, comprised of 
connective tissue matrix, which is largely elastic fiber proteins, proteoglycans, 
and collagen, which is synthesized and deposited by SMCs 1. 
Coronary anatomy and coronary artery disease 
 
Microvascular and macrovascular disorders are the two main categories of 
coronary artery disease (CAD) in our research focus. 
 
Microvessels are usually defined as small vessels with diameter less than 
100 µm 2. Microvascular dysfunction is mediated by endothelium dependent or 
independent mechanisms. Endothelium-dependent dysfunction is primarily 
attributable to an increase in endothelin-1 (ET-1) 3, a reduction in nitric oxide (NO) 
 2 
synthase 4 or responsiveness to NO 5, or a mixture of these factors. Endothelium-
independent dysfunction includes impairment of smooth muscle relaxation 6.  
 
Bradykinin (BK), a vasoactive peptide, is an endothelium-dependent 
vasodilator. BK interacts with BK type 2 receptors on the endothelial cell surface, 
increasing NO generation via endothelial NO synthase (eNOS) activation, thus 
mediating vasodilation 7. The endothelium-independent coronary vasodilators 
include dipyridamole, papaverine, and adenosine (see section 1.5) 6. In porcine 
coronary circulation and human forearm circulation, adenosine-induced 
vasodilation was mainly in NO-independent manner 8. 
 
Atherosclerosis, a disease of the conduit arteries, is responsible for about 
50% of all mortalities 1, 9. Atherosclerotic lesions are initiated from fatty streaks 
and progress to intermediate lesions and eventually to fibrous plaques 1, 9. Fatty 
streaks are mainly composed of subendothelial lipid-scavenging macrophages 
(foam cells) with minimal SMC infiltration. Intermediate lesions are composed 
primarily of SMCs and macrophages, while fibrous plaques are comprised of 
SMCs in dominance, macrophages, and T lymphocytes 1. Fibrous plaques 
usually have a fibrous cap of collagen and elastin and often enclose a lipid-rich 
necrotic core 9. A thin fibrous cap is one of the defining features of unstable 
plaque. Figure 1.2 and Figure 1.3 show many of these features. Figure 1.2 
shows Masson’s trichrome stain for collagen used to assess changes in 
atherosclerosis 10, 11. Comparison between healthy, early stage, and advanced 
 3 
stage atherosclerotic artery segment reveals that collagen deposition and foam 
cell infiltration increases as lesion progresses, lumen size decreases 
consequently. Stary classified atherosclerosis into eight different stages 12. All 
Stary stages of atherosclerosis are displayed in the Ossabaw miniature swine 
model of MetS and CAD 13. Figure 1.3A shows Picrosirius red staining as another 
index of collagen and elastin. This atherosclerotic lesion shows a thin fibrous cap 
and lipid core characteristic of unstable or vulnerable plaque 1, 14. Intense 
Verhoeff-van Gieson staining (Figure 1.3B) shows extensive elastin beyond the 
typical single layer internal elastic lamina and many layers deep into the media 
layer interspersed between SMC. This is further reinforced by immunostaining for 
smooth muscle a actin (Figure 1.3D). The inflamed feature of the lesion is shown 
by extensive scavenger receptor immunostaining (Figure 1.3C), which is a 
marker for macrophages.  
 
Atherosclerosis develops over decades in humans, having its origin in 
childhood during which the process is typically entirely benign without any 
symptoms 9, 15. When the conduit coronary diameter stenosis reaches >50% 
(usually ~70-80%), angina pectoris can arise due to insufficient coronary oxygen 
supply, especially with increased oxygen demands like exercise or emotional 
stress 9. Even worse, myocardial infarction could happen in case of an acute 
coronary artery occlusion due to thrombus formation from rupture of vulnerable 
plaque 9. 
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1.2. 
A number of medicines can be used to help relieve angina pectoris, like 
nitroglycerin, beta-blockers, and calcium channel blockers 16. However, blood 
flow-limiting atherosclerotic lesions cannot be treated effectively by 
pharmacological agents alone. First line therapy for flow-limiting coronary 
atherosclerotic lesions includes angioplasty and stent placement 17, as shown in 
Figure 1.4. 
Treatments for coronary artery disease and restenosis – exercise, drugs, 
angioplasty and stents 
 
The benefits of exercise training exist in patients with coronary 
atherosclerosis 18-23 as well as the population undergoing percutaneous coronary 
revascularization 22, 24-26. It was shown that long-term exercise training of pigs 
attenuated conduit artery neointimal proliferation after balloon angioplasty 27; 
however, microvascular effects were not determined. Further, the effects of 
plasma cholesterol and exercise on in-stent stenosis, conduit atherosclerosis, 
and microvascular dysfunction after coronary stenting have not been studied. 
Those facts led to the first hypotheis in this thesis that short-term exercise 
training prevents micro- and macrovascular disease in porcine model of 
hypercholesterolemia and coronary artery disease. 
 
1.3. 
Atherosclerosis is increased 2-4-fold in metabolic syndrome (MetS) 28-33, 
which complicates treatment for coronary atherosclerosis. Metabolic syndrome 
Metabolic syndrome 
 5 
(MetS) is a cluster of metabolic disturbances, and is defined by National 
Cholesterol Education Program (NCEP) Adult Treatment Panel-III as the 
concurrence of any three of the following abnormalities: central obesity, 
dyslipidemia, hypertension, impaired glucose tolerance, and insulin resistance 34. 
Insulin resistance and dyslipidemia are considered key attributes to the 
pathophysiology of MetS 35. 
 
 MetS is pervasive, with approximately 44% of the U.S. population over 
age 50 meeting the NCEP criteria 36. Importantly, MetS indicates increased risk 
of atherosclerotic cardiovascular disease as well as type 2 diabetes mellitus 28-33, 
37. Additionally, hyperinsulinemic MetS patients have increased restenosis after 
percutaneous coronary interventions 38-41. Dyslipidemia is usually defined as the 
combination of dyslipoproteinemia and hypertriglyceridemia 42. We found that 
increased FFA are not the main cause for CAD in MetS (data not shown), 
consistent with report that FFA are not the cause in MetS and diabetes 43. 
Instead, the research done in our lab suggests LDL gram-years as a great 
predictor for CAD severity in MetS (data not shown). The increased risk for CAD, 
type 2 diabetes, and restenosis in MetS demands therapeutic attention for those 
at high risk. The fundamental approach includes weight reduction and exercise 
training; however, pharmacological approaches are highly effective and have 
much greater patient compliance 35. Our preliminary data indicated that plasma 
aldosterone was upregulated in MetS, which put aldosterone in our research 
focuses. 
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1.4. 
Activation of the renin-angiotensin-aldosterone system (RAAS) and 
subsequent elevations in aldosterone are often seen in MetS 44. Both contribute 
to endothelial dysfunction and CAD by altered insulin/insulin-like growth factor-1 
signaling pathways, reactive oxygen species formation, and other signaling 44. 
Aldosterone, the endogenous mineralocorticoid in humans, was first isolated in 
1953 as the last discovered steroid hormones 45, which include estrogen, 
androgen, progesterone and glucocorticoids 46. Aldosterone production, 
mediated by the zona glomerulosa of the adrenal gland, increases in response to 
angiotensin II or high dietary potassium. 
Renin-angiotensin-aldosterone system 
 
Aldosterone attenuates endothelial nitric oxide synthesis, promotes SMC 
proliferation, inflammation and fibrosis, and increase oxidative stress partially 
through activation of nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase 44, 47, 48. Interestingly, aldosterone increases neointimal formation after 
ballon injury 48 and aldosterone antagonism has been shown to suppress 
neointimal proliferation after coronary stenting 49. Despite those exciting findings, 
the cellular and molecular mechanisms underlying the proatherogenic effects of 
aldosterone remain elusive to us. 
 
1.5. 
Under stress conditions, such as hypoxia, depressed cellular energy state 
leads to acute increase and release of adenosine from the cell 50. Two main 
Adenosine and adenosine receptors 
 7 
cellular events are responsible for the production of adenosine, the hydrolysis of 
AMP to adenosine by 5” nucleotidase and the catabolism of S-
adenosylhomocysteine 50. Adenosine activates plasmalemmal adenosine 
receptors to regulate various functions. Adenosine receptors (ARs) are members 
of the G protein-coupled receptor family and four AR subtypes have been cloned: 
A1R, A2AR, A2BR, and A3R 51. The discrimination of A2Rs into two subtypes 
was based on agonist binding affinity (high affinity-A2AR; low affinity-A2BR). All 
AR subtypes are distinctly distributed throughout the body. Various AR agonists 
and antagonists are listed in Table 1.1 51. 
 
AR activation regulates a diverse set of physiological functions, including 
cardiac rate and contractility, smooth muscle tone, sedation, release of 
neurotransmitters, platelet function, lipolysis, renal function, white blood cell 
function, and cellular proliferation 50. Figure 1.5 shows our model of AR actions 
on coronary SMCs. A2A/BR were shown to mediate the vasodilatory effect of 
adenosine 52-54. Since the A1R inhibit and A2R stimulate adenylyl cyclase 51, A1R 
antagonism could positively modulate the coronary vasodilaton in the 
microcirculation. The second main hypothesis in the thesis is that A1R 
antagonism potentiates coronary vasodilation in healthy Ossabaw swine. 
 
Coronary stenting was shown to mechanically damage vascular cells in 
the target conduit artery segment 55 and induce downstream microvascular 
dysfunction 56-60. The mechanisms for microvascular dysfunction associated with 
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stenting remain unclear to us. Dyslipidemic patients displayed impaired AR-
mediated coronary flow reserve 60, 61. ARs may be responsible for the 
dysregulated adenosine-induced coronary flow in dyslipidemia. The third main 
hypothesis in the thesis is that stent deployment in coronary arteries elicits 
microvascular dysfunction in dyslipidemic swine, and A1R and/or A2A/BR might 
contribute to the changes. 
 
SMCs are typically characterized as either contractile or synthetic based 
on the distribution of myosin filaments and the massive formation of secretary 
protein apparatus 1. Contractile SMCs respond robustly to vasoconstrictors and 
vasodilators and largely mediate tone. In contrast, synthetic SMCs are primarily 
responsive to growth factors and are largely responsible for synthesis of 
extracellular matrix 1, 14. Phenotypic switching of SMCs from contractile to 
synthetic phenotype is a pivotal event in atherosclerosis 1, 9, 62-64. 
 
In aortic SMC, adenosine was found antimitogenic via the A2BR 65-68. Our 
laboratory made the novel observation that the A1R mediated mitogenic effects 
of adenosine on porcine coronary artery SMC via activation of the extracellular 
signal-regulated protein kinases (ERK), the c-Jun-N-terminal kinases (JNK), 
PI3K-AKT signaling pathways 65, 69. In addition, A1R mRNA was shown 
upregulated in stented vs. non-stented porcine coronary segments 70, thus 
suggesting A1R could play a role in CAD. 
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Since increased plasma aldosterone is a hallmark of “obesity hypertension” 
71, which is a key component of MetS, aldosterone is important in the “metabolic 
syndrome milieu” that drives CAD in MetS. Both aldosterone and A1R regulate 
vascular SMC proliferation via similar signaling pathways in vitro 65, 69, 72, 73. 
Glucocorticoid receptor activation stimulated A1R gene expression in cells 74, 75 
and rat brain 76. Mineralocorticoid and glucocorticoid receptors are very similar in 
sequence and structural organization 77, therefore MR activation by aldosterone 
could potentially regulate A1R expression, thereby contributing to coronary 
atherosclerosis. 
 
Exercise training of patients in coronary atherosclerosis elicits beneficial 
effects 18-23. However, the underlying mechanisms are unknown. It is possible 
that exercise acts on systemic aldosterone and A1R in coronary artery to 
improve coronary atherosclerosis in MetS. The fourth main hypothesis in the 
thesis is that aldosterone regulation of A1R contributes to coronary 
atherosclerosis in MetS, and is mitigated by short-term exercise training. 
 
Although DES have substantially decreased restenosis vs. bare metal 
stents 78, 79, caution must be taken with current DES in human patients because 
of possible late stent thrombosis caused by the endothelial cytotoxicity of the 
eluted agents 80-85. To ensure the recovery of proper endothelial function, the 
ideal DES agent should inhibit proliferation of vascular SMCs while not 
preventing the restoration of endothelial cells.  
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In-stent restenosis (re-blockage of the stenotic artery segment) occurs in 
up to 40% of lesions after percutaneous coronary intervention 16. The abnormal 
growth and migration of vascular SMCs play major roles in restenosis after 
stenting 9, 62-64, which shares similar pathogenesis as coronary atherosclerosis. 
Based on the aforementioned facts, the fifth main hypothesis in the thesis is that 
A1R-ERK1/2 signaling contributes to the development of coronary in-stent 
stenosis in MetS. 
 
1.6. 
Several animal models recapitulate MetS 86-91; however, none are able to 
fully reproduce symptoms of MetS and CAD observed in humans. Swine are 
quite similar to humans in many ways, e.g. lipids metabolism, docine and 
sedentary behaviors. Swine coronary arteries are also similar to humans in size, 
anatomical structure, and flow dynamics 92, 93, and develop CAD spontaneously 
94. Our group has developed Ossabaw miniature swine as an excellent large 
humanoid animal model of MetS and CAD. When fed excess calorie atherogenic 
diet, Ossabaw swine develop MetS, manifesting central obesity, dyslipidemia, 
hypertension, impaired glucose tolerance 11, 92, 95, 96, and like humans (but 
different from many other laboratory animal models) develop CAD 11, 92, 95, 97. 
Because in-stent neointimal hyperplasia is greater in Ossabaws than in other 
lean swine breeds (e.g. Yucatan) 92, Ossabaw swine provide a nearly ideal model 
for study of coronary in-stent stenosis, and presumably, coronary atherosclerosis, 
especially in the setting of MetS. The profoundly greater in-stent neointimal 
Ossabaw swine model of MetS and CAD 
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hyperplasia is shown in Figure 1.6, which is accompanied by decreased fibrosis 
of neointima in Ossabaw vs. Yucatan pigs. 
 
The study of efficacy of stents and underlying cellular and molecular 
events is one of the most compelling reasons for the use of the Ossabaw swine. 
Figure 1.7 shows the comparison of the size of a relatively small conduit 
coronary artery of the pig vs. the mouse. The 2 mm pig conduit artery completely 
dwarfs the largest conduit artery in the mouse, which is the tiny speck in the 
center of the pig artery. It is completely impossible to stent any mouse coronary 
artery because the stent struts themselves are 100 μm thick. 
 
1.7. 
1. Short-term exercise training prevents micro- and macrovascular disease in 
porcine model of hypercholesterolemia and coronary artery disease. 
Major hypotheses tested in the thesis 
2. A1R antagonism potentiates coronary vasodilation in healthy Ossabaw 
swine in basal condition. 
3. Stent deployment in coronary arteries elicits microvascular dysfunction in 
dyslipidemic swine, and A1R and/or A2A/BR might contribute to the 
changes. 
4. Aldosterone regulation of A1R contributes to coronary atherosclerosis in 
metabolic syndrome, and is mitigated by short-term exercise training.  
5. A1R-ERK1/2 signaling contributes to the development of coronary in-stent 
stenosis in metabolic syndrome.  
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1.8. 
Figure 1.1. Coronary artery anatomy and arterial wall structure 
Figure legends 
A Circumflex coronary (CFX), left anterior descending artery (LAD), and right 
coronary (RC) are the main epicardial conduit coronary arteries in swine. B 
Representative histology image of Verhoeff-Van Gieson (VVG) stain in right 
coronary segments from healthy Ossabaw miniature swine. VVG stained for 
elastin in brown at internal elastic lamina (IEL) and external elastic lamina (EEL), 
thus differentiates intima (I, within IEL) and media (M, between IEL and EEL) 
from adventitia (A, beyond EEL); lumen (L) is center of each artery. 
 
Figure 1.2. Progression of atherosclerosis in MetS 
Masson’s trichrome stain for collagen was used to assess changes in 
atherosclerosis. A. Healthy artery segment in Lean. Collagen predominates in the 
adventitia as shown by the blue staining. B. Early stage atherosclerosis in MetS, 
with collagen deposition in media separating smooth muscle cells (red) and 
neointima. C. Advanced stage atherosclerosis in MetS. Lumen size decreases 
dramastically, collagen deposition increases, but smooth muscle and foam cell 
infiltration predominate in neointima. D. Magnification of the lesion in C. a - 
adventitia, b - external elastic lamina, c - media, d - internal elastic lamina, e - 
lumen, f - neointima, g - foam cells. 
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Figure 1.3. Cellular composition of complex coronary artery lesion in MetS 
(Courtesy of J.R. Turk, Amgen, Thousand Oaks, CA). Immunohistochemistry of 
left circumflex coronary atherosclerotic lesion in MetS. Picrosirius red stains for 
collagen and elastin; thin fibrous cap shown by arrow. Verhoeff-van Gieson (VVG) 
stains for elastin. Immunostain for scavenger receptor; arrow shows presence in 
neointima and fibrous cap. D Immunostain for smooth muscle actin (arrow); 
absence in neointima and fibrous cap is consistent with unstable (vulnerable) 
plaque. 
 
Figure 1.4. Coronary atherosclerosis and stent deployment 
A. Angiogram of left anterior oblique view with the arrow pointing to the stenotic 
lesion in LAD. B. An expanded bare metal stent over an inflated balloon. C, D. 
Representative intravascular ultrasound (IVUS) images of a stenotic lesion 
(intima) before (C) and right (D) after stent deployment. E. IVUS image showing 
in-stent stenosis 4 weeks after stent deployment in a lean pig. The yellow dotted 
lines indicate the location of the stent struts, blue dashed lines indicate the 
current lumen border, and area in between those lines were in-stent hyperplasia 
(Modified from Z.P. Neeb’s thesis with permission). 
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Figure 1.5. Model of AR actions on SMC 
Adenosine induces vasodilatory effect in coronary SMC via activation of A2AR. In 
aortic SMC, adenosine induces anti-mitogenic effect via interation with A2BR. 
A1R mediates a novel mitogenic effect of adenosine in coronary SMC. There are 
no conclusions yet regarding the role of A3R. 
 
Figure 1.6. Ossabaw has greater coronary in-stent neointima (NEO) 
Comparison of Mason’s trichrome staining for collagen in in-stent segments 
between Yucatan and Ossabaw. A-adventitia, L-lumen, M-media, Neo-neointima, 
S-stent strut occupied the area before sectioning.  
 
Figure 1.7. Size comparison between porcine (above) and murine (center) 
epicardial conduit coronary artery 
Verhoeff-van Gieson staining for elastin. Arrows point to internal elastic lamina 
(IEL). Neointima (NEO) is the thin layer luminal to IEL. Thickness of stent struts 
used clinically in humans is the entire lumen diameter of the mouse coronary 
artery. 
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1.9. 
Figure 1.1. Coronary artery anatomy and healthy arterial wall structure 
Figures 
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Figure 1.2. Progression of atherosclerosis in MetS 
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Figure 1.3. Cellular composition of complex coronary artery lesion in MetS 
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Figure 1.4. Coronary atherosclerosis and stent deployment 
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Figure 1.5. Model of AR actions on SMC 
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Figure 1.6. Ossabaw has greater coronary in-stent neointima (NEO) 
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Figure 1.7. Size comparison between porcine (above) and murine (center) 
epicardial coronary artery 
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1.10. 
Receptor 
Table 
cAMP Agonist Antagonist G protein 
A1 ↓ 
ADO, NECA, 
RPIA, 
PD81723,  
CCPA 
DPCPX, 
1,2-DPA 
rolofylline 
Gi 
A2A ↑ 
ADO, NECA, 
CV1808, 
CGS21680 
DMPX, 
ZM241385 
SCH58261 
Gs 
A2B ↑ ADO, NECA, CV1808 
DMPX, 
MRS1706 
Alloxazine 
Gs 
A3 ↓ ADO, NECA, 2-Cl-IB-MECA 
VUF5574 
MRS1220 Gi 
Table 1.1. Adenosine receptor pharmacology. 
ADO, adenosine. 
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2.1. 
 The purpose of this study was to determine the effects of exercise training 
on coronary blood flow and macrovascular atherosclerosis in response to stent 
deployment. Male Yucatan swine were fed control (control), high fat/cholesterol 
(hypercholesterolemic), or high fat/cholesterol diet and aerobically exercise 
trained (hypercholesterolemic exercised) starting after 36 weeks on the diet. All 
pigs underwent coronary angiography and intravascular ultrasound (IVUS) 
guided placement of a bare metal stent in the circumflex coronary artery after 40 
weeks on diets and 3 weeks later pigs underwent repeat angiography and IVUS 
and coronary blood flow (CBF) measurement. Average peak velocity (APV) was 
measured under basal conditions and in response to intracoronary application of 
the endothelium-independent vasodilator adenosine and the endothelium-
dependent vasodilator bradykinin. There was a similar ~8-fold increase in total 
cholesterol in hypercholesterolemic and hypercholesterolemic exercised groups 
compared to control. Baseline CBF was increased above control and 
hypercholesterolemic groups in hypercholesterolemic exercised group (p<0.05). 
At all doses adenosine-induced CBF was impaired in hypercholesterolemic, but 
preserved in hypercholesterolemic exercised group. Similarly, bradykinin-induced 
CBF was impaired in hypercholesterolemic vs. control, yet was potentiated in 
hypercholesterolemic exercised group. Microvessel density was decreased in 
hypercholesterolemic and preserved in hypercholesterolemic exercised vs. 
control. Native atheroma in hypercholesterolemic exercised group was lower 
relative to hypercholesterolemic and control, while in-stent stenosis in 
Abstract 
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hypercholesterolemic exercised group was not different from 
hypercholesterolemic group. Stent-induced microvascular dysfunction in 
hypercholesterolemia may be a result of reduction in microvessel density. This is 
the first report that short-term exercise training near the time of stenting prevents 
stent-induced microvascular dysfunction and attenuates native atheroma 
independent of changes in plasma cholesterol in this porcine model. 
 
Key words: microvessel, restenosis, porcine, hypercholesterolemia, Yucatan 
swine 
 
2.2. 
Deployment of a stent in a coronary artery in the setting of flow-limiting 
stable coronary artery disease (CAD) results in initial improvement in functional 
capacity and quality of life 98. However, almost half of patients undergoing 
coronary angioplasty/stenting eventually experience recurrent angina, resulting in 
a decline in functional capacity and require further medical attention 99. It has 
been shown that coronary stenting mechanically damages vascular cells in the 
target conduit artery segment and endothelium in peri-stent segments 55, and 
induces downstream microvascular dysfunction that persists for weeks and has 
been implicated in causing exertional ischemia 56-60. Camici and Crea 60 termed 
this phenomenon post-stent “iatrogenic coronary microvascular dysfunction”, 
which may be due to enhanced alpha-adrenergic constriction 100, chronic 
impairment of microvascular response 57, 58, or microemboli that may cause 
Introduction 
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microinfarcts 58, 101 and perhaps more severe rarefaction (microvessel dropout) 
102. In spite of enormous efforts to reduce in-stent stenosis and microvascular 
dysfunction, there remains significant room for improvement in addressing both 
of these post-stent procedure complications. This is especially important because 
drug-eluting stents, which are the main treatment for flow-limiting lesions, cause 
even greater microvascular dysfunction than bare metal stents 103, 104.  
 
Exercise training of patients with coronary artery disease elicits beneficial 
effects, including improvement in exercise tolerance, left ventricular function, and 
reduction in the ischemic response to submaximal workload after exercise 
training, and increased dilation of conduit and microvessel coronary arteries 18-23. 
Most of these studies have shown concomitant changes in plasma cholesterol; 
specifically, decreased total and low density lipoprotein (LDL) and increased high 
density lipoprotein (HDL) cholesterol 24-26. Hambrecht etc. 23 removed the 
confounding variable of hypercholesterolemia by excluding those patients from 
their study, thus implying that the beneficial effects of exercise may be due to 
more direct actions of exercise on the vasculature.  
 
The benefits of exercise training may also extend to the population 
undergoing percutaneous coronary revascularization 22, 24-26. Belardinelli etc. 26 
found that progression of macrovascular CAD in arterial segments proximal and 
distal to the angioplasty / stented segment, i.e. peri-stent CAD, was attenuated 
by exercise training and accompanied by an improved thallium perfusion stress 
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test that is indicative of increased metabolic vasodilation of the coronary 
microvasculature. Further, exercise training may be more beneficial and cost-
effective than percutaneous coronary intervention in the setting of chronic stable 
CAD 22. Fleenor and Bowles 27 showed that long-term exercise training of pigs 
with normal plasma cholesterol attenuated conduit artery neointimal proliferation 
elicited by overexpansion injury from balloon angioplasty; however, 
microvascular effects were not determined. Further, the effects of plasma 
cholesterol and exercise on in-stent stenosis, peri-stent CAD, and microvascular 
dysfunction after coronary stenting have not been studied. 
 
The purpose of this study was first to test the hypothesis that stent 
deployment in coronary arteries of hypercholesterolemic swine would elicit 
microvascular dysfunction and if short-term exercise training would prevent the 
microvascular dysfunction and progression of macrovascular CAD after stenting. 
A second hypothesis tested was whether exercise elicits beneficial effects by 
acting directly on the vascular wall, rather than indirectly via decreasing plasma 
risk factors (i.e. cholesterol). The final hypothesis tested was whether a decrease 
in microvessel density, i.e. rarefaction, occurs after stenting in 
hypercholesterolemia, and whether exercise training would prevent this. 
 
2.3. 
 All protocols involving animals were approved by an Institutional Animal 
Care and Use Committee and complied fully with standards 105, 106. Nineteen 
Methods 
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male Yucatan swine, 52-70 kg, were randomized to 40 weeks of control diet (C, 
n=8), high fat/cholesterol diet (H, n=8), or high fat/cholesterol diet with short-term 
exercise training (HX, n=3). H and HX were fed a diet consisting of 46% kcal 
from fat 107. The feed base consisted of mini pig chow with supplemental fat kcals 
from coconut oil (<1% trans fatty acids; Research Diets, Inc., New Brunswick, NJ) 
and cholesterol (Research Diets, Inc.). Controls were fed a diet consisting of mini 
pig chow base with 8% kcal from fat. 
 
2.3.1. Exercise Training  
 Animals randomized to the exercise group began treadmill training 4 
weeks prior to initial cardiac catheterization. During the first week of training, the 
exercise pigs ran on the treadmill at 3 mph (endurance) with 0% grade for 20-30 
minutes and at 4 mph (sprint) for 15 minutes. The speed and duration of running 
were increased progressively over the course of the following 4 weeks. During 
the 4th through the 7th week of training, a typical 70 minute training session 
consisted of the following: 1) 5 minute warm-up at 2.5 mph, 2) 15 minute sprint at 
speeds of 5.5-6 mph, 3) 40-45 minute endurance run at 3.5 mph, and 4) 5 minute 
cool down at 2 mph. Ranges of running speeds are presented because the 
exercise training advanced during the course of the week. Following coronary 
stenting, each animal resumed symptom limited exercise training. This regimen 
was maintained for three weeks after stenting when the animals returned for 
repeat cardiac catheterization. Exercise protocols were compliant with guidelines 
from the American Physiological Society 108.  
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2.3.2. Submaximal stress test 
At weeks 1, 4, and 7 of exercise training the endurance trained animals 
underwent a submaximal stress test consisting of running on a treadmill at 3.1 
MPH, 0% grade for 15 minutes at which point heart rate data were collected. 
 
2.3.3. Stent Procedure 
 Each animal received antiplatelet therapy with aspirin 325 mg daily 
starting the day prior to the initial catheterization procedure and continuing 
through the completion of the study 70, 92, 109. Each pig was fasted overnight and 
all animals arrived at the same time of day for procedure. Animals received 
preanesthesia with intramuscular injections of atropine (0.05 mg/kg), xylazine 
(2.2 mg/kg), and telazol (6.6 mg/kg). Following intubation, isoflurane (2-4%, with 
oxygen) was administered to maintain stable systemic hemodynamics and a 
stable level of anesthesia. Heart rate, blood pressure (tail cuff and aortic), 
respiratory rate and electrocardiographic data were continuously monitored 
throughout the procedure. Under steri le conditions, the right femoral artery was 
exposed with surgical cut-down technique and an 8F vascular introducer sheath 
was inserted into the femoral artery followed by administration of heparin 200 
U/kg. An 8F Amplatz L (sizes 0.75-2.0) guiding catheter (Cordis Corp., Miami, FL) 
was inserted through the sheath and advanced to engage the left main coronary 
ostium (Figure 2.1). Blood pressure measurements were recorded directly from 
the coronary ostium via a pressure transducer connected to the manifold 
assembly. A 0.014 inch flex tip Doppler Flow-wire (Cardiometrics, Rancho 
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Cordova, CA) was advanced through the guiding catheter and positioned in the 
distal left circumflex artery with the aide of angiographic images. A 3.2F, 30 MHz 
Intravascular Ultrasound (IVUS) catheter (Boston Sci., Sunnyvale, CA) was 
advanced over the Flow-wire and positioned in the distal left circumflex coronary 
artery. IVUS interrogation of the left circumflex artery was performed using an 
automated pullback technique at a rate of 0.5 mm/sec. Images were recorded on 
videotapes using Sonos Intravascular Imaging System (Hewlett Packard) for 
subsequent off line analysis. Strict comparison of IVUS and angiographic images 
were taken to ensure accurate placement of the coronary stent. Following IVUS 
pullback, the IVUS catheter was removed and the coronary stent (3.0 to 4.0 mm 
diameter by 8 to 20 mm length, Multi-link Penta Coronary stent system, Guidant 
Corp., Temecula, CA) catheter was positioned in the left circumflex artery. 
Coronary stent size was chosen using angiogram and IVUS information to match 
the recipient artery diameter with stent deployment at optimal inflation pressure. 
The coronary stent was deployed in the circumflex artery per routine deployment 
protocol. Repeat angiography was performed and apposition was confirmed by 
repeat IVUS interrogation. The IVUS catheter, guide catheter and introducer 
sheath were then removed and the right femoral artery was ligated. The skin was 
closed in two layers and the animal was allowed to recover from anesthesia. 
Arrow in Figure 2.1A indicates stent placement was performed after 4 weeks of 
exercise training in the HX pigs. 
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2.3.4. Follow up procedure  
Follow up cardiac catheterization for coronary blood flow (CBF) analysis of 
in vivo microvascular function was performed three weeks after initial stent 
placement. Preanesthesia and vascular access via the left femoral artery was 
similar to that described above. The left coronary ostium was engaged with the 
guiding catheter and a Doppler Flow-wire was positioned in the distal circumflex 
with angiographic guidance 92, 107. IVUS catheter was then advanced over the 
Flow-wire and positioned in the distal circumflex for IVUS interrogation via 
pullback as previously described in the peri-stent and in-stent regions. Following 
IVUS pullback, the IVUS catheter was removed and the Doppler Flow-wire was 
repositioned in the left circumflex artery proximal to the coronary stent. Strict 
comparison of IVUS and angiographic images were taken to ensure accurate 
placement of the Flow-wire for determination of CBF responses. 
 
Average peak velocity (APV) measured by intracoronary Doppler Flow-
wire was recorded continuously throughout the procedure using FloMap 
(Cardiometrics, Rancho Cordova, CA) for off-line analysis at a later time. The 
CBF velocity was allowed to reach a steady state (allowing any effects of 
preanesthesia to resolve) and baseline measurement of APV was obtained. 
Hyperemia was then induced with bolus doses (3 mL) of the endothelium-
independent vasodilator adenosine (3, 1, 0.33, 0.167 µg/kg) given via the guiding 
catheter into the coronary artery. Peak APV, heart rate and blood pressure were 
recorded for each adenosine administration. Subsequent doses of adenosine 
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were administered only after APV had returned to baseline and stabilized, at 
which time the baseline parameters were again documented followed by the 
administration of the next adenosine dose. The effect of adenosine typically 
lasted 15-30 seconds. After completion of the graded adenosine doses we 
investigated the response to the endothelium-dependent vasodilator bradykinin. 
The APV was allowed to return to baseline and bradykinin (1, 2, 4 ng/kg) was 
administered. APV, heart rate and blood pressure were continuously recorded as 
described above. Because of the prolonged response to bradykinin, 
hemodynamic and blood flow parameters were tracked for 2 minutes following 
each bradykinin to ensure return and stabilization of APV to its previous baseline. 
Subsequent doses of bradykinin were administered only after APV, heart rate 
and blood pressure returned to baseline and stabilized. 
 
The APVs, heart rates, blood pressures, and vasodilator-induced peak 
APVs, heart rates, blood pressures were determined from off-line analysis of 
FloMap recordings. Coronary blood flow (ml/min) was calculated as: APV 
(cm/sec) × 0.5 × CSA (artery cross sectional area, cm2) / 60 (sec/minute) 107. 
Coronary vascular resistance (CVR, mm Hg/ml/min) was calculated as mean 
arterial pressure (MAP) divided by CBF. The rate-pressure product (RPP, bpm × 
mm Hg) was calculated as heart rate (HR, bpm) multiplied by systolic blood 
pressure (SBP, mm Hg). Vessel cross-sectional area was calculated off-line from 
recorded IVUS images using the commercially available Sonos Intravascular 
Imaging software package. End systolic and end diastolic cross sectional areas 
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were determined for three consecutive cardiac cycles. The average of these six 
measurements was taken as the cross sectional area to be used in subsequent 
calculations and analysis. 
 
2.3.5. Lipid analyses 
After 18 hours of fasting blood was taken via the anterior vena cava and 
collected into vacutainers containing 0.117 ml of 15% EDTA and centrifuged in 
the cold at 4°C for 20 min at 2000 rpm in a Marathon 21000 R centrifuge (Fisher 
Scientific, Pittsburgh, PA) and frozen at -80°C. Plasma was analyzed for 
triglycerides, total cholesterol, and high density lipoprotein (HDL) while low 
density lipoprotein (LDL) was calculated from Friedewald equation: LDL = Total 
cholesterol - HDL - (triglyceride/5) 95. 
 
For each plasma analysis, all samples for a given subject were analyzed 
in a single run. Plasma triglyceride and total cholesterol were assayed directly by 
standard enzymatic kit (Thermo Trace, Melbourne, Australia). HDL was 
measured by precipitating apolipoprotein B-containing lipoproteins with heparin-
MnCl2 95, 110, 111. The supernatant was used to assess HDL using the 
aforementioned total cholesterol kit and method. 
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2.3.6. Quantification of atherosclerosis and neointima formation and coronary 
microvessel density 
 To determine extent of atherosclerosis in the coronary arteries, we 
performed IVUS catheterization on the left circumflex and left anterior 
descending arteries. The left anterior descending was not previously interrogated 
at the time of stent placement, thus the atheroma detected in this "non-stented" 
artery (Figure 2.1) was considered native, and uninfluenced by potential catheter-
related non-specific trauma of the stent procedure. The IVUS data were recorded 
on videotape for off-line analysis. Degrees of atheroma (percent wall coverage) 
were measured from IVUS images at one mm intervals. Degrees of atheroma at 
each interval of the given vessel were summed and divided by (360/mm * length 
of vessel in mm). This was multiplied by 100 to yield % atheroma to normalize for 
different lengths of arteries 70, 109. See Figure 2.1C and Table 2.3. 
 
Verhoeff-van Gieson and Masson’s trichrome staining were performed on 
sections of stented arteries. Though technically very challenging, we obtained 
several sections for histology per animal per stain. In animals where more than 
one section was obtained, values were averaged. Neointima formation was 
determined by obtaining area measurements bounded by the external elastic 
lamina and internal elastic lamina (tunica media), internal elastic lamina and 
lumen (neointima) using commercially available software (ImagePro 3.0). The 
percent stenosis was calculated by dividing the area of the neointima by the area 
demarcated by the internal elastic lamina × 100. Collagen content in the sections 
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of the stented arteries was determined by colorimetric analysis 10. The adventitia, 
which is composed predominantly of collagen, was used as the reference color 
template against which the rest of the section was compared. 
 
A small piece (1 × 1 cm2) of left ventricular myocardium was obtained at 
sacrifice and preserved in 10% formalin solution. Each piece was embedded in 
paraffin and sectioned (4 µm) for immunohistochemistry for smooth muscle a-
actin. Immediately prior to treatment with antibodies, each section was 
deparaffinized and treated with an antigen retrieval process. A monoclonal 
primary antibody to smooth muscle a actin was used as for identifying coronary 
vessel (1:1000, Sigma Chemical Co., St. Louis, MO), incubated for 1 hour. A 
biotinylated secondary antibody (Vectastain Elite, Vector Laboratories, 
Burlingame, CA) was used for the detection process. Stained samples were 
viewed under a light microscope, and images were captured with Coolpix digital 
camera. Only coronary arteries with 70-100 μm internal diameters were used and 
sections of myocardium contained a wide range of microvessels, thus were 
normalized to cross sectional area. Optical density (OD) of microvessel cross 
sections were normalized to the average of the control values and expressed as 
a percentage of control as indicated in the following: (OD each individual 
vessel)/(average OD of Control vessels) × 100% = OD as a % of Control. Finally, 
microvessel density was measured by counting the number of microvessels in 
randomly selected 6.5 mm2 areas. 
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2.3.7. Data analysis 
Statistical analysis was performed using commercially available software 
(SPSS version 10, SigmaStat 5.0). Coronary blood flow responses and 
hemodynamic parameters were compared between groups using repeated 
measures ANOVA. Vessel cross-sectional area and % degrees atheroma were 
compared between groups using single factor ANOVA. The Dunnett’s T3 multiple 
comparison test was used for data that were not normally distributed 
(microvessel density). In all cases, p < 0.05 was considered significant. 
 
2.4. 
High fat/cholesterol diet resulted in approximately 8-fold increase in 
plasma total cholesterol, greater than 20-fold increase in LDL cholesterol, and a 
slight but significant increase in HDL cholesterol in H and HX relative to control 
(Table 2.1). These differences resulted in a 16-fold increase in LDL/HDL ratio in 
H and HX vs. control. Despite the significant cholesterol response to diet, the 
experimental design assured that the body weight was not different between 
groups. Heart rate response was taken during a submaximal treadmill stress test 
with the pig running at 3.1 mph at 0% grade for 15 minutes. In HX, heart rate 
response to submaximal stress testing was approximately 25% lower after 7 
weeks of training compared to performance on submaximal stress testing 
completed at the beginning of week 1 (Table 2.1), thus confirming the efficacy of 
the exercise training regimen. Heart weight, mean arterial pressure, and rate 
pressure products were not different between groups as shown in Table 2.1. 
Results 
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IVUS interrogation revealed no flow limiting stenosis in the studied vessel. 
Baseline conduit cross-sectional area was not different between groups and did 
not change with administration of vasodilators. 
 
As shown in Figure 2.2A, CBF change in response to bradykinin was 
decreased in H relative to control at 4 ng/kg and increased in HX relative to H at 
2 ng/kg (p<0.05). Interestingly, adenosine-induced CBF change was substantially 
attenuated in H relative to control at all doses (Figure 2.2B, p<0.001). Short-term 
exercise training increased the CBF responses to adenosine relative to H at 
0.167 and 1.0 µg/kg doses (p<0.05). 
 
 Coronary vascular resistance is shown in Table 2.2. Baseline CVR was 
elevated in H relative to control (2.22 ± 0.23 vs. 1.46 ± 0.14 mm Hg/ml/min), 
whereas short-term exercise training significant reduced baseline CVR (0.96 ± 
0.05 mm Hg/ml/min). Adenosine-induced CVR was approximately two times 
higher in H vs. control at all doses (i.e. 1.60 ±  0.15 vs. 0.88 ± 0.10 mm Hg/ml/min 
at 0.33 µg/kg). Short-term exercise training preserved the CVR response to 
adenosine (0.86 ± 0.16 mm Hg/ml/min at 0.33 µg/kg). Similarly, CVR in response 
to bradykinin administration was approximately 50 to 60% higher in H than 
control at all doses (i.e. 1.34 ± 0.05 vs. 0.82 ± 0.06 at 4 ng/kg). Similar to 
adenosine, the impaired response to bradykinin was prevented with exercise 
training (0.80 ± 0.13 at 4 ng/kg).   
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In addition to assessment of microvascular function, we investigated the 
effect of exercise on the macrovascular atheroma along the entire length of the 
artery that was interrogated by IVUS. Results of IVUS analysis are shown in 
Table 2.3. The overall macrovascular atheroma in H was almost 2-fold greater 
than control as shown as circumflex percent degrees atheroma. Remarkably, this 
response was completely prevented with exercise training. At sacrifice the left 
anterior descending, which had not been previously accessed, was also 
interrogated with IVUS to determine the effects of short-term exercise on native 
atheroma not related to coronary stenting. As shown in Table 2.3 there was 
significantly higher percent degrees atheroma in left anterior descending of H vs. 
control, which was completely absent of atheroma. Importantly, exercise reduced 
LAD atheroma. Note that overall atheroma burden was evident in the CFX in the 
control group only because of the in-stent stenosis in control contributed 
substantially to the overall atheroma burden. Finally, to address the effect of 
hypercholesterolemia and exercise on the in-stent atherosclerotic processes, 
analyses for neointima formation (percent stenosis) and collagen content were 
performed on the stented sections of the circumflex artery. We report no 
statistical difference across groups with respect to percent stenosis (Figure 2.3E). 
This is in stark contrast to the percent stenosis that was determined 5 mm 
(Figure 2.3D) and 10 mm (data not shown) proximal to the stent, as H pigs had 
significantly greater % stenosis in both locations compared to the control and HX 
groups. In addition, we found significantly higher % collagen in the stented 
sections of the H animals (21.5 ± 6.8%) compared to the control (0.9 ± 0.3%) or 
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HX (2.1 ± 0.8%). Taken together, these data suggest that the higher amount of 
atheroma in the circumflex artery of the H animals was predominantly in the non-
stented sections of the interrogated artery, which is strongly supported by the 
summary comparison data of histology in Figure 2.3D and E. 
 
Finally, Figure 2.4 represents microvessel density in the left ventricular 
sections obtained from all pigs. Microvessel density was significantly decreased 
in H compared to control (47% of C). Microvessel density in the HX group was 
higher than in the H group (80% of C), suggesting that exercise training partially 
prevented this reduction in microvessel density.  
 
2.5. 
To our knowledge, this is the first study examining the effects of exercise 
training on microvascular function and macrovascular atheroma after coronary 
stenting in a model of hypercholesterolemia and CAD. Additionally, we provide 
evidence that microvascular rarefaction may underlie the blunted stent-induced 
response and normalized exercise training-induced blood flow responses to 
adenosine and bradykinin in the coronary microcirculation in 
hypercholesterolemia. Coronary stenting has been shown to mechanically 
damage vascular cells in the target conduit artery segment and endothelium in 
peri-stent segments 55, and induces downstream microvascular dysfunction that 
persists for weeks and has been implicated in causing exertional ischemia 56-60. A 
major finding of this study is bare metal stent deployment in our 
Discussion 
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hypercholesterolemic swine model results in microvascular dysfunction, as 
assessed by the decreased CBF response to intracoronary bradykinin and 
adenosine administration (Figure 2.2). Secondly, short-term exercise training 
prevented the microvascular dysfunction in response to intracoronary braydkinin 
and/or adenosine (Figure 2.2A and B). A third major finding was that stenting 
decreased microvessel density in hypercholesterolemia (Figure 2.4), thus 
providing a structural mechanism for the in vivo responses to adenosine and 
bradykinin reported herein. Interestingly, exercise training prevented the 
reduction in microvessel density (Figure 2.4). These data demonstrate the 
efficacy of short-term exercise training on preventing early pathophysiological 
responses to coronary stent deployment. Equally remarkable is that the 
beneficial effects of exercise were independent of changes in plasma lipids. 
Taken together, we conclude that exercise may act directly on the vascular wall 
or other plasma risk factors not measured here to improve microcirculation after 
stenting in hypercholesterolemia. 
 
Similar effects on endothelium-dependent microvascular dysfunction and 
CBF have been reported in the setting of hypercholesterolemia alone 3, 112-115. 
Possible mechanisms for the hypercholesterolemia-induced endothelium-
dependent dysfunction include an increase in endothelin-1 (ET-1) 3, a reduction 
in nitric oxide (NO) synthase 4 or responsiveness to NO 5. We did not measure 
protein levels of ET-1 or NO synthase nor responsiveness to NO in the 
microvessel preparations in the present study. Furthermore, coronary 
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interventions can damage vascular cells and induce endothelial dysfunction in 
arterial segments distal to the angioplasty/stent site 55, with one study suggesting 
that endothelial dysfunction following coronary interventions is related to 
inducible ischemia 56. Importantly, the impaired microvascular function and CBF 
could also be secondary to direct endothelial cell damage. The present findings 
of impaired responses to adenosine (largely endothelium-independent 
vasodilator) suggest that the microvascular dysfunction was not limited solely to 
a dysfunctional endothelium, but suggests smooth muscle function was also 
adversely affected. We acknowledge that a component of adenosine-induced 
relaxation is endothelium-dependent in rat vasculature 116; however, the effects 
of adenosine are primarily endothelium-independent pathway and as such is the 
predominant vasodilatory pathway in porcine coronary artery. 
 
Previous reports have shown beneficial effects of exercise training 
including improved myocardial perfusion and improved endothelial function 117-119. 
However these studies did not involve revascularized patients. More recent 
studies involving patients undergoing coronary interventions report improvements 
in functional capacity and quality of life, but report conflicting results regarding 
recurrent events and re-hospitalizations and these studies did not directly assess 
microvascular function 25, 26, 120-122. Hosokawa etc. directly assessed endothelial 
function in vivo and reported regular exercise training improved endothelial 
function in non-infarct related coronary arteries following coronary interventions 
for myocardial infarction 24. Importantly, that study did not evaluate function of the 
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culprit artery. Finally, it is important to note that these studies involved long-term 
exercise training, which contrasts sharply to the short-term (7 weeks) regimen in 
the present study. 
 
Short-term exercise training resulted in significantly lower native atheroma 
burden as determined by IVUS interrogation of the left anterior descending (non-
intervened vessel) (Table 2.3). These data are consistent with other investigators 
who have shown that long-term exercise training has beneficial cardioprotective 
effects with some evidence suggesting that exercise training may delay the 
progression or even induce regression of CAD 123-125. Additionally, IVUS 
interrogation of the circumflex artery revealed that short-term exercise training 
significantly decreased the macrovascular atheroma response following stenting. 
This result is noteworthy in light of recent human studies involving long-term 
exercise training following coronary interventions that did not result in significant 
differences in restenosis rates 25, 26, 120, 121. Interestingly, the formation of 
neointima within the stent was not different across groups; thus, the differences 
in atheroma burden across groups stem from difference in the non-stented 
regions. This is noteworthy as little is known regarding the progression of 
coronary artery disease in a stented vessel proximal and distal to the stent. 
Because of the increase in collagen content in the H animals in the tunica media, 
the mechanisms responsible for the alteration in cellular composition in each of 
these regions warrant additional investigation. Further punctuating these current 
findings is the fact that coronary stenting is clearly the most widely accepted 
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treatment option for patients with CAD, yet restenosis still affects 15-25% of 
patients and often requires repeated interventions even with recent advances in 
therapy 126, 127. The exact mechanisms involved in the beneficial effects of short 
term exercise are still not clearly elucidated but could involve neurohumoral, 
mechanical, direct or indirect effects on the vascular wall. 
 
Revascularization of an occluded artery with percutaneous angioplasty 
has been shown to impair conduit and microvascular dilation 55, 56, 58-60, 100, 101. We 
investigated one potential underlying mechanism related to microvascular 
dysfunction response in the present study - the reduction in microvascular 
density in the hypercholesterolemic swine (Figure 2.4). Since the hyperemic 
response to adenosine and bradykinin is a result of microvessel vasodilation, it 
stands to reason that one potential common explanation for a blunted response 
to both adenosine and bradykinin could be a reduction in number of microvessels 
per tissue area. 
 
A limitation of our study is the animals did not receive a typical medical 
regimen that would be considered standard of care for human patients 
undergoing coronary interventions. Pigs in our study were given daily aspirin and 
periprocedural heparin, but did not receive Plavix. Further, the pigs did not 
receive typical lipid lowering agents, by design, which have also been shown to 
have an ameliorating effect on endothelial dysfunction and even atheroma 
burden as well as outcomes in patients with CAD 128-133 and our model 10, 134, 135. 
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Additionally, by design, our study did not address how long the beneficial 
exercise effect was maintained, nor did it address whether the effect was 
preserved following cessation of exercise.  
 
The results of this study demonstrate that short-term exercise training 
preserves endothelium-independent coronary microvascular responses, 
potentiates endothelium-dependent coronary microvascular function, and 
significantly diminishes the overall macrovascular atheroma burden after 
coronary stenting in a porcine model of hypercholesterolemia and CAD. Our 
results add direct evidence for microvessel dropout (rarefaction), which may 
explain the parallel CBF responses to endothelium-dependent (bradykinin) and 
endothelium-independent (adenosine) dilators. Combined with the exercise-
induced decrease in macrovascular atheroma burden, these data provide a 
compelling basis for exercise to ameliorate complications associated with 
coronary stenting. To our knowledge this is the first study to report such effects 
associated with peri-procedural short-term exercise training independent of 
favorable changes in plasma cholesterol. These phenomenal effects of exercise 
training, if translatable to human clinical medicine, could offer an outstanding 
adjunct to drug-eluting stent treatment for flow-limiting lesions if exercise can 
ameliorate the even greater microvascular dysfunction in drug-eluting compared 
to bare metal stents 103, 104. 
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2.7. 
Figure 2.1. Schematic representation showing placement of coronary stent, 
positioning of IVUS and Doppler flow-wire in the circumflex artery, and IVUS 
images 
Figure legends 
A. For CBF determinations, IVUS and Doppler flow-wire (thin line in CFX) 
information were collected from a position in the circumflex (CFX) artery proximal 
to the coronary stent. The full length of the circumflex artery was interrogated 
with IVUS (thicker solid line in CFX) at stent placement and 3 weeks later. The 
non-stented left anterior descending (LAD) artery was interrogated with IVUS 
only at sacrifice and the right coronary (RC) was not interrogated. B. 
Representative IVUS image of coronary artery with minimal atherosclerosis. 
Arrows indicate location of lumen and artifact caused by IVUS catheter. C. Image 
indicating percent degree atheroma calculation. This artery shows 300 degrees 
of atheroma (wall coverage) of a thin (<0.3 mm) layer of intimal thickening. 
Degrees of atheroma for an interrogated artery were summed and divided by 
(360/mm * length of vessel in mm). This was multiplied by 100 to yield % degrees 
atheroma to normalize for different lengths of arteries 95.  
 
Figure 2.2. Coronary blood flow change in response to vasodilators 
Coronary blood flow change in response to intracoronary bolus injection of 
endothelium-dependent vasodilator bradykinin (A) or endothelium-independent 
vasodilator adenosine (B) at different doses. Flow signal was measured with an 
intracoronary flow-wire placed under the guidance of coronary angiogram as 
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described in methods section. * denotes p<0.05, C or HX vs. H (A) or HX vs. H 
(B); ** denotes p<0.001, C vs. H. 
 
Figure 2.3. Percent stenosis in areas 5 mm proximal to stented section and in-
stent section in H compared to control and HX. 
A. Represents a diagram of the circumflex artery and relative location of the 
stented section and the sections proximal to the stent. B. Representative image 
of the method used to calculate intima and media areas in histological section. 
Arrowheads indicate location of some stent struts and arrows indicate artery 
luminal border. Internal and external elastic laminas and neointima are identified.  
C. Representative images of each histological section. Stented sections of the 
circumflex artery were stained with Verhoeff-van Gieson stain to accentuate the 
internal and external elastic lamina. Areas of neointima and lumen were 
quantified to calculate percent stenosis values. D. Summary data for the percent 
stenosis determined at the location 5 mm proximal to the stent (peri-stent CAD). * 
denotes p<0.05, H vs. C and HX. E. Summary data for the percent stenosis 
obtained from histological analysis within the stent. There were no significant 
differences across groups within the stent.  
 
Figure 2.4. Myocardium coronary microvessel density in H, HX, vs. C after 
stenting 
Left ventricular sections obtained from each animal 3-week after stenting were 
preserved in formalin and stained with an antibody for smooth muscle α actin to 
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identify arteriolar microvessels. A-C. Representative section of left ventricular 
tissue from C, H, and HX animal. D. Summary data for the microvessel density 
obtained from immunohistochemical analysis in the myocardium. * indicates 
areas of cardiac muscle, arrow indicates coronary microvessels. 
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2.8. 
Figure 2.1. Schematic representation showing placement of coronary stent, 
positioning of IVUS and Doppler flow-wire in the circumflex artery, and IVUS 
images 
Figures 
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Figure 2.2. Coronary blood flow change in response to vasodilators 
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Figure 2.3. Percent stenosis in areas 5 mm proximal to stented section and in-
stent section in H compared to control and HX 
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Figure 2.4. Myocardium coronary microvessel density in H, HX, vs. C after 
stenting 
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2.9. 
Parameter 
Tables 
C H HX Significance 
Phenotypic characteristics 
Weight (kg) 59 ± 2 59 ± 4 58 ± 3 None 
Total Cholesterol (mg/dL) 
 52 ± 4 466 ± 78 393 ± 112 C vs. H, HX 
LDL (mg/dL) 14 ± 3 408 ± 72 332 ± 115 C vs. H, HX 
HDL (mg/dL) 30 ± 3 51 ± 4 50 ± 8 C vs. H, HX 
LDL/HDL 0.53 ± 0.1 7.97 ± 0.8 7.75 ± 3.4 C vs. H, HX 
TG (mg/dL) 34 ± 5 41 ± 9 61 ± 34 None 
Systolic Blood Pressure (mm Hg) 
 77 ± 4 76 ± 6 86 ± 6 None 
Diastolic Blood Pressure (mm Hg) 
 50 ± 4 52 ± 6 57 ± 6 None 
Heart Rate (bpm) 88 ± 6 77 ± 9 105 ± 9 None 
MAP (mm Hg) 59 ± 4 60 ± 6 67± 6 None 
RPP (bpm × mm Hg) 
 6730 ± 580 5800 ± 820 9000 ± 820 None 
CSA (mm2) 12 ± 3 12 ± 2 12 ± 3 None 
Heart Weight (g) 235 ± 12 265 ± 18 236 ± 7 None 
Submaximal stress test heart rate (bpm) exercise 
Start exercise training ---- ---- 200 ± 30 ---- 
Mid exercise training ---- ---- 160 ± 40 ---- 
End exercise training ---- ---- 160 ± 10 End < Start  
Table 2.1. Phenotypic characteristics of C, H, and HX and adaptations to 
exercise. 
LDL = low-density lipoprotein, HDL = high-density lipoprotein cholesterol, TG = 
triglycerides, MAP = mean arterial pressure, RPP = rate pressure product, CSA = 
conduit cross sectional area. Statistical significance at p<0.05. 
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CVR  
(mmHg/ml/min) C H HX Significance 
Baseline 1.46 ± 0.14 2.22 ± 0.23 0.96 ± 0.05 C vs. H, HX,  H vs HX 
Adenosine (µg/kg) 
0.167 0.96 ± 0.08 1.80 ± 0.20 0.83 ± 0.03 C vs. H 
0.33 0.88 ± 0.10 1.60 ± 0.15 0.86 ± 0.16 C vs. H 
1 0.71 ± 0.05 1.18 ± 0.07 0.67 ± 0.03 C vs. H 
3 0.58 ± 0.05 0.91 ± 0.13 0.60 ± 0.03 C vs. H 
Bradykinin (ng/kg) 
1 1.14 ± 0.08 1.72 ± 0.14 0.86 ± 0.11 C vs. H, HX,  H vs HX 
2 1.01 ± 0.06 1.71 ± 0.38 0.73 ± 0.15 C vs. H,  HX, H vs HX 
4 0.82 ± 0.06 1.34 ± 0.05 0.80± 0.13 C vs. H, HX,  H vs HX 
Table 2.2. Short-term exercise training prevents coronary vascular resistance 
(CVR) derangements. 
Statistical significance at p<0.05. 
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% Degree  
Atheroma C H HX Significance 
CFX 35.2 ± 5.5 59.5 ± 12.5 23.0 ± 1.1 C vs. H, HX,  H vs HX 
LAD 0 17.9 ± 2.4 3.9 ± 0.3 C vs. H, HX,  H vs HX 
Table 2.3. Short-term exercise training prevents overall atheroma burden. 
Statistical significance at p<0.05. 
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3.1. 
 Adenosine clearly regulates coronary blood flow; however, contributions of 
specific adenosine receptor (AR) subtypes (A1R, A2AR, A2BR, A3R) to coronary 
flow in swine have not been determined. ARs generally decrease (A1R/A3R) or 
increase (A2A/2BR) cAMP, a major mediator of vasodilation. We hypothesized 
that A1R antagonism potentiates coronary vasodilation and that coronary stent 
deployment in dyslipidemic Ossabaw miniature swine elicits impaired 
vasodilation to adenosine that is associated with increased A1R/A2AR 
expression. The left main coronary artery was accessed with a guiding catheter 
allowing intracoronary infusions. Following placement of a flow-wire into the left 
circumflex coronary artery the responses to bolus infusions of 0.167, 0.33, and 1 
μg/kg adenosine were obtained. Steady state infusion of other AR-specific 
agents utilized a small catheter fed over the flow-wire in lean swine. Flow was 
increased by the nonselective A2R agonist CV1808 dose-dependently. No other 
AR subtype-specific agents changed baseline flow, except the highly A1R-
selective antagonist DPCPX, which increased baseline flow. The A2R antagonist 
DMPX and A2AR specific antagonist ZM241385 abolished adenosine-induced 
flow, while A2BR and A3R antagonism had no effect. Dyslipidemia and stenting 
decreased adenosine-induced flow ~70%, while A1R, A2AR, and A2BR mRNA 
were upregulated >5-fold in microvessels distal to the stent. Conclusions: In 
healthy Ossabaw swine A1R antagonism by DPCPX positively regulated 
coronary vasodilation under basal conditions. Impaired adenosine-induced flow 
Abstract 
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after stenting in dyslipidemia is most likely due to altered balance between A1R 
and A2AR signaling. 
 
3.2. 
 Adenosine contributes to maintenance of coronary blood flow, especially 
during cardiac ischemia 51, 136-138 and is used clinically to elicit maximal 
vasodilation to diagnose flow-limiting conduit artery stenosis and microvascular 
dysfunction 139. Four different subtypes of adenosine receptors (AR) have been 
cloned and pharmacologically characterized - A1R, A2AR, A2BR, and A3R 51. All 
are G-protein coupled and either inhibit (A1R/A3R, Gi/q) or stimulate (A2A/2BR, 
Gs) adenylyl cyclase 51. Adenosine predominantly dilates arterioles <100 µm in 
diameter 138 and the vasodilatory mechanism is not fully understood yet, but 
involves A2 receptor activation and consequent elevation of cAMP-dependent 
protein kinase (PKA), resulting in vasodilation mainly via opening of ATP-
sensitive K+ (KATP) channels 140, 141 and voltage-dependent K+ (Kv) channels 142, 
143. Since the A1R inhibit and A2R stimulate adenylyl cyclase 51, A1R antagonism 
could positively modulate coronary vasodilaton. Tawfik etc. 144 provided 
outstanding evidence for A1R regulation of coronary blood flow in an A1R 
knockout mouse, but surprisingly studies have not been done on A1R in large 
animals that more closely mimic human coronary physiology. 
Introduction 
 
 Deployment of a stent in a flow-limiting coronary atherosclerotic lesion 
results in substantial improvement in functional capacity and quality of life. 
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However, almost one third of patients undergoing coronary stenting eventually 
experience recurrent angina 99. It has been shown that coronary stenting induces 
downstream microvascular dysfunction that persists for weeks and has been 
implicated in causing exertional ischemia 56-60. Camici and Crea 60 termed this 
phenomenon post-stent “iatrogenic coronary microvascular dysfunction”, which 
may be due to enhanced alpha-adrenergic constriction 100, chronic impairment of 
microvascular response 57, 58, or microemboli that may cause microinfarcts 101. 
The mechanisms for microvascular dysfunction associated with stenting remain 
unclear and deserve careful study. This is especially important because drug-
eluting stents, which are the main treatment for flow-limiting coronary lesions, 
cause even greater microvascular dysfunction than bare metal stents 103, 104. 
 
 Dyslipidemic and metabolic syndrome patients displayed impaired 
adenosine receptor-mediated coronary flow reserve 60, 61, which has been shown 
convincingly in dyslipidemic swine models by in vivo flow measures 145. ARs may 
be responsible for the dysregulated adenosine-induced coronary flow in 
dyslipidemia. Recently, our lab made a novel discovery that A1R mediate 
mitogenic effects of adenosine in porcine coronary artery smooth muscle cells, 
while having minimal effects in aortic smooth muscle cells 65, 69, 70. Further, A2BR 
mediated antimitogenic effects in aortic, but not coronary, smooth muscle cells 
and the A2AR had no effect on mitogenesis in coronary and aortic cells 65-68. 
Thus, there is high specificity of AR functions that is dependent on AR subtype, 
vascular bed, species, etc. Since the vasodilatory effect of adenosine involves 
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A2R activation 140-143, we propose that A2R and A1R may contribute to impaired 
adenosine-induced coronary flow in longer duration dyslipidemia after stenting. 
 
 We tested two major hypotheses in the present study: 1) A1R antagonism 
potentiates coronary vasodilation in healthy Ossabaw swine, and 2) coronary 
stent deployment in dyslipidemic Ossabaw swine elicits impaired vasodilation to 
adenosine, which is associated with increased A1R/A2AR expression in the 
microvessels downstream from stented conduit arteries. 
 
3.3. 
3.3.1. Animal care and coronary stenting 
Methods  
 All protocols involving animals were approved by an Institutional Animal 
Care and Use Committee and complied fully with standards 105, 106. Ten control 
male Ossabaw swine (age 14±4 months) were fed a diet consisting of mini pig 
chow with 22% kcal from protein, 70% kcal from carbohydrates, and 8% kcal 
from fat. The data in Figure 3.1, Figure 3.2, and Figure 3.3 were all obtained from 
those pigs. Another ten male Ossabaw swine (age 14 months; n=5/group) were 
randomized to control or dyslipidemic groups in the stenting study. The data in 
Figure 3.4 and Figure 3.5 were obtained from the pigs in the stenting study. The 
atherogenic diet was composed of mini pig chow supplemented with (percent by 
weight): cholesterol 2.0, coconut oil 17, corn oil 2.5, and sodium cholate 0.7. This 
mixture yielded a diet of 13% kcal from protein, 40% kcal from carbohydrates and 
47% kcal from fat 107. Control and dyslipidemic groups were calorie-matched 
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(3200 kcal/day) for 43 weeks unti l sacrifice. After 40 weeks on the diets, control 
and dyslipidemic groups in the stenting study received a bare metal stent (2.5-4.0 
mm diameter by 8 mm length; Express2, Boston Scientific, Minneapolis, MN) in 
the circumflex coronary artery at stent/artery ratio of 1.0 with optimal inflation 
pressure and recovered for 3 weeks before sacrifice as described previously 11, 70, 
92, 109. Swine received 325 mg aspirin as antiplatelet therapy starting the day 
before the stenting and continuing for 3 weeks after stenting unti l completion of 
the study. Cephalexin (1000 mg) was given twice a day for six days following the 
stent procedure. All pigs were housed and fed in individual pens and provided a 
12-hr light/12-hr dark cycle. Water was provided ad libitum. 
 
3.3.2. Coronary blood flow 
 The pigs were pre-anesthetized using telazol/xylazine and maintained 
using 2-4% isoflurane with oxygen. Heart rate, blood pressure, respiratory rate, 
oxygen saturation, and electrocardiographic data were continuously monitored. 
The right femoral artery was accessed by surgical cut-down and an 8 F vascular 
introducer sheath was inserted followed by administration of heparin (200 U/kg). 
A Cordis 8 F Amplatz L (sizes 0.75-2.0) guiding catheter was advanced into the 
aortic arch and a guiding catheter was engaged with the ostium of the left main 
artery. A 0.014-inch diameter Doppler flow-wire (JoMed Inc., Rancho Cordova, 
CA) or combination pressure- and flow-wire (ComboMap, Volcano Therapeutics, 
Inc., Rancho Cordova, CA) was advanced down the circumflex artery under 
angiographic guidance and a non-branching section was selected for baseline 
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and drug-induced flow measurements 92, 107. Anatomical landmarks were noted in 
case the wire moves and requires re-positioning. In some of the pigs an 
intravascular ultrasound (IVUS; 3.2 F 30 MHz, Boston Scientific, Inc.) catheter 
was then advanced over the flow-wire and positioned in the circumflex to align 
the IVUS imaging transducer with the flow-wire tip to obtain accurate diameter 
measurement of the artery at the location where the flow velocity measurements 
were acquired 107 (Figure 3.1). For constant infusion of drugs the IVUS catheter 
was placed with only the tip in the most proximal circumflex and drugs were 
infused through the IVUS catheter. Flow velocity signals were allowed to stabilize 
for several minutes for determination of coronary blood flow (CBF) velocity 
responses. For the pigs with stent deployment, coronary blood flow analysis of in 
vivo microvascular function was done 3 weeks following stenting and in a non-
branching section of the circumflex artery proximal to the stent. 
 
 Hyperemia was induced with 3 mL bolus doses of the endothelium-
independent vasodilator adenosine (0.167, 0.33, and 1 µg/kg) given via the 
guiding catheter into the coronary artery as we described 107 and is identical to 
clinical catheterization assessment in humans 139. Adenosine injection was 
followed by 10 mL saline flush. Saline artifact was tested in each animal and, if 
present (usually less than 10% peak APV induced by adenosine), was subtracted 
from subsequent flow measurements following bolus. Peak average peak 
velocity (APV), heart rate, and blood pressure were recorded for each adenosine 
administration. Figure 3.1A shows baseline instantaneous CBF velocity 
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measures oscillating in systole and diastole during baseline (base; left) measures 
and at the peak response to adenosine. Each APV value was calculated on-line 
using the automated data acquisition system as an average of instantaneous 
CBF velocity over 2 consecutive cardiac cycles shown by the systolic (S) and 
diastolic (D) interval markers in Figure 3.1A. Subsequent doses of adenosine 
were administered only after APV, heart rate, and blood pressure had returned to 
baseline and stabilized, at which time the baseline parameters were again 
documented followed by the administration of the next adenosine dose. The 
effect of adenosine typically lasted 15-30 seconds (Figure 3.1A; right). 
 
 The adenosine A2R non-selective agonist CV1808 (10-6, 10-5, 10-4 M) was 
administered via bolus injection. The IVUS catheter was placed in the proximal 
circumflex in lean swine for steady state infusion of selected drugs to observe 
their effects over a relatively longer period of time (CCPA, 10-5 M, A1R-selective 
agonist, Tocris Science, Ellisville, MO; DPCPX, 10-4 M, A1R-selective antagonist, 
Tocris Science; DMPX, 10-4 M, A2R non-selective antagonist, Sigma, St. Louis, 
MO; ZM 241385, 10-7 M, A2AR-selective antagonist, Tocris Science; MRS 1706, 
10-7 M, A2BR-selective antagonist, Tocris Science; MRS 1220, 10-7 M, A3R-
selective antagonist, Tocris Science) at a rate of 1 mL/minute and was followed 
by concurrent bolus injection of adenosine. Vehicle control (1% DMSO) for 
DMPX was not used in parallel, which should be used for future experiments. 
The vehicle controls for other reagents were either water or phosphate-buffered 
saline. Continuous infusion of saline flush was done between each constant 
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infusion treatment to make sure the flow returns to baseline. The drug infusions 
were done in random order in each pig. 
 
 The analog Doppler signals were continuously digitized both as 
instantaneous CBF velocity and APV values. All flow data were stored on 
videotape and personal computer for further off-line analysis. Data are also 
expressed as percent APV increase, which equals to [peak APV-base APV] / 
base APV × 100. Volumetric CBF was calculated as: CBF (in mL/min) = (artery 
cross sectional area in cm2) × (velocity in cm/s) × 0.5 × 60 s/min 107. Vessel cross 
sectional area was calculated off-line from recorded IVUS images using the 
commercially available Sonos Intravascular Imaging software package. 
Angiography and IVUS showed no change in conduit artery diameter during any 
drug exposures, thus coronary flow velocity represented microvascular effects. 
 
3.3.3. Plasma lipid assays 
 Venous blood samples were obtained following overnight fasting and were 
analyzed for triglyceride and total cholesterol [fractionated into high density 
lipoprotein (HDL) and low density lipoprotein (LDL) components] 95. 
 
3.3.4. Real-time reverse transcription-polymerase chain reaction (Real-time RT-
PCR) 
 RNA was extracted from coronary microvessels downstream of left 
circumflex coronary artery using Trizol (Invitrogen, Carlsbad, CA, USA), then 
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treated with DNase (DNA free, Ambion, Austin, TX, USA) to remove 
contaminating genomic DNA, and analyzed by NanoDrop spectrophotometer 
(ND-1000; ThermoScientific, Wilmington, DE, USA) to assess purity (A260/280) 
and concentration. RNA (1 µg) was converted to cDNA using the iScript cDNA 
synthesis kit (Bio-Rad, Hercules, CA, USA) in a standard thermocycler (DNA 
Engine PTC-200, MJ Research, Waltham, MA, USA). A1R, A2AR, A2BR and 
A3R gene expression were assessed using quantitative real-time RT-PCR in an 
ABI 7500 instrument (Applied Biosystems, Foster City, CA, USA). Primers for 
PCR amplification were as follows:  
A1R:  forward, 5’-GGCCATGCTGGCAATTG-3’;  
  reverse, 5’-CCTGAGCGGGATCTTGACA-3’;  
A2AR:  forward, 5'-CCCCTTCATCTATGCCTACCG-3';  
  reverse, 5’-CATTCCCTCACACTCCCTCCAC-3';  
A2BR:  forward, 5'- TGTGCTGGCTGCCTCTTCAC-3';  
  reverse, 5'-ACACGATGGGGTTGACGACC-3';  
A3R:   forward, 5'-GAACCTCACCTTCCTTTCCTGC-3';  
  reverse, 5'-GAACTCCCGTCCATAAAATGC-3'  
(Integrated DNA Technologies, Coralville, IA, USA). Taqman probes were used 
to detect A1R gene amplification and were as follows: 5'-/6-
FAM/TCGACCGCTACCTCC/MGBNFQ/-3' (Applied Biosystems). SYBRGreen 
Universal PCR Master Mix (Applied Biosystems) was used to detect A2AR, 
A2BR and A3R gene expression followed by a dissociation curve to rule out non-
specific amplifications and primer-dimers. All results were normalized to the 
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signal of 18s RNA, which was amplified in separate reactions using TaqMan 
Universal PCR Master Mix and TaqMan 18s Detection Reagents (Applied 
Biosystems). 
 
3.3.5. Data Analysis  
 Data were presented as means ± SEM. Statistical analysis was performed 
using commercially available software (SPSS version 12 and Prism version 4.0). 
Means of more than 2 groups were compared by one way Analysis of variance 
(ANOVA) with Least Significant Difference (LSD) post-hoc analyses (by SPSS) 
or by 2 way ANOVA followed by Bonferroni post-test (which is the only option in 
Prism). Means of 2 groups were compared by student t-test (unpaired, two-tailed). 
In all cases, p < 0.05 was considered statistically significant. 
 
3.4. 
3.4.1. Metabolic characteristics of healthy control and dyslipidemic pigs with 
coronary stent deployment 
Results 
 Atherogenic diet resulted in significantly higher plasma total cholesterol, 
LDL, HDL, and LDL/HDL vs. healthy control pigs fed standard chow diet (Table 
3.1). There were no differences in body weight, plasma triglycerides, fasting 
insulin, fasting glucose (Table 3.1), or resting blood pressure (Table 3.2). The 
plasma lipids defined the atherogenic diet fed group as dyslipidemia, but not 
having metabolic syndrome. 
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3.4.2. Adenosine A2 receptors contribution to coronary blood flow 
 Instantaneous blood flow velocity shows classical oscillations with diastolic 
APV exceeding systolic APV (Figure 3.1A, left). A typical doubling of the APV 
and return to baseline in ~30 s in response to a bolus dose of adenosine (1.0 
µg/kg) is shown in Figure 3.1A (right). The A2R non-selective antagonist DMPX 
did not change base APV (Figure 3.1B), but abolished peak APV (Figure 3.1C) 
response to adenosine at 0.33 and 1.0 µg/kg doses. The A2R non-selective 
agonist CV1808 elevated percent APV increase ([peak APV-base APV] / base 
APV × 100) in a dose-dependent manner in the absence of exogenous 
adenosine (Figure 3.1D). The CV1808-induced percent APV increase at 10-4 M 
dose was comparable to adenosine-induced percent APV increase at 1.0 µg/kg 
dose, which was calculated from the base and peak APV in panel B and C. 
 
3.4.3. Adenosine A2A, A2B, and A3 receptors contribution to coronary blood flow 
 Figure 3.2 displays data as absolute blood flow in pigs in which conduit 
diameter was accurately measured with IVUS before flow measures. Bolus 
injection of adenosine in the presence of vehicle control increased peak CBF vs. 
base in a dose-dependent manner (Figure 3.2A). Continuous intracoronary 
infusion of the A2A-selective antagonist ZM241385 abolished the adenosine-
induced peak CBF (Figure 3.2E), while having no effect on baseline CBF (Figure 
3.2A and B). The A2BR-selective antagonist MRS1706 (Figure 3.2E) and A3R-
selective antagonist MRS1220 (Figure 3.2F) had modest effects on the 
  
68 
adenosine-induced peak CBF compared to ZM241385 and no effect on base 
CBF (Figure 3.2A, C, and D). 
 
3.4.4. Adenosine A1 receptors contribution to coronary blood flow 
 Constant infusion of the highly A1R-selective antagonist DPCPX 
increased base APV in the absence of exogenous adenosine and peak APV 
response to 1.0 µg/kg adenosine (Figure 3.3). The highly A1R-selective agonist 
CCPA did not alter base APV in the absence of exogenous adenosine nor alter 
peak APV response to adenosine (Figure 3.3). 
 
3.4.5. Comparison of coronary blood flow in control and dyslipidemic pigs 
undergoing stenting 
 There were no significant differences in hemodynamic characteristics 
across groups (Table 3.2), e.g. heart rate, mean arterial pressure, rate pressure 
product, and baseline coronary blood flow. The CBF (Figure 3.4) response to 
0.167, 0.33, and 1.0 µg/kg adenosine was decreased in dyslipidemic vs. healthy 
control pigs 3-week after stenting.  
 
3.4.6. Adenosine receptors expression in coronary microvessels in control and 
dyslipidemic pigs 3-week after the stent deployment 
A1R, A2AR, and A2BR mRNA in coronary microvessels downstream from the 
stented left circumflex coronary artery were upregulated >5-fold in dyslipidemic 
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compared to control pigs (Figure 3.5A-C). A3R mRNA was not different between 
groups (Figure 3.5D). 
 
3.5. 
 We present several key findings on adenosine regulation of coronary 
blood flow. First, adenosine-induced vasodilation was mediated almost 
exclusively by A2A receptors (A2AR) in Ossabaw swine. Second, adenosine A1 
receptors (A1R) antagonism augments vasodilatory effects of some vasodilators 
other than adenosine in porcine coronary microvessels under basal condition in 
vivo. Third, bare metal stent deployment in conduit coronary arteries and 
dyslipidemia in Ossabaw swine elicited microvascular dysfunction, which was 
associated with increased A1R and, paradoxically, increased A2AR and A2BR 
expression. Collectively, these data emphasize the delicate balance between 
A1R and A2AR signaling in control of coronary blood flow in the setting of 
stenting and dyslipidemia. 
Discussion 
 
 Interestingly, there is variance in peak APV response to exogenous 
adenosine among different animals. Peak APV response to adenosine was 
partially blunted in Figure 3.3 vs. Figure 3.1C, which coincided with some human 
studies 146. It was suggested that varied potencies of adenosine-induced dilations 
among patients resulted in inconsistent potency of dilations between figures 146. It 
is possible that among Ossabaw swine there were variable potencies of dilation 
in response to adenosine due to differences in age, genetic background, relative 
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health status, etc. Therefore, the inconsistency in dilation potencies to adenosine 
could lead to variations in response to adenosine between figures (Figure 3.1C 
and Figure 3.3) 
 
It was reported that adenosine was a vasodilator in porcine coronary 
microcirculation via activation of A2AR 147-149. A2BR was suggested to mediate 
vasodilation of adenosine in human small coronary arteries 150, rat coronary 
circulation 151 and murine heart 149, 152. A3R either inhibited or negatively 
modulated the vasodilatory effect of adenosine in mouse coronary circulation 153. 
Studies in pigs 154 and humans 146 demonstrate A1R mRNA and protein 
expression in coronary arterioles. In our current study, the non-selective A2R 
antagonist DMPX did not change base APV (Figure 3.1B); therefore, A2R were 
not tonically activated under normal, baseline conditions. The A2AR-selective 
antagonist ZM241385 decreased peak CBF induced by exogenous adenosine 
(Figure 3.2E), while MRS1706 and MRS1220 showed relatively little effect 
(Figure 3.2E and F), thus providing evidence that mainly A2AR mediates 
vasodilatory effects of exogenous adenosine in Ossabaw swine. The highly A1R-
selective antagonist DPCPX increased base APV in the absence of exogenous 
adenosine (Figure 3.3), indicating A1R antagonism by DPCPX might potentiate 
vasodilatory effects of some physiologically active vasodilators other than 
adenosine. In contrast, the highly A1R-selective agonist CCPA did not change 
APV whether in the absence or presence of exogenous adenosine. There are 
several possible reasons for that. First, CCPA effect could be masked by 
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endogenous adenosine. Since the binding affinity of adenosine for A1R is higher 
than A2R, and the desensitization of A1R is much slower than A2R (t1/2 = 10 
hours vs. 20 minutes) 155, it could be that tonically A1R was activated by 
adenosine while A2R was not. Second, we used 10-5 M CCPA for steady state 
intracoronary infusion (1 mL/min), which was di luted by continuous coronary 
blood flow (~20 mL/min) and might not be effective enough to regulate coronary 
flow. Research done in the isolated hearts from A1R knockout and wild type mice 
showed that at higher (10-5 M) instead of lower concentration (10-9-10-7 M) CCPA 
increased coronary blood flow 144. Intracoronary infusion of CCPA at different 
concentrations may help to address that. 
 
 Our data support the A1R antagonism-mediated porcine coronary 
vasodilation, consistent with research done by Pelleg etc. 156 in canine heart and 
Tawfik etc. in A1R knockout mouse heart 144. However, Hein etc. 147 suggested 
that A1R are not functionally significant in porcine microvessels, since A1R 
blockade did not alter arteriolar dilation to adenosine, consistent with other 
reports that A1 antagonism did not affect adenosine induced vasodilatation in 
swine heart 141, 154. There are several possible reasons for the discrepancies 
regarding the role of A1R in adenosine-induced CBF, e.g. the difference in 
experimental design, animal species, and developmental state. A major factor is 
that Hein etc. 147 used healthy, juvenile domestic pigs, while we used sexually 
mature adult Ossabaw pigs that are predisposed to metabolic syndrome 11, 70, 92, 
142, 157. Another very important factor for explanation of the difference is the 
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experimental preparation. Our studies and others were done in vivo 144, 156, whi le 
other studies used isolated coronary arterioles in vitro 141, 147, 154. It is clear that in 
vitro manipulation cannot always be applied directly to in vivo conditions. The 
local environment changes once arterioles are isolated from the live animals and 
the drug dose response and time course can be different between in vivo and in 
vitro studies. Most importantly, the systemic metabolic feedback and sympathetic 
feedforward network system can be lost by isolation from the integrated system. 
We feel more confident in our in vivo study compared to those in vitro studies, 
although in vitro experiments usually can provide us more flexibility and 
possibility of manipulation. 
 
 Based on our current studies, A2R were not tonically activated under 
normal, basal conditions, which did not support a role of adenosine in 
maintenance of CBF under basal conditions. This finding was echoed by 
numerous studies done under basal conditions and in exercise hyperemia in the 
normal heart of dogs, swine, or humans 136, 138, 158-160. However, adenosine plays 
an important role in coronary vasodilation when the myocardium is ischemic or 
hypoxic and abundant adenosine release arises 136, 138, 146, 160, 161. 
 
 Ossabaw swine are predisposed to metabolic syndrome 11, 70 and possible 
coronary microvascular dysfunction compared to other animal models. 
Dyslipidemia in the present study was manifested as described previously 11, 92, 
142, 157. Interestingly, A1R, A2AR, and A2BR genes were all upregulated in 
  
73 
coronary microvessels distal to the stent in dyslipidemic swine (Figure 3.5). The 
A2BR gene upregulation was reported in ischemic mouse heart 162. We made a 
novel discovery that A1R was upreguated in microcirculation downstream from 
the stent in dyslipidemia. Why did adenosine-induced CBF decrease in the 
presence of A2AR and A2BR gene upregulation? There are several possible 
explanations. First, receptor mRNA does not correspond directly to receptor 
protein. Also, receptor protein, i.e., A2AR and A2BR, may not function normally, 
especially under the influence of stenting and dyslipidemia. Second, the most 
important reason could be that the affinity of adenosine for A1R is higher than 
A2R, and the desensitization of A1R is much slower than A2R (t1/2 = 10 hours vs. 
20 minutes) 155. The net result is greater coupling of A1R to adenosine, while less 
coupling of A2R to adenosine, to regulate CBF. Since A1R gene expression 
increased in coronary microcirculation in stented, dyslipidemic pigs and A1R 
could have been occupied with high affinity by adenosine, A1R activation 
possibly overcame the vasodilatory effect of adenosine mediated by A2R in case 
of possible elevated adenosine in stenting and dyslipidemia. Third, some other 
factors besides adenosine receptors are responsible for adenosine-induced 
vasodilation, e.g., KATP channels, prostaglandins, etc. 138. It could be that A1R but 
not A2R are negatively linked to those factors in regulation of adenosine-induced 
flow, which deserves further study in the Ossabaw swine. 
 
 To our knowledge, this is the first study examining the effects of stenting 
on coronary microcirculation in a porcine model of dyslipidemia. Stenting and 
  
74 
early dyslipidemia are two possible causes for the dysregulation of adenosine-
induced CBF in dyslipidemic Ossabaw swine after 3-week stent deployment 
(Figure 3.4). Despite the findings that adenosine receptor-mediated coronary flow 
was impaired in dyslipidemic and metabolic syndrome patients 60, 61, as well as in 
dyslipidemic swine models 145, previous study in our lab 107 showed that diabetic 
dyslipidemia in Yucatan pigs did not cause microvascular dysfunction 
(0.05<p<0.1). Coronary stenting has been shown to mechanically damage 
vascular cells in the target conduit artery segment and endothelium in peri-stent 
segments 55, and induces downstream microvascular dysfunction 56-60. However, 
none of those studies were done in a swine model of dyslipidemia prone to 
metabolic syndrome and the microcirculation dysfunction was either attributable 
to endothelium 56 or unclarified 57-59. Further studies are needed to clarify 1) 
whether dyslipidemia or stenting alone or the combinations of those two are the 
cause for the impaired adenosine-induced flow in the setting of dyslipidemia and 
stenting, and 2) which adenosine receptors are responsible for the flow 
dysregulation. 
 
 We conclude that A1R antagonism by DPCPX might promote vasodilation 
induced by some vasodilators other than adenosine in “healthy”, anesthetized 
Ossabaw swine. An imbalance of A1R/A2AR upregulation and signaling in 
coronary microcirculation distal to a stent may be responsible for the 
dysregulated adenosine-induced CBF in dyslipidemia. The use of novel 
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adenosine analogs for vasodilation in the diseased condition deserves further 
pharmacological and mechanistic study. 
 
3.6. 
 The authors thank James Byrd and James W. Wenzel for their excellent 
technical assistance. This work was supported by National Institutes of Health 
[grants RR013223, HL062552] to M.S.; Boston Scientific, Inc.; Research Animal 
Angiography Laboratory of Indiana Center for Vascular Biology & Medicine; 
Purdue-Indiana University Comparative Medicine Program; Fortune-Fry 
Ultrasound Research Fund; Indiana University School of Medicine Translational 
Research Fellowship to J.M.E. and Z.P.N.; National Institutes of Health 
Translational Research Fellowship [grant UL1 RR025761] to Z.P.N.; and an 
American Heart Association Predoctoral Fellowship to X.L. 
Acknowledgments  
 
3.7. 
Figure 3.1. Vasodilation effect of adenosine mediated by adenosine A2 receptors 
(A2R) 
Figure legends 
A. Left panel, instantaneous coronary blood flow velocity (cm/s) responses to 
adenosine during diastole and systole. Base and peak are indicated at the 
bottom. The start of systole (S) and diastole (D) are indicated by the horizontal 
lines. Right panel, typical average peak coronary blood flow velocity (APV, cm/s) 
response to 1.0 µg/kg adenosine vs. time; B-baseline APV, S-time for starting the 
search for adenosine-induced peak APV, P-peak APV in response to 1.0 µg/kg 
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adenosine. B, C. Effects of continuous intracoronary infusion of A2R non-
selective antagonist DMPX on base APV (B) and peak APV (C) during 
concurrent bolus injection of 0, 0.167, 0.33, or 1.0 µg/kg adenosine (n=5). Flow 
signal was measured with an intracoronary flow-wire placed under the guidance 
of coronary angiogram as described in methods section. D. Effects of 
intracoronary bolus injection of the A2R non-selective agonist CV1808 on 
percent APV increase (percent APV increase = [peak APV-base APV] / base 
APV × 100; n=5). Ado only means pure adenosine dose response, Ado+DMPX 
means adenosine dose response with concurrent continuous infusion of DMPX. *, 
p<0.05; #, p<0.001, vs. Ado only at corresponding dose or as indicated by lines.  
 
Figure 3.2. Adenosine A2A receptors (A2AR), not A3R, contributed to adenosine-
induced vasodilation 
Base and peak coronary blood flow measurement in typical adenosine dose 
responses was done in control animals (n=5) as described in Figure 3.1, except 
that conduit diameter measures enabled calculation of volumetric blood flow. 
Effects of continuous intracoronary infusion of vehicle control (A), A2AR-selective 
antagonist ZM241385 (B), A2BR-selective antagonist MRS1706 (C), or A3R-
selective antagonist MRS1220 (D) on base and peak coronary blood flow during 
concurrent bolus injection of adenosine at 0.167, 0.33, or 1.0 µg/kg were 
depicted. Peak CBF was compared between A2A/2BR antagonism (E) or A3R 
antagonism (F) and vehicle control. * denotes p<0.05, # p<0.001, peak vs. base 
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CBF (A-D), or ZM241285 vs. vehicle control (E) at corresponding adenosine 
doses. 
 
Figure 3.3. Contribution of adenosine A1 receptor (A1R) to coronary blood flow  
Highly A1R-selective agonist CCPA, A1R-selective antagonist DPCPX, or vehicle 
control was constantly infused through an intracoronary catheter. After coronary 
blood flow was stabilized, base average peak velocity (APV) was measured 
(n=10). Concurrent bolus injection of adenosine at 0.167, 0.33, or 1.0 µg/kg was 
done afterwards and flow signal was measured as in Figure 3.1. Effects of CCPA 
and DPCPX on peak APV upon adenosine bolus injection was depicted vs 
vehicle control. *, p<0.05 vs. vehicle control at corresponding adenosine dose or 
at baseline. 
 
Figure 3.4. Adenosine induced coronary flow in control and dyslipidemic pigs 
undergoing stenting 
Flow signal was measured in a non-branching section of the left circumflex 
coronary artery in control and dyslipidemic pigs 3-week after stenting (n=5/group). 
Bolus injection of adenosine at 0.167, 0.33, or 1.0 µg/kg was done as in Figure 
3.2 to elicit peak CBF response. Change of CBF means peak CBF-base CBF. * 
indicates p<0.05 vs. control. 
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Figure 3.5. Adenosine receptors expression in coronary microvessels in control 
and dyslipidemic pigs 3-week after the stent deployment 
Gene expression levels of A1R, A2AR, A2BR, and A3R in panels A, B, C, and D, 
respectively, were determined by real-time RT-PCR in mRNA isolated from 
coronary microvessels distal from stented coronary conduit segments in control 
and dyslipidemic pigs (n=5/group). *, p<0.05 vs. control. 
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3.8. 
Figure 3.1. Vasodilation effect of adenosine mediated by adenosine A2 receptors 
(A2R) 
Figures 
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Figure 3.2. Adenosine A2A receptors (A2AR) not A3R contributed to adenosine 
induced vasodilation 
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Figure 3.3. Contribution of adenosine A1 receptor (A1R) to coronary blood flow 
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Figure 3.4. Adenosine induced coronary flow in control and dyslipidemic pigs 
undergoing stenting 
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Figure 3.5. Adenosine receptors expression in coronary microvessels in control 
and dyslipidemic pigs 3-week after the stent deployment 
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3.9. 
Metabolic panel 
Tables 
Control Dyslipidemic p value 
Body weight (kg) 74 ± 2 76 ± 2 >0.05 
Fasting plasma glucose 
(μU/mL) 74 ± 4 86 ± 5 >0.05 
Fasting plasma insulin 
(mg/dL) 7 ± 1 10 ± 2 >0.05 
Total cholesterol (mg/dL) 62 ± 3 299 ± 33 0.0003 
LDL (mg/dL) 24 ± 2 216 ± 34 0.001 
HDL (mg/dL) 34 ± 1 73 ± 12 0.01 
Triglycerides (mg/dL) 19 ± 3 45 ± 12 0.06 
LDL/HDL 0.7 ± 0.1 3.6 ± 1.1 0.007 
Table 3.1. Metabolic data from control and dyslipidemic pigs with stent 
deployment. 
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Hemodynamics Control Dyslipidemic p value 
HR (bpm) 101 ± 4 109 ± 4 0.57 
SBP (mm Hg) 75 ± 3 76 ± 3 0.78 
DBP (mm Hg) 53 ± 3 53 ± 3 0.86 
MAP (mm Hg) 60 ± 3 61 ± 3 0.84 
RPP (bpm*mm Hg) 7610 ± 820 8340 ± 820 0.54 
CBF (mL/min) 46 ± 7 42 ± 6 0.68 
CSA (mm2) 10 ± 1 9 ± 1 0.33 
Table 3.2. Hemodynamic characterics comparison during coronary blood flow 
measures in control and dyslipidemic pigs 3-week after stenting. 
HR = heart rate, SBP = systolic blood pressure, DBP = diastolic blood pressure, 
MAP = mean arterial pressure, RPP = rate pressure product, CBF = coronary 
blood flow, and CSA = vessel cross sectional area. 
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4.1. 
 Background: Coronary artery disease (CAD) is increased several-fold in 
metabolic syndrome (MetS) and is attenuated by exercise training. We found the 
adenosine A1 receptor (A1R) paradoxically mediates mitogenic effects of 
adenosine in cultured coronary smooth muscle cells, suggesting A1R 
dysregulation could contribute to CAD. Aldosterone is increased in MetS, but the 
cellular and molecular mechanisms underlying aldosterone actions on the 
vascular wall are unclear. We utilized the Ossabaw miniature swine model of 
MetS and CAD and in vitro models of CAD to test the hypothesis that 
aldosterone regulation of A1R contributes to CAD in MetS and all are attenuated 
by exercise training. Methods and Results: Lean swine were fed standard chow 
and sedentary MetS and exercise trained MetS (XMetS) fed excess calorie 
atherogenic diet for 14 months (n=5/group). Exercise training was 4 d/wk, 30 
min/d, at 65-75% maximum heart rate for 7 wk before sacrifice. MetS exhibited 
all MetS characteristics and none were attenuated in XMetS. MetS had the 
greatest CAD, aldosterone, and A1R mRNA and protein, which were all 
attenuated in XMetS. Aldosterone upregulated A1R mRNA and protein 
expression in subcultured coronary smooth muscle cells. A1R antagonism 
blocked the increase in medial collagen content in organ culture. Aldosterone 
further increased medial collagen and aldosterone antagonism partially abolished 
the effect. Conclusions: Aldosterone regulation of A1R in vitro promotes CAD 
and in vivo in MetS is associated with coronary atherosclerosis and may 
Abstract 
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contribute to the exercise training-induced attenuation of coronary 
atherosclerosis. 
 
Key Words: adenosine, mineralocorticoid receptor, exercise, Ossabaw miniature 
swine, spironolactone  
 
4.2. 
 Metabolic syndrome (MetS; “pre-diabetes”) affects approximately 27% of 
the U.S. adult population, and is defined as the combination of any three of the 
following abnormalities: central obesity, dyslipidemia, hypertension, impaired 
glucose tolerance, and insulin resistance 34. Coronary artery disease (CAD), the 
leading cause of death in westernized societies, is increased greatly in patients 
with MetS 28-33. Therefore, it is important to delineate cellular and molecular 
mechanisms underlying coronary atherosclerosis in the setting of MetS.  
Introduction 
 
 Phenotypic switching of vascular smooth muscle cells (SMC) from a 
healthy contractile phenotype to a proliferative (synthetic) phenotype is a pivotal 
event in CAD 1, 9, 62-64. SMC contribute to atherosclerotic and fibrotic lesions also 
through the formation of extracellular matrix, including collagen 1, 9, 14, 62, 63. 
Adenosine has been widely shown to elicit coronary vasodilation and attenuate 
SMC proliferation via adenosine A2A/B receptors, thereby providing 
cardioprotection 54, 65-68. Adenosine A1 and A3 receptors are the other 2 
adenosine receptor (AR) subtypes cloned and pharmacologically characterized 
  
89 
so far 51. A pivotal study from our lab demonstrated a trophic effect of adenosine 
in porcine coronary SMC mediated by the A1R 65, 69. In addition, A1R expression 
was upregulated in stented coronary segments compared to non-stented 
segments in our swine model 70, thus suggesting A1R dysregulation could play a 
role in CAD. 
 
 Renin-angiotensin-aldosterone system (RAAS) blockade exerts potent 
anti-atherosclerotic effects, not only through antihypertensive actions, but also 
through anti-inflammatory, anti-proliferative, and antioxidant properties 44, 163. 
Aldosterone is synthesized in the adrenal cortex in response to angiotensin II 
stimulation 164. Aldosterone antagonism prevented aortic SMC proliferation and 
vascular inflammation induced by angiotensin II 72, 164-166. Clinical studies showed 
aldosterone antagonism reduced morbidity and mortality in patients with heart 
failure or after myocardial infaction 167, 168, consistent with beneficial effects of 
angiotensin converting enzyme inhibitors and angiotensin receptor blockers in 
recent clinical trials 169, 170. Despite all these exciting findings, the molecular 
mechanisms underlying aldosterone proatherogenic effects remain elusive to us. 
 
 Aldosterone, a steroid hormone, binds to the mineralocorticoid receptor 
(MR), a ligand-activated transcription factor 164. The MR belongs to the steroid 
receptor family that includes the glucocorticoid receptor 46. Glucocorticoid 
receptor activation stimulated A1R gene expression in Chinese hamster ovary 
cells 74, DDT1 MF-2 SMC 75, and rat brain 76. Both aldosterone and A1R regulate 
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vascular SMC proliferation via activation of mitogen activated protein kinase in 
vitro 65, 69, 72, 73. MR and glucocorticoid receptors share extensive sequence and 
structural organization similarities 77, therefore MR activation by aldosterone 
could potentially regulate A1R expression, thereby contributing to coronary 
atherosclerosis. Finally, since elevated plasma aldosterone is a hallmark of 
“obesity hypertension” 71, the systemic milieu in MetS seems to be an ideal 
stimulus for atherosclerosis. 
 
 Our group has developed Ossabaw miniature swine as an excellent large 
humanoid animal model of MetS. When fed excess calorie atherogenic diet, 
Ossabaw swine develop MetS 11, 92, 95, 96 and, like humans (but different from 
many other laboratory animal models) develop CAD 11, 92, 95, 97. Organ culture is a 
useful in vitro model of coronary atherosclerosis which manifests increased 
neointimal thickness, collagen content and cellular proliferation 65, 171-175, which 
are common features of atherosclerosis 1, 9, 14, 62, 63. 
 
 Exercise training of patients with CAD elicits beneficial effects, including 
improvement in exercise tolerance, left ventricular function, etc. 18. Fleenor and 
Bowles 27 showed that long-term exercise training of pigs with normal plasma 
cholesterol attenuated conduit artery neointimal proliferation and collagen 
expression elicited by overexpansion injury from balloon angioplasty and we 
showed that exercise training decreased collagen in stented coronary arteries 11. 
However, the beneficial effects of exercise on systemic aldosterone, coronary 
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A1R expression, and native atherosclerosis in MetS have never been explored to 
our knowledge. 
 
 The purpose of this study was first to test the hypothesis that plasma 
aldosterone and A1R are increased in CAD in MetS and whether exercise 
training reverses this effect. A second hypothesis is that aldosterone regulates 
A1R expression, thereby contributing to CAD via A1R upregulation in the in vitro 
organ culture model of coronary atherosclerosis. Using our novel in vivo MetS 
swine and in vitro organ culture models, we clearly show for the first time a 
strong association and causal role, respectively, of aldosterone regulated A1R in 
the development of CAD in vivo and in vitro. Exercise attenuation of plasma 
aldosterone elevation, A1R upregulation in atheroma, and CAD strongly supports 
exercise and antagonism of MR and A1R as treatments for CAD in MetS. 
 
4.3. 
4.3.1. Animal care 
Methods 
 All protocols involving animals were approved by an Institutional Animal 
Care and Use Committee and complied fully with recommendations in the Guide 
for the Care and Use of Laboratory Animals 105 and the American Veterinary 
Medical Association Panel on Euthanasia 106. Male Ossabaw swine (age 20±2 
months at sacrifice) were assigned to 3 different diet groups for 14 months, 5 in 
each group and were a subset of another study 11. Lean control swine were fed 
were fed standard chow containing 22% kcal from protein, 70% kcal from 
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carbohydrates, and 8% kcal from fat (5L80; Purina TesDiet, Richmond, IN). 
Sedentary MetS and exercise trained (XMetS) groups were fed a high fat / 2% 
cholesterol atherogenic diet composed of lean chow supplemented with (percent 
by weight): cholesterol 2.0, hydrogenated soybean oil 16.7 (56% trans fatty 
acids), corn oil 2.5, and sodium cholate 0.7. This mixture yielded a composition 
of 11% kcal from protein, 43% kcal from carbohydrates and 46% kcal from fat. 
Pigs in the lean group ate 2500 kcal/day. Atherogenic diet groups ate 6000 
kcal/day unti l sacrifice. All animals were housed in individual pens and provided a 
12-hr light / 12-hr dark cycle. Water was provided ad libitum. 
 
4.3.2. Exercise training 
 Animals randomized to the exercise group began treadmill training 7 
weeks before sacrifice as described 11. During the first week of training, the 
exercise pigs ran on the treadmill at 4 mph (endurance) with 0% grade for 20-30 
minutes and at 5.6 mph (sprint) for 15 minutes. After acclimation a typical daily 
45 minute training session continued over the course of the following 6 weeks. 
The training consisted of the following stages: 1) 5 minute warm-up at 2.2 mph, 2) 
5 minute sprint at speeds of 6.1 mph, 3) 30 minute endurance run at 7.7 mph, 
and 4) 5 minute cool down at 3.5 mph. Exercise protocols were compliant with 
guidelines from the American Physiological Society 108. 
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4.3.3. Submaximal stress test 
 At weeks 1, 4, and 7 of exercise training the endurance trained animals 
underwent a submaximal stress test consisting of running on a treadmill at 3.1 
MPH, 0% grade for 15 minutes at which point heart rate data were collected.  
 
4.3.4. Intravenous glucose tolerance test (IVGTT) 
 Swine were acclimatized to restraint in a specialized sling for 5-7 days 
before the IVGTT was conducted. Following percutaneous catheterization of the 
right jugular vein under isoflurane anesthesia 11, 92, 95, swine were allowed to 
recover for 3 hours before the IVGTT to avoid any effect of isoflurane on insulin 
signaling 176. Conscious swine were restrained in the sling and baseline blood 
samples were obtained. Dextrose (1 g/kg body weight) was administered 
intravenously and timed blood samples were collected 176.  
 
4.3.5. Cardiac catheterization procedures 
 Cardiac catheterization, angiography, and intravascular ultrasound (IVUS) 
were performed as previously described at sacrifice (detailed description in the 
online supplemental materials) 11, 70, 92.  
 
4.3.6. Intravascular ultrasound analysis 
 Native atheroma was quantified as percent circumferential lumen wall 
coverage. Each cross-sectional IVUS image was divided into 16 equal radial 
segments, and percent circumferential wall coverage was calculated as (# radial 
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segments containing atheroma ÷ 16) x 100 %. Images were captured every 1 
mm along the whole pullback length of IVUS and 8 images quantified and 
averaged for each coronary segment 11, 70, 92. 
 
4.3.7. Histological analysis 
 Masson's trichrome stains were performed on phosphate buffered 
formalin-fixed and paraffin-embedded sections of organ cultured arteries. Images 
were captured at × 10 magnification with a Nikon CoolPix 990 (3.34 MegaPixel) 
digital camera attached to a Nikon Diaphot inverted microscope with a CoolPix 
MDC optical adapter (Nikon, Melvi lle, NY, USA). Masson’s trichrome stain was 
used to assess collagen content in the media, determined by colorimetric 
analysis using Image Pro Plus v.4.1 software (Media Cybernetics, Silver Springs, 
MD, USA) and calculated as (collagen staining area / total area) × 100% 10, 11. 
 
4.3.8. Cell culture 
 Porcine coronary artery SMC enzymatically dispersed from right coronary 
arteries of Ossabaw pigs were cultured as previously described in our laboratory 
65, 69, 177. SMC lineage was confirmed by smooth muscle α actin 
immunocytochemistry. Stock coronary artery SMC cultures were maintained in a 
subconfluent state and used between passage 4 and 10 177. Cells were serum 
starved for 24 hours before treatment with vehicle control, aldosterone or 
spironolactone. Vehicle control, aldosterone, and spironolactone were 
replenished every 24 hours. 
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4.3.9. Real-time reverse transcription-polymerase chain reaction (Real-time RT-
PCR) 
 Primers for PCR amplification of A1R were designed from the pig A1R 
sequence (GenBank accession number AY772411) using Primer Express 
software (Applied Biosystems, Foster City, CA, USA) (detailed description in the 
online supplemental materials). 
  
4.3.10. Western blotting for A1R, proliferating cell nuclear antigen (PCNA), and 
p-ERK1/2 
 Coronary artery segments were pretreated with 10-6 M CCPA at 37° C for 
5 minutes, then lysed and western blotted for A1R (rabbit polyclonal antibody; 
1:1000 dilutions; Abcam, Cambridge, MA, USA), PCNA (mouse monoclonal 
antibody; 1:1000 dilutions; Cell Signaling, Danvers, MA, USA) and p-ERK1/2 
(mouse monoclonal antibody; 1:1000 dilutions; Cell Signaling). Membranes were 
stripped and re-probed with anti-GAPDH (1:1000; Fitzgerald, Concord, MA, USA; 
for A1R and PCNA) or anti-total ERK1/2 (1:1000 dilutions; Cell Signaling). For 
coronary SMC lysis, the same protocol was used as in tissues, except there was 
no CCPA treatment for cells (detailed description in the online supplemental 
materials). 
 
4.3.11. In vitro organ culture model of atherosclerosis 
 Freshly isolated right coronary arteries from lean Ossabaw swine were cut 
into 2-4 mm segments and cultured for 36 hours, 2 or 4 days in a humidified 5% 
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CO2 incubator at 37° C in RPMI Medium 1640 (Invitrogen, Carlsbad, CA, USA) 65, 
70, 171-173. Medium was supplemented with 10-6 M 2-Chloro-N6-
cyclopentyladenosine (CCPA, TOCRIS, Ellisville, MO, USA), 10-5 M 8-
Cyclopentyl-1, 3-dipropylxanthine (DPCPX, TOCRIS), 10-7 M aldosterone (Sigma, 
St. Louis, MO, USA), or 10-7 M spironolactone (Sigma) as needed. 
 
4.3.12. Blood analysis 
 Venous blood samples were obtained following overnight fasting. Blood 
glucose was measured using YSI 2300 STAT Plus Glucose analyzer. Plasma 
insulin assays were performed by Linco Research Laboratories (St. Charles, MO, 
USA) 95. Plasma lipid assays were done using Infinity lipid kit (ThermoFisher 
Scientific, VA, USA) and a manganese precipitate method validated for swine 
plasma 95. Aldosterone was determined in heparinized plasma by 
radioimmunoassay by Dr. J. Howard Pratt’s laboratory at Indiana University 
School of Medicine 178. 
 
4.3.13. Statistics 
 Data were presented as mean ± SEM. Statistical analysis was performed 
using commercially available software (SPSS version 12, Prism version 4.0). 
Means of 2 groups were compared using Student t test (unpaired, two tailed). 
Means of more than 2 groups were compared using Kruskal–Wallis one-way 
analysis of variance (ANOVA) followed by post-hoc testing using Least-
  
97 
Significant-Difference test. Correlation and linear regression analysis were done 
between different parameters. P<0.05 was considered statistically different. 
 
4.4. 
4.4.1. Phenotypic comparison between Lean, MetS, and XMetS pigs 
Results 
 Following 14 months of feeding body weight, fasting plasma insulin, 
fasting plasma glucose, total cholesterol, LDL, HDL, LDL/HDL, triglycerides, 
mean blood pressure, and plasma aldosterone were all significantly elevated in 
MetS and Pre-X XMetS (XMetS before the initiation of 7-week exercise training) 
vs. Lean. Among those factors, only LDL/HDL and plasma aldosterone were 
significantly reduced by 7-week exercise training in Post-7Wk-X XMetS (XMetS 
after 7-week exercise training) vs. MetS and Lean (Table 4.1). 7-week exercise 
training reduced resting heart rate as well as the heart rate response to 
submaximal stress test (data not shown). 
 
4.4.2. Comparison of native coronary atherosclerosis, A1R, and PCNA 
expression in Lean, MetS, and XMetS pigs  
 IVUS analysis done in vivo in left circumflex coronary in Lean, MetS, and 
XMetS at sacrifice revealed profound native coronary atheroma in MetS vs. Lean 
and attenuation in XMetS to Lean levels (Figure 4.1A, B). Intact coronary 
atherosclerotic segments harvested at sacrifice showed A1R mRNA (Figure 
4.1C), A1R (Figure 4.1D, E), and PCNA (Figure 4.1D, F) proteins were all 
elevated in the native coronary atherosclerotic lesions of MetS vs. Lean. A1R 
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expression decreased in XMetS 7-week post-exercise based on real-time RT-
PCR (Figure 4.1C) and quantitative analysis of immunoblots (Figure 4.1E). 
 
4.4.3. Correlation among plasma aldosterone, A1R, and PCNA 
 To explore possible interactions among different systemic, local factors, 
and coronary atheroma in lean, MetS and XMetS, different combinations were 
used for correlation analysis (Figure 4.2). Plasma aldosterone significantly 
correlated to A1R in native coronary atherosclerotic segments (Figure 4.2A). And 
A1R correlated to PCNA in coronary segments with atheroma (Figure 4.2B). 
 
4.4.4. Aldosterone upregulation of A1R expression 
 Subcultured coronary artery SMC isolated from healthy lean Ossabaw 
right coronary arteries were treated with aldosterone, aldosterone + 
spironolactone (mineralocorticoid receptor antagonist), or vehicle control for 12, 
24, and 36 hours. Both A1R mRNA (Figure 4.3A) and protein (Figure 4.3B) were 
upregulated by aldosterone treatment at the 36-hour treatment. Interestingly, at 
36-hour time point A1R mRNA upregulation was partially attenuated by 
spironolactone (Figure 4.3A), but A1R protein (Figure 4.3B) was not altered by 
spironolactone although there seemed a trend toward decrease of A1R protein 
by spironolactone. 
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4.4.5. A1R expression, collagen, and A1R-ERK1/2 activity in the in vitro organ 
culture model of early coronary atherosclerosis 
 To carry out more manipulations of the factors and proteins, an in vitro 
organ culture model of early coronary atherosclerosis was uti lized to mimic in 
vivo coronary atherosclerosis. A1R gene, protein expression and exogenous 
ERK1/2 activation (CCPA-induced ERK1/2 activation; highly A1R-selective 
agonist CCPA) were assessed in organ cultured coronary artery segments over 
time vs. freshly harvested coronary segments. Masson’s trichrome stain for 
collagen revealed increased medial collagen content at 4-day organ culture 
(Figure 4.4A). A1R mRNA was upregulated transiently in 2-day organ culture and 
returned to the level of fresh arteries by 4-day based on real-time RT-PCR 
analysis (Figure 4.4B). A1R protein (Figure 4.4C) and exogenous A1R-mediated 
ERK1/2 activation (Figure 4.4D) were elevated at 4-day organ culture.  
 
4.4.6. A1R antagonism and aldosterone treatment in the in vitro organ culture 
model of early coronary atherosclerosis 
 To define the role of A1R in early coronary atherosclerosis in vitro, the 
highly A1R-selective agonist CCPA and antagonist DPCPX were used in the 4-
day organ culture model and followed by histological analysis to assess their 
direct effects. Organ cultured coronary segments with vehicle control or CCPA 
treatment showed increased medial collagen content vs. fresh coronary 
segments and no difference between vehicle control and CCPA treatment. 
Segments supplemented with DPCPX or CCPA and DPCPX concurrently 
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showed comparable medial collagen content vs. fresh (Figure 4.5A). To test 
whether aldosterone affects the atheroma development via regulation of A1R in 
vitro, 4-day organ culture model was employed (Figure 4.5B). Organ cultured 
coronary segments with vehicle control had increased medial collagen content vs. 
fresh and segments supplemented with aldosterone had further increased 
collagen content vs. vehicle control. Aldosterone plus spironolactone or 
aldosterone plus DPCPX showed less medial collagen content vs. aldosterone 
alone, similar content vs. vehicle control, and greater content vs. fresh (Figure 
4.5B). There was no difference between aldosterone plus spironolactone and 
aldosterone plus DPCPX (Figure 4.5B). 
 
4.5. 
 We have made the novel findings that plasma aldosterone, and A1R and 
PCNA expression in atherosclerotic lesions all increased in MetS pigs and those 
factors correlated with each other. Endurance exercise training attenuated the 
MetS effects. Using a novel in vitro organ culture model of CAD, we 
demonstrated for the first time: 1) aldosterone upregulates A1R expression in 
coronary SMC and intact coronary segments, 2) A1R upregulation and A1R 
activation contribute to CAD in in vitro organ culture, and 3) aldosterone 
contribution to CAD in in vitro organ culture was partially mediated by 
upregulation of A1R. 
Discussion 
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 In the present study, we found A1R elevated in MetS and reduced in 
XMetS, while A2AR mRNA was not changed in MetS and A2AR, A2BR and A3R 
mRNA remained high in XMetS (see online supplemental data Figure 4.6). Those 
data showed that the AR changes in MetS and exercise are A1R subtype specific, 
not a global change of all adenosine receptors. This suggests that the A1R holds 
different functions than other adenosine receptors in contribution to coronary 
atherosclerosis. 
 
 This is the first report of A1R upregulation in coronary atherosclerotic 
lesions in MetS, which is consistent with findings that A1R is elevated in diabetes 
179, hypertension 180, and oxidative stress 181 and clearly indicates A1R 
involvement in different metabolic disorders. Our finding of exercise-induced 
regression of coronary atherosclerosis in MetS further reinforces the benefit of 
exercise therapy for human patients with CAD and MetS. Of course, lipid 
lowering agents show beneficial effects on the vascular wall in humans 182 and 
swine models 183. High levels of plasma aldosterone were observed in obese 
human subjects 184, therefore elevated plasma aldosterone in MetS pigs was an 
outstanding validation of this porcine model. The effect of MR blockade on 
diabetes, metabolic syndrome and coronary atherosclerosis has not been 
evaluated in human subjects yet 47. The literature above and our novel finding of 
aldosterone upregulation of A1R provide several new targets (A1R or MR 
antagonist alone or in combination) for CAD treatment in MetS. 
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 Organ culture is an excellent in vitro model of coronary atherosclerosis 65 
171-175. Interestingly, upregulation of A1R mRNA was at 2-day organ culture 
whereas the increase of A1R protein occurred at 4-day organ culture. It is likely 
that some post-transcriptonal regulation mechanisms are responsible for the lag 
between mRNA and protein expression. Elevated media collagen content 
indicates higher synthetic (proliferative) activity of media smooth muscle cells 1, 9, 
62, 63, which indirectly supports A1R contribution to coronary atherosclerosis by 
stimulation of coronary SMC proliferation. A1R antagonism decreased medial 
collagen content to a level comparable to freshly harvested arteries, regardless 
of the presence or absence of A1R-selective agonist CCPA, which suggests: 1) 
there is endogenous adenosine production by the organ cultured coronary 
segments in the organ culture condition and 2) A1R was the main player in the 
pure organ culture model to induce medial collagen content.  
 
 MR-responsive genes in vascular SMC are poorly characterized, but type I 
and type III collagen are among them 185. Type I and type III collagen have been 
implicated in aldosterone-induced cardiac and conduit fibrosis, which is 
consistent with our in vitro organ culture findings that aldosterone treatment 
increased medial collagen content vs. vehicle control 186. Interestingly, A1R 
antagonism or MR antagonism in the presence of aldosterone reduced collagen 
content to vehicle control level, instead of freshly harvested artery level. These 
data suggest that: 1) the A1R-induced collagen increase mediates only part of 
the aldosterone-induced collagen synthesis, possibly via A1R actions on SMC 
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and/or 2) aldosterone acts on the vascular wall in a MR-independent pathway to 
increase collagen content, i.e. contribute to CAD. It was reported that 
aldosterone exerts pro-inflammatory effects via MR-dependent and -independent 
pathways. Treatment with spironolactone or inhibitors of transcription or protein 
synthesis prevent the late effect of aldosterone, suggesting that this effect occurs 
through an MR-dependent, genomic pathway. In contrast, spironolactone does 
not block rapid phosphorylation of ERK1/2 by aldosterone, which is a MR-
independent pathway. Besides, aldosterone was shown to affect hepatic 
gluconeogenesis through the glucocorticoid receptor in cultured mouse 
hepatocytes 187, which suggests aldosterone could act on glucocorticoid 
receptors as well as mineralocorticoid receptors in promoting collagen synthesis. 
Therefore, lack of full blockade by spironolactone could include an MR-
independent mechanism 188. 
 
 In addition to the possible mitogenic effect mediated by aldosterone 
regulation of A1R in coronary SMC, MR also function in human vascular 
endothelial cells, regulating intercellular adhesion molecule-1 (ICAM-1) 
expression and promoting leukocyte adhesion 189, which may contribute to the 
beneficial effects of MR antagonism in patients with heart disease. It was 
reported that MR blockade reversed adipocyte dysfunction and insulin resistance 
in obese mice 47. MR activation was reported to promote proliferation, 
inflammation and fibrosis, which argues for MR antagonism in treatment of CAD 
to combat multiple facets of CAD 47, 190. Steroid receptors bind to specific 
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hormone response elements in the promoters of hormone responsive genes, 
recruiting cofactors in a ligand-dependent manner, thereby modulating gene 
expressions 46. Understanding of the molecular mechanism by which aldosterone 
regulates A1R and further delineation of other MR-responsive genes relevant to 
CAD may make our understanding of aldosterone contribution to CAD more 
complete and potentially identify more therapeutic targets for CAD. 
 
 In summary, our in vivo data showing the association of A1R upregulation 
in coronary atherosclerosis and elevated plasma aldosterone in MetS and 
exercise attenuation of coronary atheroma, A1R upregulation and aldosterone 
elevation, provide strong evidence that aldosterone and A1R upregulation might 
play important roles in coronary atherosclerosis in vivo in MetS. Our in vitro cell 
studies discovered a novel MR-responsive gene - the A1R in coronary SMC. 
Aldosterone partially contributed to the development of CAD in the in vitro organ 
culture model via upregulation of A1R. Collectively, aldosterone regulation of 
A1R could potentially contribute to the development of coronary atherosclerosis 
in MetS. Further study defining the role of aldosterone in regulation of A1R in 
vivo will aid in improving therapeutics for coronary atherosclerosis, especially in 
the setting of MetS. 
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4.7. 
Figure 4.1. A1R expression in native coronary atherosclerotic lesions in lean, 
metabolic syndrome (MetS), and metabolic syndrome aerobically exercised 
(XMetS) Ossabaw swine 
Figure legends 
A. Representative intravascular ultrasound (IVUS) image showing 54 percent of 
the arterial wall lined with atheroma as marked by the double arrows and arcs 
(195 / 360 × 100 % = 54 %). The distance between the 2 neighboring dots is 1 
mm. B. Native coronary atherosclerosis was quantified as the percent degree of 
circumferential arterial wall covered with atherosclerotic lesions in the distal left 
circumflex coronary artery (CFX) in vivo using IVUS right before sacrifice 
(n=5/group). C. Real-time RT-PCR for detection of A1R mRNA in those three 
groups (n=5/group). D-F. Immunoblots for detection of A1R and proliferation cell 
nuclear antigen (PCNA) proteins were performed in intact coronary segments 
with native atherosclerosis in lean (n=4), MetS (n=3), and XMetS (n=5) right after 
sacrifice. Representative immunoblots of A1R, PCNA, and GAPDH (loading 
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control) in lean, MetS, and XMetS were shown in D. Quantitative analysis of the 
results of A1R/GAPDH (E) and PCNA/GAPDH (F) was depicted as shown. *, 
p<0.05; #, p<0.001 as indicated by lines. 
 
Figure 4.2. Correlation study among plasma aldosterone, A1R and PCNA protein 
expression in native coronary atherosclerosis 
Different combinations of those parameters in Lean, MetS and XMetS were used 
for correlation study. All parameters were determined in Figure 4.1. P values and 
Pearson r were indicated in each panel. 
 
Figure 4.3. Aldosterone upregulation of A1R expression in vitro 
A-B Subcultured coronary artery smooth muscle cells isolated from lean 
Ossabaw right coronary arteries were treated with vehicle control, aldosterone 
(10-7 M), aldosterone (10-7 M) + spironolactone (10-7 M, mineralocorticoid 
receptor antagonist) for either 12, 24, or 36 hours. Real-time RT-PCR in 
detection of A1R mRNA was done in the treated cells from five independent 
experiments performed in duplicates (A). Immunoblots of A1R and GAPDH 
(loading control) were done in the cells treated for 36-hour from five independent 
experiments performed in duplicates (B). Aldo mean aldosterone treated. * 
denotes p<0.05 vs the other conditions.  
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Figure 4.4. A1R expression and A1R-ERK1/2 activity in the in vitro organ culture 
model of early coronary atherosclerosis 
A Histology analysis of Masson’s trichrome stains was performed in coronary 
segments (Fresh, 2- and 4-day organ culture) from five different lean pigs. 
Representative image in each treatment was shown on the right side of the bar 
graph. Blue indicates collagen staining, and red indicates cellular materials. 
Internal elastic lamina (IEL) and external elastic lamina (EEL) differentiates 
intima (I, within IEL) and media (M, between IEL and EEL) from adventitia (A, 
beyond EEL); lumen (L) is center of each artery. Representative histology 
images are shown above the group data averages. B-D Real-time RT-PCR for 
detection of A1R mRNA (B) and immunoblots for detection of A1R protein (C) 
and A1R-ERK1/2 activity (D) were performed in the coronary segments (Fresh, 
2-, and 4-day organ cultured, n=5/group). Representative blots of A1R, GAPDH 
(C) and phosphorylated-ERK1/2, total-ERK1/2 (D) are shown above the group 
data averages. Fresh served as control. * shows p<0.05 vs. Fresh. 
 
Figure 4.5. Effect of A1R antagonism and aldosterone treatment in the in vitro 
organ culture model of early coronary atherosclerosis 
A Coronary segments from lean pigs were organ cultured for 4 days, either in 
vehicle control media, or media supplemented with DPCPX (10-5 M), highly A1R-
selective antagonist, or CCPA (10-6 M), highly A1R-selective agonist, or both 
(n=5/group). B Similarly, coronary segments from lean pigs were organ cultured 
for 4 days, either in vehicle control media, or media supplemented with 
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aldosterone (10-7 M) alone, or aldosterone (10-7 M) and spironolactone (10-7 M)-
mineralocorticoid receptor antagonist, or both aldosterone (10-7 M) and DPCPX 
(10-5 M). Fresh coronary served as control (n=5/group). They were then followed 
by histology analysis of Masson’s trichrome stains. Percent media collagen 
content was quantitatively analyzed and depicted as shown. Fresh coronary 
segments are referred to as Fresh; 4-day organ cultured + vehicle treated 
segments as Vehicle; 4-day organ cultured + DPCPX, or CCPA, or both CCPA 
and DPCPX, or aldosterone alone, or aldosterone plus spironolactone, or 
aldosterone plus DPCPX treated segments as DPCPX, CCPA, CCPA + DPCPX, 
Aldosterone, Aldosterone + Spirono (short for spironolactone) or Aldosterone + 
DPCPX. * means p<0.05 vs non-star labeled groups (A) or vs Fresh (B); #, 
p<0.002 vs Aldo; **, p<0.0001 vs Fresh.  
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4.8. 
Figure 4.1. A1R expression in native coronary atherosclerotic lesions in lean, 
metabolic syndrome (MetS), and metabolic syndrome aerobically exercise 
trained (XMetS) Ossabaw swine 
Figures 
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Figure 4.2. Correlation study among plasma aldosterone, A1R and PCNA protein 
expression in native coronary atherosclerosis 
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Figure 4.3. Aldosterone upregulation of A1R expression in vitro 
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Figure 4.4. A1R expression and A1R-ERK1/2 activity in the in vitro organ culture 
model of early coronary atherosclerosis 
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Figure 4.5. Effect of A1R antagonism and aldosterone treatment in the in vitro 
organ culture model of early coronary atherosclerosis 
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4.9. 
Metabolic Index 
Table 
Lean MetS Pre-X XMetS  
Post-
7Wk-X 
XMetS 
Significance 
(p<0.05) 
Weight (kg) 71±2 108±10 102±12 105±13 Pre-X XMetS, MetS > Lean 
Fasting Plasma  
Insulin (μU/mL) 10±1 23±1 17±3 26±8 
Pre-X XMetS, 
MetS > Lean 
Fasting Plasma 
Glucose (mg/dL) 62±4 87±3 86±3 88±2 
Pre-X XMetS, 
MetS > Lean 
Total Cholesterol 
(mg/dL) 48±2 243±36 223±40 232±45 
Pre-X XMetS, 
MetS > Lean 
LDL (mg/dL) 23±2 183±33 169±38 142±26 Pre-X XMetS, MetS > Lean 
HDL (mg/dL) 21±2 56±13 48±4 85±21 Pre-X XMetS, MetS > Lean 
LDL/HDL 1.2± 0.2 3.7±0.9 3.5±0.7 1.7±0.2 
Pre-X XMetS, 
MetS > Lean, 
Post-7Wk-X 
XMetS 
Triglycerides 
(mg/dL) 17±2 22±3 29±5 29±4 
Pre-X XMetS > 
Lean 
Mean Blood  
Pressure 
(mm Hg) 
84±2 119±4 91±26 108±5 Pre-X XMetS, MetS > Lean 
Aldosterone 
(ng/dL) 
0.30± 
0.16 
2.06± 
1.0 
2.32± 
0.63 
0.10± 
0.04 
Pre-X XMetS, 
MetS > Lean, 
Post-7Wk-X 
XMetS 
Table 4.1. Metabolic data and aldosterone of Lean, MetS and XMetS Ossabaw 
pigs near the end of the 14-month study. 
Statistical differences between Lean, MetS, PreX XMetS, and Post-7Wk-X 
XMetS groups (n=5/group) are indicated in the right column. Pre-X XMetS means 
XMetS before the initiation of 7-week exercise training, Post-7Wk-X XMetS 
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means XMetS after 7-week of exercise training. LDL = low-density lipoprotein, 
HDL = high-density lipoprotein. 
 
4.10. 
4.10.1. Cardiac catheterization procedures 
Supplementary methods 
 Following an overnight fast, swine received (in mg/kg; i.m.) 0.05 atropine, 
2.2 xylazine, and 5.5 telazol. Swine were intubated and anesthesia was 
maintained with isoflurane (2-4%, with supplemental O2). The isoflurane level 
was adjusted to maintain anesthesia with stable hemodynamics. Heart rate, 
aortic blood pressure, respiratory rate, and electrocardiographic data were 
continuously monitored throughout the procedure. Under sterile conditions, the 
right femoral artery was exposed with a surgical cut-down technique and a 7F or 
8F vascular introducer sheath was inserted into the femoral artery followed by 
administration of heparin (200 U/kg). A 7F Amplatz L (sizes 0.75-2.0) guiding 
catheter (Guidant, Indianapolis, IN, USA) was inserted through the sheath and 
advanced to engage the left main coronary ostium under angiographic guidance. 
An Ultracross 3.2, 30 MHz intravascular ultrasound (IVUS) catheter (Boston 
Scientific, Sunnyvale, CA, USA) was advanced over a guide wire and positioned 
first in the left anterior descending (LAD) coronary arteries. IVUS images were 
recorded on videotapes using a Sonos Intravascular Imaging System (Hewlett 
Packard, Andover, MA, USA) for off-line analysis. Automated IVUS pullbacks 
were performed at 0.5 mm/sec. The IVUS catheter, guide catheter, and 
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introducer sheath were removed and the right femoral artery ligated. The incision 
was closed and the animal was sacrificed then.  
 
4.10.2. Real-time reverse transcription-polymerase chain reaction (Real-time RT-
PCR) 
 RNA was extracted from arterial samples using Trizol (Invitrogen, 
Carlsbad, CA, USA), then treated with DNase (DNA free, Ambion, Austin, TX, 
USA) to remove contaminating genomic DNA, and analyzed by NanoDrop 
spectrophotometer (ND-1000; ThermoScientific, Wilmington, DE, USA) to assess 
purity (A260/280) and concentration. 1 µg of RNA was converted to cDNA using 
the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA) in a standard 
thermocycler (DNA Engine PTC-200, MJ Research, Waltham, MA, USA). A1R, 
A2AR, A2BR and A3R gene expression was assessed using quantitative real-
time RT-PCR in an ABI 7500 instrument (Applied Biosystems, Foster City, CA, 
USA). Primers for PCR amplification were as follows:  
A1R:  forward, 5’-GGCCATGCTGGCAATTG-3’;  
  reverse, 5’-CCTGAGCGGGATCTTGACA-3’;  
A2AR:  forward, 5'-CCCCTTCATCTATGCCTACCG-3'; 
  reverse, 5’-CATTCCCTCACACTCCCTCCAC-3';  
A2BR:  forward, 5'- TGTGCTGGCTGCCTCTTCAC-3';  
  reverse, 5'-ACACGATGGGGTTGACGACC-3';  
A3R:   forward, 5'-GAACCTCACCTTCCTTTCCTGC-3';  
  reverse, 5'-GAACTCCCGTCCATAAAATGC-3'  
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(Integrated DNA Technologies, Coralville, IA, USA). Taqman probes were used 
to detect A1R gene amplification and were as follows: 5'-/6-
FAM/TCGACCGCTACCTCC/MGBNFQ/-3' (Applied Biosystems). SYBRGreen 
Universal PCR Master Mix (Applied Biosystems) was used to detect A2AR, 
A2BR and A3R gene expression followed by a dissociation curve to rule out non-
specific amplifications and primer-dimers. All results were normalized to the 
signal of 18s RNA, which was amplified in separate reactions using TaqMan 
Universal PCR Master Mix and TaqMan 18s Detection Reagents (Applied 
Biosystems). 
 
4.10.3. Western Blotting for A1R, PCNA, and p-ERK1/2 
 For the western blots of A1R, PCNA, and p-ERK1/2, coronary artery 
segments were pretreated with 10-6 M CCPA at 37°C for 5 minutes before lysed 
with 1% SDS lysis buffer with addition of protease inhibitor cocktail and 
phosphatase inhibitor cocktail (Sigma, St. Louis, MO, USA). Lysates were 
sonicated to disrupt DNA before BSA assay (Pierce, Rockford, IL, USA) for 
protein concentration determination, solubilized in Laemmli sample buffer with 
200 M dithiothreitol, and boiled for 2 minutes and proteins were separated on 
SDS-PAGE gels. The proteins were then electrophoretically transferred to 
nitrocellulose membrane in 25 M Tris, 192 M glycine, and 20% methanol. The 
nitrocellulose was blocked with 5% nonfat dry milk in 10 M Tris (pH 7.4), 150 M 
NaCl, and 0.01% Tween 20. The membranes were probed with the individual 
primary antibody (anti-adenosine A1 receptor; 1:1000 dilutions; Abcam, 
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Cambridge, MA, USA; anti-p-ERK1/2; 1:1000 dilutions; Cell Signaling, Danvers, 
MA, USA) overnight in 10 M Tris (pH 7.4), 150 M NaCl, 5% nonfat dry milk, and 
0.01% Tween 20. The blots were washed in 10 M Tris (pH 7.4), 150 M NaCl, and 
0.01% Tween 20, and bound antibody was detected by a horseradish 
peroxidase-conjugated anti-rabbit or anti-mouse IgG and enhanced 
chemiluminescence (Pierce). Equal protein loading was verified by stripping off 
the original antibody, and reprobing with the primary antibody anti-GAPDH 
(1:1000; Fitzgerald, Concord, MA, USA) or anti total-ERK1/2 (1:1000 dilutions; 
Cell Signaling).  
 
4.11. 
Figure 4.6. Adenosine subtypes expression in coronary native atherosclerotic 
lesions in Lean, MetS and XMetS 
Supplementary figure legend 
Real-time RT-PCR for detection of A1R (A), A2AR (B), A2BR (C), and A3R 
mRNA (D) was performed in intact coronary segments with native 
atherosclerosis in lean, MetS, and XMetS (n=5/group) right after sacrifice. 
Quantitative analysis of the results was depicted as shown. *, p<0.05 as 
indicated by lines. 
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4.12. 
Figure 4.6. Adenosine subtypes expression in coronary native atherosclerotic 
lesions in Lean, MetS and XMetS 
Supplementary figure 
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5.1. 
 Background: Adenosine is widely known to elicit coronary vasodilation and 
attenuate smooth muscle proliferation, thereby providing cardioprotection. We 
cloned the porcine adenosine A1 receptor (A1R) subtype and found that it 
paradoxically stimulated proliferation of cultured coronary smooth muscle cells by 
the extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) signaling 
pathways, thus suggesting A1R dysregulation could modulate coronary in-stent 
restenosis. We utilized the Ossabaw swine model of metabolic syndrome (MetS) 
and coronary disease to test the hypothesis that A1R upregulation and A1R 
signaling contribute to coronary in-stent stenosis in MetS. Methods and Results: 
Swine were fed standard chow or excess calorie atherogenic diet for up to 7 
months, which elicited MetS characteristics. Intracoronary stent deployment 
followed by different durations of recovery from stenting showed A1R 
upregulation occurred before maximal in-stent stenosis. In MetS selective A1R 
antagonism with DPCPX-eluting stents decreased coronary ERK1/2 activation 
and in-stent stenosis ~50%, which rivaled effectiveness of Taxus® (paclitaxel-
eluting) stents. Conclusions: A1R upregulation and A1R activation contribute to 
coronary in-stent stenosis in vivo in the setting of MetS and offer promising 
targets for drug-eluting stents.  
Abstract 
 
5.2. 
 Metabolic syndrome (MetS; “pre-diabetes”) afflicts approximately 27% of 
the US adult population, drastically increasing in prevalence, and indicates 
Introduction 
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increased risk of atherosclerotic cardiovascular disease and/or type 2 diabetes 
mellitus 28-33. MetS is defined as the combination of any three of the following 
abnormalities: central obesity, dyslipidemia, hypertension, impaired glucose 
tolerance, and insulin resistance 34. First line therapy for flow-limiting coronary 
atherosclerotic lesions involves stent placement 17. However, hyperinsulinemic 
MetS patients have increased restenosis after percutaneous coronary 
interventions 38-41. These are compelling reasons for determining cellular and 
molecular signals for coronary restenosis in the setting of MetS. 
 
 The abnormal growth and migration of vascular smooth muscle cells 
(SMC) play major roles in restenosis after stenting 9, 62-64. Adenosine has been 
widely shown to elicit coronary vasodilation and attenuate SMC proliferation, 
thereby providing cardioprotection 54. Four adenosine receptor (AR) subtypes 
have been cloned: A1R, A2AR, A2BR, A3R 51. The vasodilator effect of 
adenosine was mediated via the A2AR and/or A2BR, which are expressed by 
endothelial cells (EC) and SMC 52-54. In aortic SMC, adenosine was found 
antimitogenic via the A2BR 65-68. The exact physiological function of the A3R, 
which is expressed in some vascular SMC, has not been conclusively 
characterized 52. We challenged this dogma with the finding that A1R mediated 
mitogenic effects of adenosine on porcine coronary artery SMC through 
activation of ERK1/2 - members of the mitogen-activated protein kinase (MAPK) 
superfamily, c-Jun-N-terminal kinase (JNK), and PI3K-AKT signaling pathways 65, 
69. We also reported A1R upregulation in in-stent coronary segments 4 weeks 
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after stent-induced vascular injury 70. Despite those exciting findings, it remains 
unknown whether A1R activation plays a causal role in the pathogenesis of 
coronary in-stent stenosis. 
 
 Although drug-eluting stents have substantially decreased restenosis 78, 
further study is needed because of possible increased risk of platelet aggregation 
and late stent thrombosis caused by non-selective cytotoxins employed 80-85. Our 
goal is to find a novel target for clinical application in reducing coronary in-stent 
stenosis, while avoiding possible late stent thrombosis in MetS and type 2 
diabetes 80. Several animal models recapitulate MetS 86-91; however, none are 
able to fully reproduce symptoms of MetS and CAD. Further, transgenic mouse 
models are simply not adequate for coronary vascular interventions using stents 
identical to those used in humans 70, 92, 109, 191-195, which is essential for translation 
to the clinic. Our group has developed Ossabaw miniature swine as an excellent 
large humanoid animal model of MetS. Swine coronary arteries are similar to 
humans in size, anatomical structure, and flow dynamics 92. When fed excess 
calorie atherogenic diet, Ossabaw swine develop MetS 11, 92, 95, 96, and like 
humans (but different from many other laboratory animal models) develop CAD 11, 
92, 95, 97. Because in-stent neointimal hyperplasia is greater in Ossabaws than in 
other lean swine breeds (e.g. Yucatan) 92, Ossabaw swine provide a unique and 
nearly ideal model for study of coronary in-stent stenosis, especially in the setting 
of MetS.  
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 The overall hypothesis is that A1R activation contributes to the 
development of coronary in-stent stenosis in MetS. Using our novel swine model, 
we clearly show for the first time the causal role of A1R activation in coronary in-
stent neointimal hyperplasia, especially in MetS. 
 
5.3. 
5.3.1. Relation of A1R upregulation to in-stent stenosis  
Results 
 To determine if A1R upregulation ocurrs before the development of 
coronary in-stent stenosis for either normal expanded or over-expanded stents, 
different stenting recovery durations were given to lean pigs with varying degrees 
of stent-induced injury. Taxus as well as bare metal stents were used to 
determine if the anti-proliferative property of Taxus relates to A1R regulation or 
not. After 4-week recovery, all in-stent coronary segments (Figure 5.1A-C) 
showed maximal in-stent stenosis. A1R protein, determined by immunoblots, was 
upregulated after 1-, 2- and 4-week stenting recovery in all 3 corresponding in-
stent coronary segments: 1.0 (normal expansion) bare metal, 1.3 (over-
expansion) bare metal, and 1.0 Taxus (Figure 5.1D, E, and F, respectively). 
Importantly, A1R protein upregulation preceded the maximal coronary in-stent 
stenosis for normal-expanded and over-expanded bare metal stents (1.0 and 1.3 
bare metal), and drug-eluting stents (1.0 Taxus). 
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5.3.2. A1R-ERK1/2 signaling in in-stent segments 
 The highly A1R-selective agonist CCPA-induced ERK1/2 activation 
(phosphorylated to total ERK1/2 ratio) was measured in right coronary artery 
segments from healthy lean pigs with CCPA treatment for different durations. 
CCPA-induced ERK1/2 activation was biphasic, with peaks at 5 and 60 minutes 
(Figure 5.2A), thus all subsequent measures of CCPA-induced ERK1/2 activation 
were done after 5-minute CCPA stimulation. To assess A1R downstream 
mitogenic signaling strength, CCPA-induced ERK1/2 activation was compared in 
the in-stent (1.0 and 1.3 bare metal and 1.0 Taxus) and non-instrumented 
coronary segments (non-ST) in the same animals from the above mentioned 
study. CCPA-induced ERK1/2 activation was significantly reduced in all 3 stented 
vs. non-stented coronary segments at 1-week stenting recovery (Figure 5.2B). At 
2-week recovery from stenting, CCPA-induced ERK1/2 activation was still 
repressed in 1.0 Taxus stented segments (Figure 5.2C). At 4-week stenting 
recovery, CCPA-induced ERK1/2 activation remained low in 1.0 Taxus stented 
vs. non-stented and bare metal stented coronary segments (Figure 5.2D). 
Collectively, the data in Figure 5.1 and Figure 5.2 show that functional A1R-
ERK1/2 signaling lags behind the A1R protein upregulation in the development of 
in-stent stenosis. 
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5.3.3. Effects of two different drug-eluting (paclitaxel- and DPCPX-eluting) stents 
on coronary in-stent stenosis in MetS  
 To determine the effects of commercially available Taxus (paclitaxel-
eluting) stents on in-stent stenosis in the setting of MetS, bare metal and Taxus 
stents were deployed at both 1.0 and 1.3 stent / artery ratios in coronary arteries 
of lean and MetS pigs. Following 6 months of feeding body weight, fasting 
plasma glucose and insulin, total cholesterol, LDL, HDL, LDL/HDL, triglycerides, 
systolic and diastolic blood pressure were all significantly elevated in MetS vs. 
Lean (data not shown). At 4-week stenting recovery, Taxus significantly reduced 
in-stent stenosis compared to bare metal stents in the lean and MetS pigs at both 
stent / artery ratios (Figure 5.3A and B), more evident at 1.3 stent / artery ratio 
(Figure 5.3B). 
 
 Direct involvement of A1R in coronary in-stent stenosis was assessed 4-
week after the deployment of PLGA-coated (Polymer) and DPCPX (highly A1R-
selective antagonist)-eluting stents (DPCPX) in coronary arteries of lean and 
MetS pigs at 1.1 stent / artery ratio. Following 6 months of feeding body weight, 
peak plasma glucose during IVGTT, total cholesterol, LDL, HDL, LDL/HDL, 
triglycerides, systolic and diastolic blood pressure were all significantly elevated 
in MetS vs. Lean (Table 5.1). Intravascular ultrasound (IVUS) quantification 
revealed that DPCPX significantly reduced coronary in-stent stenosis ~50% 
compared to Polymer in lean and MetS pigs (Figure 5.3C), which was echoed by 
representative in vivo angiogram (Figure 5.3D), IVUS images (Figure 5.3E), and 
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in vitro stereoscope images (Figure 5.3F). These results provide definitive 
evidence for A1R contribution to coronary in-stent stenosis in healthy swine and 
in the setting of MetS. 
 
5.3.4. A1R expression and ERK1/2 signaling in DPCPX in-stent segments 
 For the same groups of pigs as in Figure 5.3C-F, we examined A1R 
protein expression and CCPA-induced ERK1/2 activation in the in-stent and non-
stented coronary segments. A1R was upregulated in both Polymer and DPCPX 
vs. non-stented segments (Non-ST) in Lean (Figure 5.4A) and MetS (Figure 5.4B) 
pigs. CCPA-induced ERK1/2 activation significantly decreased in DPCPX vs. 
Polymer and non-stented segments in Lean (Figure 5.4C) and MetS (Figure 5.4D) 
pigs. In MetS pigs, CCPA-induced ERK1/2 activation was reduced in Polymer vs. 
non-stented (Figure 5.4D). For non-stented coronary segments, A1R protein 
were significantly upregulated in MetS compared to Lean pigs, and CCPA-
induced ERK1/2 activation was not different between Lean and MetS pigs (not 
shown). 
 
5.4. 
 We made the novel discovery that the A1R upregulation occurred before 
the maximal coronary in-stent stenosis in Ossabaw swine, consistent with a 
causal role of A1R in neointimal proliferation. CCPA-induced ERK1/2 activation 
paralleled the development of in-stent stenosis for bare metal stent, supporting 
the involvement of A1R-ERK1/2 signaling in neointimal hyperplasia. Using novel 
Discussion 
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DPCPX-eluting stents we demonstrated for the first time 1) A1R upregulation and 
A1R activation contributes to coronary in-stent stenosis and 2) selective A1R 
antagonism rivals the effectiveness of the clinically used Taxus stents in reducing 
coronary in-stent stenosis in the Ossabaw swine model of MetS. This work has 
progressed from a fundamental and paradoxical finding in subcultured vascular 
cells in vitro to demonstration of a novel, efficacious drug-eluting stent in a MetS 
and CAD swine model in vivo that mimics complex human disease - collectively 
significant steps in translational medicine. 
 
 The Ossabaw pig is an excellent model for study of in-stent stenosis 
because it develops MetS and CAD and simulates the response to stent 
deployment in humans better than juvenile domestic swine 11, 92, 95, 97. Our 
clinically used angiography and IVUS methods provide compelling data that are 
highly relevant to clinical medicine 196 and mirror histopathology measures 11. 
 
 A possible uncoupling of post-receptor signaling from A1R was supported 
by the fact that CCPA-induced A1R-ERK1/2 activation was low in all in-stent vs. 
non-stent 1-week after stenting (Figure 5.2B). A1R-ERK1/2 activation returned to 
normal at 2-week after stenting for bare metal stents (Figure 5.2C). This transient 
uncoupling might exist for the sake of self protection. It was showned that during 
a brief period of preconditioning ischemia, adenosine release protects the heart 
by uncoupling of A1R from signal transduction mechanisms that lead to injury 197. 
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Porcine studies suggested that 1-3 days after coronary stenting there is 
platelet/fibrin deposition surrounding the stent struts 198. Potentially, huge 
amounts of adenosine arises from ATP released by platelets and other cell types, 
largely occupies and activates A1R in coronary SMC or other cell types, and via 
negative feedback or some unknown mechanisms uncouples A1R from ERK1/2 
signal transduction to protect coronary artery from A1R activation-induced 
possible smooth muscle cell proliferation. 
 
Besides ERK1/2, JNK1/2 and PI3K/AKT are also downstream of A1R 
activation 69, which may be involved in the A1R contribution to in-stent stenosis, 
but those other two signaling pathways (JNK1/2 and PI3K/AKT) were not 
measured in the present study due to the technical difficulties. Jonas etc. 
reported that in insulin resistant and diabetic rats, ERK1/2 and AKT signaling 
changed in different directions in stented vascular segments 199. Therefore, A1R-
JNK1/2 and/or A1R-PI3K/AKT signaling could be upregulated in stented 
segments (BMS or Polymer) vs. non-stent, although A1R-ERK1/2 signaling was 
not. Another possible explanation for the similar A1R-ERK1/2 activation in in-
stent (BMS) vs. non-stent in Lean (Figure 5.2D and Figure 5.4C), or decreased 
A1R-ERK1/2 activation in Polymer vs. non-stent in MetS (Figure 5.4D) at 4-week 
post-stent is that the in-stent coronary segments were much thicker than non-
stent due to the in-stent stenosis. Fully exposure to CCPA could be partially 
blunted by layers of proliferative extracellular matrix, e.g. collagen and elastin, in 
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the arterial wall of the in-stent segments. Therefore, there might be less CCPA-
induced ERK1/2 activation detected in the in-stent segments than it actually 
would be if there were no layers of barriers preventing CCPA from contacting 
coronary smooth muscle cells. As for why A1R-ERK1/2 activation decreased in 
Polymer vs. non-stent in MetS (Figure 5.4D) while not in Lean (Figure 5.4C), it 
might be due to the self-protection mechasim that the in-stent segments 
compensate for the high elevation of A1R protein by downregulating A1R-
ERK1/2 signaling. It may be the case that A1R-JNK1/2 and/or A1R-PI3K/AKT 
signaling are in opposite direction to A1R-ERK1/2 signaling in the stent as well. 
 
 Interestingly, along the whole time course of recovery from stenting, 
exogenously A1R-ERK1/2 activity in Taxus stented coronary segments was 
always lower than non-stented segments. Paclitaxel was reported to cause 
inactivation of ERK1/2 in human KB-3 carcinoma cells 200. Also, rapamycin, 
another major drug-eluting stent compound, was reported to inhibit JNK and p38 
MAPK in cultured human coronary smooth muscle cells and in rat carotid artery 
14 days following injury 201. It is possible that Taxus acts partially by inhibition of 
ERK1/2 signaling to prevent cell proliferation in Ossabaw swine. Although A1R 
protein expression was similar between bare metal and Taxus stents at 1-, 2-, 
and 4-week post-stenting, in-stent stenosis was significantly reduced in Taxus vs. 
bare metal stents only at 4-week post-stenting. Endogenous ERK1/2 activity (not 
requiring stimulation with CCPA; Figure 5.4) after 4 weeks recovery from stenting 
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was partially blocked by A1R antagonism by DPCPX. This is consistent with the 
action of Taxus to attenuate ERK1/2 activity and decrease in-stent stenosis. 
Collectively, these data suggest that both A1R upregulation and A1R-ERK1/2 are 
important for development of coronary in-stent stenosis.  
 
 Both neointima and media layers of in-stent segments showed parallel 
A1R expression and exogenous ERK1/2 activity at 4-week post-stenting (data 
not shown), which suggests that neointima and media layers probably came from 
the same cell type or different cell types acting in parallel with each other in A1R 
expression and exogenous ERK1/2 activity. Christen etc. reported that SMCs are 
the main components of coronary artery neointima after stent deployment 202, 
which supports the first interpretation. A1R was upregulated in endothelium intact 
coronary in-stent segments, therefore the increase of A1R can occur in coronary 
SMC, endothelial cells, or even surrounding macrophages, leucocytes, etc. in the 
in-stent segments. A1R are expressed in neutrophils, macrophages, and T-cells 
in human asthma patients 203 and peaked in mouse macrophages during 
leukocyte recruitment 204. However, we are not aware of reports of A1R 
upregulation selectively in those cell types in coronary artery disease or in-stent 
restenosis, thus indicating that further study is needed. 
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 There are sti ll many discrepancies regarding whether EC express A1R or 
not. A1R was reported not expressed in human umbilical vein EC and skin 
microvascular EC 205, 206. In contrast, A1R was reported to lower basal 
permeability in human umbilical vein EC in response to oxidant injury 207, or 
regulate mouse embryonic endothelial progenitor cells adhesion to cardiac 
microvascular EC 208, or decrease nitric oxide production by human iliac arterial 
EC and porcine carotid arterial EC 209. Our study showed that A1R protein is 
present in subcultured EC isolated from right coronary artery of Ossabaw swine 
(see Figure 5.5B available in the online data supplement). A1R involvement in 
proliferation of coronary EC, and other cardioprotective functions mediated by 
A1R in coronary EC are completely unknown. Since A1R and A2R are coupled 
with Gi and Gs proteins separately 51, 69 and their functions were reported almost 
exclusively opposite to each other 65-68, it is highly probably that A1R mediate 
antimitogenic effect of adenosine in coronary EC. If true, then we further propose 
that A1R activation has deleterious actions in both coronary SMC and EC. Along 
this line, the benefit of local administration of the highly selective A1R antagonist 
DPCPX not only lies in prevention of coronary SMC proliferation, but also in 
potentiation of coronary EC growth in the in-stent segments, which would help 
reduce late stent thrombosis risk accompanying clinically used drug eluting 
stents 80-85. Since important design criteria for drug eluting stents include more 
cell-type specificity and promotion of endothelialization and healing 79, DPCPX-
eluting stents could be a substantial innovation in drug-eluting stents if the A1R 
mediates antimitogenic effects of adenosine in coronary EC. Further study is 
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definitely needed regarding the possible antimitogenic effect of A1R in coronary 
EC. 
  
 Further, A2AR protein was found by immunoblot in subcultured coronary 
SMC isolated from Ossabaw swine, while A2BR was not detectable (Figure 5.5A), 
consistent with our previous findings of low levels of A2BR gene in cultured 
coronary SMC and endothelium-denuded porcine right coronary 65. In 
endothelium-intact porcine right coronary arteries there are A1R, A2AR, A2BR 
and A3R expression revealed by real-time RT-PCR (Figure 5.5C). Since A2BR 
was not detected in isolated porcine coronary SMC, A2BR are present 
exclusively in coronary EC, consistent with our previous study 65. A2BR and 
A2AR were reported to mediate the antimitogenic effect of adenosine in porcine 
coronary artery EC and human umbilical vein EC, respectively 210, 211. Because 
A2BR is present in porcine coronary EC and may mediate antimitogenic effects 
of adenosine in coronary EC, A2BR could be another potential target in drug 
eluting stents (DES) to help reduce late stent thrombosis associated with DES. 
And A2AR could be targeted to decrease coronary in-stent stenosis if the A2AR 
mediates antimitogenic effects of adenosine in coronary artery smooth muscle 
cells. 
 
 In summary, our in vivo data showing the association of A1R expression 
with coronary in-stent stenosis and the attenuation of both events by selective 
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A1R antagonism provide strong evidence that A1R upregulation and A1R 
signaling contributes to coronary in-stent stenosis in MetS. Our novel DPCPX-
eluting stents offer a promising, novel therapy for coronary in-stent stenosis in 
human MetS patients. 
 
5.5. 
5.5.1. Animal care and cardiac catheterization procedures 
Materials and Methods 
 All protocols involving animals were approved by an Institutional Animal 
Care and Use Committee and complied fully with recommendations in the Guide 
for the Care and Use of Laboratory Animals 105 and the American Veterinary 
Medical Association Panel on Euthanasia 106. Cardiac catheterization, 
angiography, stenting (detailed description in the online supplemental materials), 
and intravascular ultrasound (IVUS) were performed as previously described at 
the time of stent deployment and several weeks later (detailed in the following 
paragraphs) at sacrifice 70, 92. To prevent thrombosis after stent placement, each 
animal received standard daily antiplatelet therapy (75 mg Plavix and/or 325 mg 
aspirin) beginning the day before the initial catheterization procedure and 
continuing until sacrifice in accordance with standard clinical postoperative care. 
 
 We studied the time course of A1R, A1R-ERK1/2 signaling and coronary 
in-stent stenosis in Ossabaw swine by allowing 1, 2, or 4 weeks of recovery after 
coronary stenting (Figure 5.1 and Figure 5.2). Bare metal and paclitaxel-eluting 
(Taxus; Boston Scientific, Inc., Minneapolis, MN, USA) stents were placed in 
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either left circumflex or left anterior descending coronary by random assignment 
in 15 male Ossabaw swine (n=5/group; age 8 ± 0.5 months at sacrifice) that were 
fed standard chow diet (5L80; Purina TestDiet, Richmond, IN, USA). Right 
coronary artery served as non-stented control. Stent to artery ratio (determined 
by intravascular ultrasound) was 1.0 or 1.3 for bare metal and 1.0 for Taxus 
stents. Due to the limited artery length and dimension, stent / artery ratio of 1.3 
was omitted for Taxus. A total of 3 stents was placed in each pig. 
 
 The effects, of bare metal and Taxus stents deployed at 1.0 and 1.3 stent / 
artery ratio on in-stent stenosis were also studied in the setting of MetS in 
another 10 male Ossabaw swine (n=5/group; age 20 ± 2 months at sacrifice). 
Pigs were assigned to 2 different diet groups for 6 months. The Lean group was 
fed standard chow consisting of (% kcal): 18.5 protein, 71 carbohydrate, and 8 fat. 
The MetS group was fed hypercaloric, atherogenic diet consisting of (% kcal): 8 
protein, 18 fructose, 31 complex carbohydrates, and 43 fat. A total of 4 stents 
(1.0 / 1.3 bare metal and Taxus) were placed in coronary arteries (similar 
strategy as the above protocol) and 4 weeks of recovery was given before 
sacrifice. 
 
 The effects of the A1R-selective antagonist 8-cyclopentyl-1, 3-
dipropylxanthine (DPCPX) on A1R and A1R-ERK1/2 signaling and coronary in-
stent stenosis were studied with DPCPX-eluting stents. Ossabaw swine (n=5 
pigs/group; age 17 ± 2 months at sacrifice) were assigned to Lean and MetS diet 
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groups described above for 7 months. The Lean group was again fed standard 
chow and MetS group fed atherogenic diet very similar to the previous MetS diet, 
but included mixed fat sources (5B4L; Purina TestDiet). Polymer-coated stents 
and DPCPX-eluting stents were placed in either circumflex or left anterior 
descending coronary by random assignment. Stent to artery ratio was 1.1 for 
both stents and 4 weeks of recovery was allowed before sacrifice.  
 
5.5.2. Polymer/drug loading  
 The biodegradable polymer used on the drug-eluting stent system was 
poly(glycolic acid-co-lactic acid) (PLGA), an aliphatic polyester copolymerized 
from glycolic acid and lactic acid. PLGA is hydrophobic and undergoes bulk 
erosion as water diffuses into the polymer bulk where hydrolytic degradation 
occurs. Stents were coated by a solution of PLGA (50: 50) and DPCPX in 
tetrahydrofuran (final concentration of 30% DPCPX; DPCPX, Tocris Bioscience, 
Ellisville, MO, USA). The PLGA or PLGA/DPCPX mixture was sprayed onto the 
stents and dried to constant mass. DPCPX content of the stent was determined 
by gravimetric analysis and verified by dissolving the coating off the stents and 
measuring the DPCPX content by high-performance liquid chromatography 
(HPLC). In vitro elution kinetics were determined on non-expanded stents 
immersed in 3 ml aliquots of agitated PBS with 0.05% Tween 20 at 37ºC for 28 
days 212. Buffer was changed periodically and the DPCPX content determined by 
HPLC. The DPCPX-eluting stents contained a 7: 3 polymer-to-DPCPX ratio for a 
total dose density of 18.75 µg/mm of stent length. 
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5.5.3. Intravascular ultrasound (IVUS) analysis 
 IVUS methods identical to human clinical use were used in vivo to 
determine coronary in-stent stenosis in Lean and MetS swine and off-line 
analysis was performed by a blinded operator, as described previously 11, 70, 92, 95. 
In-stent stenosis was quantified as percent area stenosis and calculated as 
(plaque area ÷ [original lumen area + plaque area]) × 100%. Images were 
captured every 1 mm along the whole pullback length of IVUS and 8 images 
quantified and averaged for each in-stent coronary segment. 
 
5.5.4. Intravenous glucose tolerance test (IVGTT) 
 Swine were acclimatized to restraint in a specialized sling for 5-7 days 
before the IVGTT was conducted. Following percutaneous catheterization of the 
right jugular vein under isoflurane anesthesia 11, 92, 95, swine were allowed to 
recover for 3 hours before the IVGTT to avoid any effect of isoflurane on insulin 
signaling 176. Conscious swine were restrained in the sling and baseline blood 
samples were obtained. Dextrose (1 g/kg body weight) was administered 
intravenously and timed blood samples were collected 176. Blood glucose was 
measured using YSI 2300 STAT Plus Glucose analyzer. Plasma insulin assays 
were performed by MILLIPORE Research Laboratories (St. Charles, MO, USA). 
 
5.5.5. Immunoblots for A1R and p-ERK1/2 
 Coronary artery segments were pretreated with 10-6 M of highly A1R-
selective agonist 2-chloro-N-6-cyclopentyladenosine (CCPA; Tocris Bioscience) 
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at 37° C for 5 minutes for detection of exogenous A1R activation induced-
ERK1/2 activition. Detailed immunoblot methods are included in the online 
supplemental materials. The membranes were immunoblotted for A1R (rabbit 
polyclonal antibody; 1:1000 dilutions; Abcam, Cambridge, MA, USA) and p-
ERK1/2 (mouse monoclonal antibody; 1:1000 dilutions; Cell Signaling, Danvers, 
MA, USA). Membranes were stripped and reprobed with anti-GAPDH (1:1000; 
Fitzgerald, Concord, MA, USA) or anti-total ERK1/2 (1:1000 dilutions; Cell 
Signaling). 
 
5.5.6. Lipid analysis 
 Venous blood samples were obtained following overnight fasting and 
analyzed for triglyceride and total cholesterol [fractionated into high density 
lipoprotein (HDL) and low density lipoprotein (LDL) components]. Plasma lipid 
assays were done using Infinity lipid kit (ThermoFisher Scientific, VA, USA). 
Apolipoprotein-B-containing lipoproteins were precipitated with heparin-MnCl2 
and the supernatant was assayed to determine cholesterol in lipoprotein fractions 
95. LDL was calculated from the Friedewald equation: LDL = total cholesterol - 
HDL - (triglyceride ÷ 5). 
 
5.5.7. Statistics 
 Data were presented as mean ± SEM. Statistical analysis was performed 
using commercially available software (SPSS version 12, Prism version 4.0 and 
SAS). Means of 2 groups were compared using Student t test (unpaired, two 
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tailed). Means of more than 2 groups (except data from Figure 5.3) were 
compared using Kruskal-Wallis one-way analysis of variance (ANOVA), followed 
by post-hoc testing using Least-Significant-Difference test. For data from Figure 
5.3A-B, group comparison was done using two-way ANOVA, followed by post-
hoc testing using Bonferroni test. For data from Figure 5.3C, general linear model 
was used for multivariate analysis of variance between groups. The p<0.05 level 
was considered significant. 
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5.7. 
Figure 5.1. Coronary in-stent stenosis and A1R expression in pigs with different 
amounts of stent expansion and durations of recovery from stenting  
Figure legends 
Stent/artery expansion ratio were 1.0 (normal artery diameter) and 1.3 (30% 
over-expansion in artery diameter). Stenting recovery durations were 1, 2 or 4 
weeks. A-C: In-stent stenosis of 1.0 bare metal (A), 1.3 bare metal (B) and 1.0 
Taxus (C) was quantified in vivo using intravascular ultrasound (IVUS) as percent 
area stenosis along the whole length of in-stent segments. Percent area in-stent 
stenosis = (Area of Neointima) / (Area of Original Lumen indicated by stent struts) 
x 100. Inset in A shows a representative IVUS image of in-stent stenosis with the 
stent struts (dotted line), artery lumen (dashed line), and neointima (area 
between stent struts and lumen) marked for clarity. D-F: Immunoblots for 
detection of A1R protein were performed in in-stent coronary segments with 
varying stent/artery ratio (D-1.0 bare metal, E-1.3 bare metal, F-1.0 Taxus) 
harvested from lean pigs after 1, 2 or 4-week stenting recovery (n=5/group with 
different stenting recovery). Non-stented (Non-ST) coronary segments served as 
control. Representative blots of A1R (upper lanes) and GAPDH (lower lanes) are 
shown above group data averages. *, p<0.05 vs indicated groups; #, p<0.01 vs 
marked groups; **, p<0.001 vs indicated groups.  
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Figure 5.2. A1R-ERK1/2 signaling in non-stented and in-stent coronary segments 
with different stent types and different stenting recovery durations (same as 
described in Figure 5.1) 
A: Right coronary segments freshly harvested from lean pigs were treated with 
the highly A1R-selective agonist CCPA at 10-6 M for different durations (5, 10, 15, 
30, or 60 minutes). Immunoblots of phosphorylated ERK1/2 (p-ERK1/2) and total 
ERK1/2 (t-ERK1/2) were done in the CCPA-treated and non-treated coronary 
segments. The p-ERK1/2 to t-ERK1/2 ratio (p/t-ERK1/2) with CCPA treatment, as 
determined by immunoblot quantification, was used to evaluate exogenous A1R 
activation (CCPA-induced ERK1/2 activation). B-D: P-ERK1/2 and t-ERK1/2 
levels were determined by immunoblot in non-stented and in-stent coronary 
segments (1.0 bare metal, 1.3 bare metal, and 1.0 Taxus, as in Figure 5.1) 
harvested from pigs either 1- (B), 2- (C), or 4-week (D) after stenting (n=5/group 
with different stenting recovery). All segments were treated with CCPA for 5 
minutes before immunoblot analysis to determine exogenous A1R-ERK1/2 
activity. Non-stented (Non-ST) served as control. Representative blots of p-
ERK1/2 and t-ERK1/2 are shown above the group data averages. *, p<0.05 vs. 
samples at 0, 10, 15, 30-minute treatment (A); #, p<0.01 vs. samples at 0, 10, 15, 
30-minute treatment (A) or marked groups (B-D). 
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Figure 5.3. In-stent stenosis in pigs treated with bare metal stents and Taxus or 
DPCPX (highly A1R-selective antagonist)-eluting stents 
Bare metal stents and Taxus stents were deployed in coronary arteries in lean 
and metabolic syndrome (MetS) Ossabaw pigs (n=5/group) with stent / artery 
ratios of 1.0 (A) and 1.3 (B). Polymer-coated (Polymer) and DPCPX-eluting 
stents (DPCPX) were deployed concurrently in coronary arteries with stent / 
artery ratio of 1.1 in lean and MetS pigs (n=5/group). Polymer served as control 
(C). A-C: Intravascular ultrasound (IVUS) was done 4 weeks after stenting in vivo 
to evaluate in-stent stenosis for different conditions. Percent area stenosis along 
the whole length of in-stent segments was quantified by IVUS, as defined in 
Figure 5.1. D-F: Representative images of two in-stent coronary segments 
(Polymer, DPCPX) from the same MetS pig under in vivo angiography (D), IVUS 
(E) and stereomicroscope (F). D: Left anterior oblique 30 degree view of LAD: 
White arrows indicate DPCPX; black arrows indicate polymer. E: Stent struts 
(dotted line), artery lumen (dashed line), and neointima (area between stent 
struts and lumen) were depicted for clarification. The distance between each 
neighboring dot horizontally or vertically is 1 mm. F: In-stent coronary segments 
were cut open after harvesting at sacrifice. Adventitia was outside stainless steel 
struts and neointima was inside the stent struts. *, p<0.01 as indicated by lines. 
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Figure 5.4. A1R and ERK1/2 activation in non-stented and in-stent coronary 
segments 
As in Figure 5.3C, polymer-coated (Polymer) and DPCPX-eluting stents (DPCPX) 
were deployed concurrently in coronary arteries with stent / artery ratio of 1.1 in 
lean and MetS Ossabaw pigs (n=5/group). Coronary segments were harvested 
freshly for analysis 4-week after stenting. Immunoblots of A1R, GAPDH (A-B), 
phosphorylated-, and total-ERK1/2 (p-ERK1/2, t-ERK1/2, C-D) were done in non-
stented (Non-ST), and in-stent coronary segments (Polymer, DPCPX) in the 
Lean (A, C) and MetS (B, D) pigs. Representative blots of A1R and GAPDH, p-
ERK1/2 and t-ERK1/2 are shown above group data averages. GAPDH served as 
loading control. P-ERK1/2 to t-ERK1/2 ratio (p/t-ERK1/2) was used to evaluate 
CCPA-induced ERK1/2 activation. *, p<0.05; #, p<0.01 as indicated by lines. 
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5.8. 
Figure 5.1. Coronary in-stent stenosis and A1R expression in pigs with different 
amounts of stent expansion and durations of recovery from stenting 
Figures 
 
 
  
 145 
Figure 5.2. A1R-ERK1/2 signaling in non-stented and in-stent coronary segments 
with different stent types and different stenting recovery durations 
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Figure 5.3. In-stent stenosis in pigs treated with bare metal stents and Taxus or 
DPCPX (highly A1R-selective antagonist)-eluting stents 
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Figure 5.4. A1R and ERK1/2 activation in non-stented and in-stent coronary 
segments 
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5.9. 
Metabolic Index 
Table 
Lean MetS p value 
Body Weight (kg) 110.5 ± 1.8 140.4 ± 2.1 0.0001 
Peak Plasma Insulin 
(μU/mL) 72.0 ± 7.4 123.0 ± 28.6 0.11 
Peak Plasma Glucose 
(mg/dL) 595.2 ± 25.6 710.6 ± 44.8 0.0499 
Total Cholesterol 
(mg/dL) 58.6 ± 2.7 457.3 ± 51.8 0.00005 
LDL (mg/dL) 27.3 ± 1.7 340.7± 37.9 0.0008 
HDL (mg/dL) 26.7 ± 1.7 103.9 ± 18.5 0.0004 
LDL/HDL 1.0 ± 0.1 4.3 ± 0.8 0.001 
Triglycerides 
(mg/dL) 23.0 ± 1.5 63.1 ± 13.8 0.0118 
Systolic Blood 
Pressure(mm Hg) 110.0 ± 1.8 140.4± 2.1 0.00003 
Diastolic Blood 
Pressure(mm Hg) 68.0± 2.2 92.9 ± 1.6 0.000063 
Table 5.1 Metabolic data of the Lean and MetS Ossabaw pigs in Figure 5.3C-F 
and Figure 5.4. 
Statistical difference between the Lean and MetS groups are indicated in the 
right column. LDL = low-density lipoprotein, HDL = high-density lipoprotein. 
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5.10. 
5.10.1. Western Blotting for A1R and p-ERK1/2 
Supplementary methods 
 For the western blots of p-ERK1/2 and A1R, coronary artery segments 
were pretreated with 10-6 M CCPA at 37° C for 5 minutes before lysed with 1% 
SDS lysis buffer with addition of protease inhibitor cocktail and phosphatase 
inhibitor cocktail (Sigma, St. Louis, MO, USA). Lysates were sonicated to disrupt 
DNA before BSA assay (Pierce, Rockford, IL, USA) for protein concentration 
determination, solubilized in Laemmli sample buffer with 200 M dithiothreitol, and 
boiled for 2 minutes and proteins were separated on SDS-PAGE gels. The 
proteins were then electrophoretically transferred to nitrocellulose membrane in 
25 M Tris, 192 M glycine, and 20% methanol. The nitrocellulose was blocked 
with 5% nonfat dry milk in 10 M Tris (pH 7.4), 150 M NaCl, and 0.01% Tween 20. 
The membranes were probed with the individual primary antibody (anti-
adenosine A1 receptor; 1:1000 dilutions; Abcam, Cambridge, MA, USA; anti-p-
ERK1/2; 1:1000 dilutions; Cell Signaling, Danvers, MA, USA) overnight in 10 M 
Tris (pH 7.4), 150 M NaCl, 5% nonfat dry milk, and 0.01% Tween 20. The blots 
were washed in 10 M Tris (pH 7.4), 150 M NaCl, and 0.01% Tween 20, and 
bound antibody was detected by a horseradish peroxidase-conjugated anti-rabbit 
or anti-mouse IgG and enhanced chemiluminescence (Pierce). Equal protein 
loading was verified by stripping off the original antibody, and reprobing with the 
primary antibody anti-GAPDH (1:1000; Fitzgerald, Concord, MA, USA) or anti 
total-ERK1/2 (1:1000 dilutions; Cell Signaling). 
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5.11. 
Figure 5.5. AR expression in porcine coronary SMC, EC, and endothelium-intact 
right coronary artery 
Supplementary figure legends 
A. Immunoblots of A1R, A2AR, A2BR were done in subcultured coronary SMC 
isolated from Ossabaw right coronary artery. GAPDH served as control. B. 
Immunoblots of A1R were done in subcultured coronary EC isolated from 
Ossabaw right coronary. Vinculin served as loading control. C. RT-PCR for 
detection of the A1R, A2AR, A2BR, and A3R mRNA expression levels was 
performed with endothelium-intact right coronary artery freshly isolated from 
Ossabaw swine. RT-PCR done without reverse transcriptase or without template 
is indicated as -RT or NTC, respectively. 
 
Figure 5.6. Other adenosine receptor subtype expression in 1.0 bare metal stent 
during time course following stenting recovery 
Real-time RT-PCR for detection of A2AR (A) and A2BR (B) mRNA expression 
levels was performed in 1.0 bare metal stent (as denoted in Figure 5.1) in pigs 1-, 
2-, and 4-week post stenting (n=5/group).  
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5.12. 
Figure 5.5. AR expression in porcine coronary SMC, EC, and endothelium-intact 
right coronary artery 
Supplementary figures 
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Figure 5.6. Other adenosine receptor subtype expression in 1.0 bare metal stent 
1-, 2-, or 4-week following stenting 
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CHAPTER 6. COMPREHENSIVE DISCUSSION 
6.1. 
 Adenosine was widely thought to mediate vasodilation and also attenuate 
SMC proliferation, thus providing cardioprotection 54. A1R became really 
interesting to us in that SMC proliferation plays an important role in CAD and 
restenosis 9, 62-64 and our lab made a novel discovery that A1R mediated 
mitogenic effect of adenosine in coronary SMCs. The work in this thesis focused 
on the role of A1R in native coronary atheroma, in-stent stenosis and coronary 
blood flow regulation (Chapter 4, 5 and 3 respectively). In general, the effects of 
exercise were usually opposite to those elicited by MetS and CAD. Exercise 
training in this thesis consisted of 7-week treadmill running and was used to 
evaluate the beneficial effects of exercise in circumstances of microvessel 
dysfunction (Chapter 2) and macrovascular atherosclerosis with or without 
stenting (Chapter 2 and 4 respectively). Most of the studies presented in this 
dissertation utilized the Ossabaw swine model of MetS and CAD (Chapter 4 and 
5) or dyslipidemia (Chapter 3). Yucatan swine was used in addition to that 
(Chapter 2). The major findings from these studies include 1) A1R promotes CAD 
in vitro and may contribute to coronary atherosclerosis in vivo in the setting of 
MetS (Chapter 4); 2) A1R upregulation and A1R signaling contribute to coronary 
in-stent stenosis in MetS (Chapter 5); 3) A1R antagonism by DPCPX might 
promote vasodilation induced by some vasodilators other than adenosine in 
“healthy” Ossabaw swine and an imbalance of A1R/A2AR upregulation and 
signaling in coronary microcirculation distal to a stent may contribute to the 
General overview 
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impaired adenosine-induced flow in dyslipidemia (Chapter 3); 4) Short-term 
exercise training near the time of stenting prevented stent-induced microvascular 
dysfunction and attenuated native atheroma in the genetically lean Yucatan 
swine (Chapter 2) as well as Ossabaw swine (Chapter 4). 
  
6.2. 
 SMC proliferation is a key step in the development of occlusive vascular 
diseases, like atherosclerosis and restenosis after stenting 9, 62-64. The novel 
findings of the A1R-mediated trophic effect of adenosine via ERK1/2 activation in 
coronary SMCs led to the hypothesis that A1R upregulation and A1R signaling 
contribute to both native coronary atherosclerosis and in-stent stenosis in MetS 
(Chapter 4 and 5 respectively). Selective A1R antagonism strongly supported the 
causal role of A1R activation in in-stent stenosis in vivo and atherosclerosis in 
vitro (Chapter 5 and 4 separately). To our knowledge this is the first discovery 
that A1R contributes to coronary atherosclerosis in vitro and in-stent stenosis in 
vivo in the setting of MetS.  
A1R contribution to native coronary atherosclerosis and in-stent stenosis 
 
 A1R activation produced myocardial preconditioning in the canine heart by 
opening KATP channels 213, 214 and reduced ischemia-induced ventricular 
arrhythmias and fibrillation in the porcine heart 215, thus providing 
cardioprotection. Adenosine A2A receptor (A2AR) activation inhibited foam cell 
formation by stimulation of the reverse cholesterol transport protein expression, 
thereby preventing atherosclerosis 216. The functions of A1R and A2R were 
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reported almost exclusively opposite to each other 65-68, so A1R could potentially 
promote atherosclerosis, contradictory to its traditional role. The in vitro studies 
done in the thesis verified proatherogenic actions of the A1R (Chapter 4 and 5). 
 
 Aldosterone is often elevated in MetS and contributes to CAD by altered 
insulin/IGF-1 signaling pathways, reactive oxygen species formation, etc. 44. 
Dexamethasone was reported to regulate A1R expression 74-76, but aldosterone 
regulation of A1R has never been reported. We discovered for the first time that 
aldosterone upregulated A1R mRNA and protein expression in subcultured 
coronary SMCs (Chapter 4, Figure 4.3). Aldosterone contribution to CAD in the in 
vitro organ culture model was found partially mediated through A1R activation, 
which is a novel discovery (Chapter 4, Figure 4.5). Interestingly, aldosterone was 
reported to increase neointimal formation after balloon injury 48, suggesting 
possible contribution of aldosterone regulation of A1R in coronary in-stent 
stenosis as well, which deserves further study. 
  
 A1R upregulation was observed in both types of occlusive coronary 
diseases, native atherosclerosis and in-stent stenosis in MetS (Chapter 4 and 5 
respectively). We propose that aldosterone contributes to A1R upregulation in 
native atheroma (Chapter 4, Figure 4.5); however, other factors could contribute 
to the A1R upregulation in the occlusive coronary disease as well. Angiotensin II 
in relation to A1R expression was studied, but the connection was not observed 
(data not shown). Lipids, reactive oxygen species, inflammatory factors, and 
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cytokines are all possible driving forces for A1R upregulation in atherosclerosis 
and in-stent stenosis, which may need further clarification. 
 
 As a summary for the role of A1R contribution to CAD and in-stent 
stenosis, I have refined the model originally proposed by Shen etc. 65, 69 (Chapter 
6, Figure 6.1). Large amounts of platelets adhere to coronary stents, resulting in 
ATP release from platelets and coronary endothelial cells. ATP breaks down into 
adenosine, which leads to A1R and downstream signaling activation in coronary 
SMCs, and promotes coronary in-stent stenosis. In MetS, aldosterone elevates 
and activates mineralocorticoid receptor (MR) or other factors, which potentially 
serves as a transcriptional factor and upregulates A1R in coronary SMCs, thus 
contributing to coronary atherosclerosis.  
 
6.3. 
 Adenosine is a nucleoside with a half life < 20 seconds in human blood 139, 
and regulates coronary blood flow especially during stress and ischemia 136-139. 
Adenosine is largely an endothelium independent vasodilator, especially in the 
porcine coronary microcirculation, with little influence on the macrocirculation 138, 
139. There are 4 different subtypes of adenosine receptors (AR)-A1R, A2AR, 
A2BR and A3R 51. Adenosine binds to adenosine A2 receptor (A2R), increases 
cytosolic cyclic adenosine monophosphate (cAMP) as the second messenger, 
and results in vasorelaxation 139, which is consistent with our finding that A2R 
Adenosine and adenosine receptors in regulation of coronary blood flow 
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mainly A2AR mediates vasodilation effects in porcine coronary microcirculation 
(Chapter 3, Figure 3.2). 
 
 We found adenosine A1 receptor (A1R) antagonism potentiates 
vasodilatory effects of some vasodilators other than adenosine in the porcine 
coronary microvessels under basal conditions (Chapter 3, Figure 3.3), consistent 
with research done by Pelleg etc. in canine heart 156, while in sharp contrast to 
the findings that A1R does not contribute to adenosine-induced flow in swine 141, 
147, 154. Experimental design might count for the differences, but experimental 
condition might be a more important cause. Our study and Pelleg study 156 were 
done in vivo, and in vitro manipulations were done by the other groups 141, 147, 154. 
As the in vivo experiments are more integrative and systemic, our in vivo study is 
more physiologically relevant vs. in vitro studies. 
 
 We found that bare metal stent deployment in conduit coronary arteries 
elicited impaired adenosine-induced flow in dyslipidemic Ossabaw swine 
(Chapter 3, Figure 3.4) and hypercholesterolemic Yucatan miniature swine 
(Chapter 2, Figure 2.2), which was associated with increased A1R and A2AR 
expression (Chapter 3, Figure 3.5). The altered balance between A1R and A2AR 
signaling might contribute to that. However, AR specific agonists or antagonists 
were not used in either control or dyslipidemic swine, which would be a further 
step in the future. 
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6.4. 
 Exercise training of patients with CAD induces multi-benefits, including 
improvement in exercise tolerance and increased coronary conduit and 
microvessel dilation 18-23. We found that short-term exercise training partially 
restored the impaired braydkinin and/or adenosine-induced flow in 
hypercholesterolemic swine after stenting (Chapter 2, Figure 2.2) and decreased 
coronary conduit atheroma burden in MetS (Chapter 4, Figure 4.1) and 
hypercholesterolemia (Chapter 2, Figure 2.3). Noticeably, the beneficial effects of 
exercise were independent of changes in plasma lipids in MetS and 
hypercholesterolemia (Chapter 4, Table 4.1, and Chapter 2, Table 2.1, 
respectively). Interestingly, plasma aldosterone and A1R protein expression in 
native atheroma were altered by exercise in MetS (Chapter 4, Figure 4.1), 
suggesting aldosterone and A1R could contribute to decreased atheroma by 
exercise.  
Beneficial effects of exercise in macrovascular and microvascular circulation 
 
 The findings of impaired responses to adenosine (largely endothelium-
independent vasodilator) suggest that the microvascular dysfunction was not 
limited to endothelium, but smooth muscle function could be adversely affected 
as well. We also found that hypercholesterolemia decreased microvessel density 
and exercise training prevented that (Chapter 2, Figure 2.4), suggesting that 
microvessel rarefaction might be the underlying mechanism for microvascular 
dysfunction in hypercholesterolemia.  
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6.5. 
 The A1R contribution to coronary atherosclerosis was verified in the in 
vitro organ culture model of coronary atherosclerosis. However, the causal role of 
the A1R in coronary atherosclerosis in vivo was not verified yet. We may be able 
to test the causal role of A1R in atherosclerosis in vivo via chronic systemic 
infusion of A1R-selective antagonist DPCPX. If DPCPX decreases the coronary 
atherosclerosis vs. vehicle infusion in MetS, it suggests that A1R plays a causal 
role in the development of CAD in vivo. 
Future directions 
 
 A1R was upregulated by aldosterone in coronary SMCs, however, the 
umderlying mechanisms were not explored yet. Upon ligand binding, steroid 
receptors interact with specific hormone response elements in the promoters of 
hormone responsive genes, recruiting cofactors in a ligand-dependent manner, 
thereby regulating gene expressions 46. Aldosterone is a steroid hormone 164, 
upon binding to MR (a ligand-activated transcription factor) 164, enters the 
nucleus and possibly binds to the corresponding DNA sequence or other factors 
to regulate A1R gene expression. We could perform luciferase and ß-
galactosidase assays with plasmid construction in coronary SMCs to test if 
aldosterone-MR complex directly binds to A1R promoter and thus increases A1R 
transcriptional activity or not. Promoter A and B controls A1R gene expression 74. 
Promoter A is more active but only observed in selected tissues and promoter B 
is constitutively expressed but at much reduced levels. It was reported that A1R 
expression was enhanced when only promoter B was present 74. It could be 
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aldosterone upregulation of A1R was mediated through interaction with promoter 
B, and we can determine if promoter B is involved in the gene regulation process 
or not in the above mentioned experiments.  
 
 Aldosterone possibly contributes to coronary atherosclerosis, which 
shares similar pathophysiological process with in-stent stenosis, thus aldosterone 
could potentially regulate A1R expression in in-stent stenosis as well. To test the 
hypothesis, we could first determine if aldosterone increases in the stented pigs 
or not. If that is the case, we could go further with systemic infusion of 
aldosterone-specific antagonist-spironolactone in the pigs with stent deployment. 
If spironolactone infusion decreases A1R expression and the in-stent stenosis vs. 
vehicle infusion, aldosteone regulation of A1R plays a causal role in the 
development of in-stent stenosis. The finding will be of great therapeutic potential 
in alleviating in-stent stenosis. 
 
 Besides aldosterone, other mechanisms could upregulate A1R expression 
in native coronary atherosclerosis and in-stent stenosis. Possible contributors 
include: lipids, reactive oxygen species, and inflammatory factors, all of which 
deserves our research attention. We could explore their possible roles in 
regulation of A1R expression by combination of in vitro cell or tissue culture and 
in vivo animal study as we did with aldosterone regulation of A1R gene. 
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 The research presented in this thesis dissertation unveiled the important 
roles of A1R in native coronary atherosclerosis, in-stent stenosis, and coronary 
blood flow regulation especially in MetS. The beneficial effects of exercise in 
alleviation of coronary conduit atheroma and microvessel dysfunction in 
dyslipidemia were also discovered. These novel findings provide new targets for 
possible clinical application in reducing coronary in-stent stenosis, which 
potentially will benefit many patients with severe coronary atherosclerosis. 
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6.6. 
Figure 6.1. Proposed model of A1R contribution to coronary atherosclerosis and 
in-stent stenosis 
Figure legend 
Stent placement in coronary arteries leads to platelets adherence to the stent 
and adenosine release from platelets as well as endothelial cells. Adenosine 
activates A1R and downstream mitogenic signaling pathways (ERK, JNK, PI3K-
AKT) in coronary SMCs, thus promoting in-stent stenosis. In metabolic syndrome, 
elevated aldosterone binds to mineralocorticoid receptor (MR) or acts via some 
unknown mechanisms, potentially upregulates A1R in coronary SMCs, and 
contributes to the development of coronary atherosclerosis in vivo. ERK, JNK are 
both mitogen-activated protein kinase family members. ERK, the extracellular 
signal-regulated kinases; JNK, the c-Jun-N-terminal kinases. 
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6.7. 
Figure 6.1. Proposed model of A1R contribution to coronary atherosclerosis and 
in-stent stenosis 
Figure 
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A. 
Xin Long, Michael Sturek, PhD 
Monolayer Culture of Vascular Smooth Muscle Cells 
A.1. 
A.1.1.
Primary culture of vascular smooth muscle cells 
 Get arteries immediately after sacrifice and rinse them in 70% ethanol for 
2 seconds. This method was different than done previously in the laboratory for 
the past more than 20 years. 
Artery harvest 
 
 Rinse the arteries fiercely with phosphate-buffered saline (PBS, GIBCO, 
catalog number 10010-072) or sterile saline twice to get rid of the ethanol and put 
the arteries in DMEM culture media (GIBCO, catalog number 11885-092, 0% 
serum) to keep the cell viable. Always keep arteries on ice to reduce cell 
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degradation. 
[Animal: #           , Age       , Time dead        , Misc.                                       ] 
[Portion of artery: Proximal   , Middle   , Distal           
Artery: LAD_ RC    CFX    Peripheral      ]  
[Date     -    -    , Time       ]  
 
A.1.2.
 In a Class II laminar airflow culture cabinet, dissect free the extravascular 
tissue (e.g. fiber, lipid) in PBS in a 100 mm Petri dish. Arteries need to be on ice 
as always. 
Clean artery 
 
 At this point, the artery can be stored in the refrigerator in storage media 
for up to 5 days, if necessary. 
[Storage media = ________ +        + ______% penicillin-streptomycin (P/S, 
GIBCO, catalog number 15140-122)] 
[In refrigerator: Date     -    -     Time      , Misc._______________________] 
 
A.1.3.
 Cut arteries open, lumen facing up, pin the arterial wall down in 30 mL jars 
with Sylgard in the bottom containing ~2 mL Low Ca. Expose the intima as much 
as possible to increase its contact area with digestion enzyme and thus increase 
digestion efficiency. 
Pin down the arteries for dispersion 
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A.1.4. 
Remove Low Ca and add 1.5-2.0 mL collagenase solution to each jar. Put 
jars in shaking water bath (55-65 strokes/min) at 37° C for 40-60 minutes. The 
jars should be placed correctly so that the direction of the shaking is parallel with 
blood flow direction in the vessel. 
 
Be careful to set the lids of jars higher than the water surface level in 
water bath to prevent contamination of arteries. The jars can be wrapped in 
cellophane to ensure separation from water, if needed.  
[Collagenase batch: Date     -    -    , Lot #             ] 
[Dispersion: Date     -    -    , Time started           , Time ended           ] 
[Misc.:                                                                                ] 
Misc. is for notes regarding uniqueness of dispersion, etc. 
 
A.1.5. 
In culture hood aspirate supernatant in jars and pipette over arterial lumen 
several times forcefully to remove endothelial cells stuck in lumen. Transfer 
supernatant to 1.7 mL Eppendorf tubes. 
 
Centrifuge for 3 minutes at 900 RPM only if the artery is very small, thus 
few cells would be expected. Remove supernatant, leave 100-150 µL enzyme 
solution to resuspend the pellet (if centrifuged). For the arteries in jars, add 2 mL 
more collagenase solution and start shaking again as in step 4. 
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A.1.6. 
Place drop of supernatant from step A.1.5 or resuspended pellet in 35 mm 
petri dish and observe under microscope. Dispersion may vary from day to day. 
At this point, mostly debris of connective tissue, endothelial cells, etc. are seen, 
but few SMC. The endothelial cells (EC) are round and clump together in 
bunches.  
 
Note appropriately: A) If few SMCs, you can discard (unless EC fraction 
will be retained for fresh use or culture). B) If many SMCs, keep for cell culture. C) 
If no SMCs, discard it and that means you need more time to digest the intima 
and media. Label as CORED 1.00 Month - Day - Year  Species Vessel (e.g., 5-8-
06 Porcine CFX
CORED 1.00     -    -______ ________ _________ 
 included in blanks as date, species, and vessel, respectively. 
The subscript "D" refers to enzymatic dispersion and "CORE" denotes coronary 
EC. AORE could denote aortic EC. CORSMC could denote coronary smooth 
muscle cell. 
Ignore this section if discarded ______              
[EC                                  ; SMC                                                    ] 
 
A.1.7. 
 For conditions in step A.1.6: A), you can shake the jars for another 30-50 
minutes before you collect the supernatants again as in step A.1.5. For condition 
B), you can shake the jars for another 30-40 minutes. For condition C), you can 
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shake the jars for another 20-40 minutes till you can see SMCs under 
microscope.  
 
A.1.8. 
Repeat step A.1.4 to A.1.7 unti l the arteries seem mostly digested.  
[Dispersion: Time started           , Time ended           ] 
____D __.00     -    -______ ________ _________  
[EC                                   ; SMC                                                    ] 
 
A.1.9. 
For the cell suspension need to culture, add 1 mL DMEM + 10-20% fetal 
bovine serum (FBS, GIBCO, catalog number 16000-044) + 1% P/S and pipette 
up and down to make cells evenly distributed. 
[Growth media =            +            + _____ P/S] 
 
A.1.10. 
 Obtain cell count by loading 10 µL of cell suspension onto the 
hemacytometer, counting the cells (using a hand counter) in the 25 squares, and 
multiplying the resulting count by 1 × 102. This will give the cell density (cells/mL). 
To determine total number of cells, multiply cell density by total volume of 
medium cells that are suspended in. If the cell density is great (determined by 
visualization), one can count 5 squares (usually the 4 corner and the middle 
squares) and multiply resulting cell count by 5 × 102. 
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 Inoculate at 10,000 cells per cm2 in culture dishes or flasks for rapid 
growth (e.g. primary cell culture), or at 6,000 cells per cm2 for regular 
subculturing. Following inoculation, swirl the medium in the culture vessel to 
distribute the cells. CSMC attach to culture surfaces quickly. If the medium is not 
distributed immediately following inoculation, the cells may grow in uneven 
patterns. 
 
 Put culture dishes or flasks in 37° C, 5% CO2 / 95% air, humidified cell 
culture incubator O/N. For best results, do not disturb the culture for at least 24 
hours after the culture has been initiated. 
 
A.2. 
 Cells may be maintained as a viable culture by feeding and splitting as 
necessary, depending on how rapidly you wish the cells to proliferate. Change 
the culture medium to freshly supplemented medium 24 to 36 hours after 
establishing the primary cultured cells. For subsequent subcultures, change the 
medium 48 hours after establishing the subculture. Change the medium every 
other day thereafter, until the culture is approximately 80% confluent. Once the 
culture reaches 80% confluence, change the medium every day. To achieve the 
highest cell densities, the culture medium should be changed every day as the 
cultures approach confluence. 
Maintenance of cultured VSM cells 
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 To feed the cells, remove the old medium by aspiration. Gently pipet the 
appropriate volume of fresh culture medium into the dish or flask - 1mL for 96-
well plate, 2 mL for 35 mm dish or 6-well tissue culture plate (Falcon, catalog 
number 353046), 5 mL for 60 mm dish, 10 mL for 100 mm dish, 15 mL for 
150mm dish, 5 mL for 25 cm2 flask, 15-20 mL for 75 cm2 flask. 
  
Label culture vessel and be sure to include the correct passage # and 
date. For coronary SMC, we can label as CORSMCD 1.00 Month - Day - Year -
 Species – Vessel. 
 
Here the decimal values indicated the passage number. In 
this case, since the cells are still primary, they are 1.00. After you subculture 
once (in steps below), the cells would be 1.01; a second subculture (thus second 
trypsinization) would be 1.02, etc. We retained the whole number value to denote 
the fraction from which we harvested the SMC. This might be important, since 
fraction 1.00 would be closer to the intima, thus perhaps different properties than 
fraction 2.00 or 3.00, which would be farther into the media and perhaps closer to 
the adventitia. 
 Incubate cultures in a 37° C, 5% CO2 / 95% air, humidified cell culture 
incubator. 
 
A.3. 
 For rapidly proliferating subcultures, cells should be subcultured before 
the culture becomes confluent. 
Subculture of VSM cells 
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 Once the culture reaches 90% confluence, remove all of the culture 
medium from the flask by aspiration. Wash the flask with PBS and remove the 
solution by aspiration. Pipette certain volume of Trypsin/EDTA solution (GIBCO, 
catalog number 25200-056) to the culture vessel - 100 µL for 96-well plate, 400 
µL for 35 mm dish or 6-well plate, 1 mL for 60 mm dish or 25 cm2 flask, 2 mL for 
100 mm dish, 3 mL for 150 mm dish or 75 cm2 flask. Rock the culture vessel 
gently to ensure that the entire surface is covered. Put the culture vessel back 
into the cell incubator. 
 
 Take flask out of cell incubator in 2-3 minutes and view the culture under a 
microscope. If cells are detached, they mostly will become round. By gently 
tapping the bottom of the flask some cells can dislodge from the surface of the 
flask. When most of cells become detached from the culture vessel, add Trypsin 
Neutralizer solution (DMEM growth medium, 3 to 4 times volume of 
Trypsin/EDTA solution) to the culture vessel.  
[Trypsin neutralizer media =            +            + _____ P/S]  
 
 Transfer the detached cells to a sterile 15 mL conical tube. Observe 
culture vessel under microscope, if there are more than 20% cells attaching at 
the culture vessel surface, repeat trysinization and neutralization steps. Add the 
solution to the 15 mL conical tube too. Centrifuge the cells at 180 × g for 7 min. 
Observe the cell pellet. Discard supernatant, being careful not to dislodge the cell 
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pellet. Resuspend the cell pellet in 2 mL DMEM growth medium. Pipette the cells 
up and down with 10 mL pipette to ensure a homogeneous cell suspension. 
 [Growth media =            +            + _____ P/S] 
 
 Determine the concentration of cells in the suspension (as described 
above). Dilute the cells in prewarmed, pregassed growth medium and seed new 
culture flask with 6,000 cells / cm2. Instead of counting cell density, you can 
simply transfer the cell suspension (in equal volume) to new culture vessel 
containing appropriate volume of prewarmed, pregassed growth medium (3 
dishes for 1:3 split, 5 dishes for 1:5 split, etc.). Incubate cultures in a 37° C, 5% 
CO2 / 95% air, humidified cell culture incubator. 
 
A.4. 
 If you wish to preserve the cells for long-term storage, later use, etc., it is 
recommended that the cells be frozen in liquid nitrogen (-196° C).  Again, the 
cells are harvested off the culture vessel by trypsinization (see above), diluted 
with 5-10 mL medium, placed into a 15 mL tube, and centrifuged for 10 minutes 
at the minimum setting. 
Cryopreservation of cultured VSM cells 
 
 Discard the supernatant then add 1 mL freezing medium (DMEM + 20% 
FBS + 1% P/S + 10% DMSO). Transfer cell suspension into appropriately 
labeled Nunc tubes. 
[Freezing media =            +            + _____% P/S + ______% DMSO] 
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 Place Nunc tubes in freezing tray in liquid nitrogen refrigerator. After 2-4 hr, 
place tube(s) in a cane of liquid nitrogen tank. Take a record of the relative 
position of labelled Nunc tubes in liquid nitrogen tank. 
 
A.5. 
 To bring cells up from liquid nitrogen, place cryovial in a 50 mL tube in 37° 
C water bath (to prevent too-rapid thawing and also ensure sterility). After 
contents of the vial thaw, wipe the outside of vial with 70% ethanol and move to a 
Class II laminar flow culture hood. Transfer vial contents in a 15 mL tube, add 5-
10 mL growth medium. 
Initiating cultures from cryopreserved cells 
 [Growth media =            +            + _____ P/S] 
 
 Centrifuge 10 min at the minimum setting to remove DMSO. Discard 
supernatant, add 1 mL growth medium. Pipette the suspension up and down with 
1 mL pipette to disperse the cells. Remove 10-20 µL from the vial, using a 
hemacytometer, determine the number of viable cells per mL. Dilute the contents 
of the vial so that cells can be seeded at 6,000 cells / cm2 (XL noted on 3/26/09 
that primary cultured CASM cells can be seeded at 10, 000 cells / well for 6-well 
plate) in culture dish or flask. Add 5 mL of cell suspension to each 25 cm2 culture 
flask or 15 mL of cell suspension to each 75 cm2 culture flask. 
 [Growth media =            +            + _____ P/S] 
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Incubate cultures in a 37° C, 5% CO2 / 95% air, humidified cell culture 
incubator. From here, the cells can be maintained in culture (as described above) 
or used for experiments, etc. NOTE IMPORTANTLY: To keep the hood from 
possible contamination, please clean the suction tubing right after your usage 
with 10% bleach or 70% ethanol followed by distilled water and dispose of the 
remaining bleach or ethanol in the cylinder. The waste container inside the hood 
needs to be cleaned either when the liquid reaches 700 mL or when the hood is 
inactive for a couple of weeks. 
 
A.6. 
Collagenase Recipe (in Low Ca) 
Collagenase solution 
Components Final Concentration 20 mL total 10 mL total 
BSA, Fraction V 0.2% (wt/vol) 40 mg       20 mg 
Soybean Trypsin 
Inhibitor, Type I-S 0.1% 20 mg 10 mg 
DNase I, Type IV  4 mg 2 mg 
Collagenase, CLS II   20 mg 10 mg 
[Collagenase batch: Date     -    -    , Lot #             ] 
Note: Adjust pH of Low Ca to 7.55, and then add collagenase and pH will 
be exactly 7.40. Then filter with 0.2 μm syringe driven filter unit (Millipore, catalog 
number SLGV013SL). Make in 10-20 mL quantities. Each step of isolation above 
mentioned requires at least 4-6 mL collagenase. Remaining collagenase solution 
may be frozen at -20° C for at least 10 days. 
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B. 
B.1. 
Immunoblots 
Prepare mixture of 100 µL lysis buffer + 1 µL protease inhibitor cocktail 
(Sigma, catalog number P8340). If phosphorylated proteins are detected later, 
add 1 µL phosphatase inhibitor cocktail 1 (Sigma, catalog number P2850) + 1 µL 
phosphatase inhibitor cocktail 2 (Sigma, catalog number P5726) in addition to the 
100 µL lysis buffer mix. Remove the culture media or other buffer and wash cells 
with PBS twice. Lyse the cells with 100 µL 1% SDS lysis buffer mix for each well 
of 6-well plate at room temperature for 1 minute. Scrape cell lysates off the plate. 
For cells in a 75 cm2 flask, add 120 µL lysis buffer mixture, resulting in higher 
protein concentration. 
Preparation of cell lysates 
 
Sonicate cell lysis to break genomic DNA, or use 25G / 1.5 needle 10 
times up and down. Spin at 14,000 rpm (16,000 × g) in an Eppendorf microfuge 
for 10 minutes at 4° C. Transfer the supernatant to a new tube and discard the 
pellet. Determine the protein concentration by Bradford BCA assay (Pierce, 
catalog number 23225). Mix 1000 µL of Reagent A + 20 µL Reagent B (1:50 
dilution) for each sample. 5 µL sample + 45 µL ddH2O (1:10 dilution) or 50 µL 
BSA standards + 950 µL Reagent mix, incubate for 30 minutes at 60° C, then do 
protein concentration assay. 
 
Take X µL (= Y µg protein) and mix with X µL of 2 × Laemmli sample 
buffer (Bio-rad, catalog number 161-0737) with 200 mM dithiothreitol (Sigma, 
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catalog number D9163). Make the protein loading amount equal for each well. 
The loading volume doesn’t matter. Heat the mix for 3-5 minutes at 95° C. Cool 
at room temperature for 5 seconds. Flash spin to bring down condensation prior 
to loading gel. Use immediately to load gel or store at -20° C (reboil before 
loading gel). 
 
B.2. 
Setup gel in electrophoresis apparatus, fill reservoirs with 1 × Running 
Buffer. Remove comb and rinse wells with 1 × Running Buffer.  
Gel electrophoresis 
 
Boil samples (15-35 µL for 15-well mini-gel, 20-75 µL for 10-well mini-gel) 
for 5 minutes, flash spinning the samples, then load samples and 5 µL standards 
(Precision plus protein dual color standard, Bio-Rad, catalog number 161-0374) 
to the gel. Run until bromophenol blue (BPB)-dye reaches bottom of gel (about 
1.5-hr for mini-gel at 25 mA per gel, about 2-2.5 hrs for mini-gel at 100V). 
 
B.3. 
Remove gel from plate-sandwich (note left to right orientation), cut away 
stacking gel, and rinse running gel briefly in 1 × Transfer Buffer. Cut two 
Whatmman filter papers and one nitrocellulose filter membrane (Bio-rad, catalog 
number 162-0112) to the size of the gel, make mark in the nitrocellulose 
membrane and then wet all filters with 1 × Transfer Buffer. 
Gel to Filter Blotting 
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a) Lay 2-gel plastic manifold in Electro-blotter.  
b) Lay 1 wetted filter paper for each gel onto platform of Blotter. 
c) Place nitrocellulose membrane onto filters (need to mark or cut 
notch on desired corner of filter to maintain gel-lane orientations).  
d) Place gel in known orientation onto the nitrocellulose fi lter 
membrane (Stacking gel heading up, the nitrocellulose membrane 
should be closer to + anode (white plastic manifold) than the gel is).  
e) Lay 1 wetted filter paper on top of the gel. Remove bubbles by 
rolling pipets. 
f) Install top of Electro-blotter (Membrane facing white stack and 
anode) and run at 80 mA overnight. 
 
Remove nitrocellulose membrane, transfer the membrane to small dish 
and add 10 mL Ponceau S solution (Sigma, catalog number P7170) to confirm 
the transfer of proteins to the membrane. (Usually, you will be able to see protein 
ladders in all the samples and standards.) After you are done, put Ponceau S 
back to the container for reuse. Can begin western probing immediately or store 
filter, either  
a) rinse in 1 × TBST for 3-time, place in seal-bag and store at 4° C, or 
b) place in Blocking Solution in seal-bag and store at -20° C. 
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B.4. 
Rinse filter in 1 × TBST for 3 × 5-10 minutes, then place in seal-bag or 
small blotting box with 10-20 mL Blocking Solution for at least one hour at room 
temperature. For A1R, incubate for 3-5 hours at room temerature to reduce non-
specific binding. Blocking Solution: 5% nonfat dry milk in 1 × TBST buffer (10 mM 
Tris, pH 7.4, 150 mM NaCl, and 0.1% Tween 20) or StartingBlock (TBS) blocking 
buffer (Pierce, catalog number 37542) with 0.1% Tween-20 (TBST blocking 
buffer). If for p-ERK detection, the TBST buffer is different from for A1R, so 
please refer to B.5. After blocking the membranes will be probed with a rabbit 
polyclonal antibody specific for the A1R (1:1000 dilutions, Abcam, catalog 
number AB3460-100) in Blocking Solution or TBST blocking buffer at 4° C 
overnight. Five-six mL is enough for each membrane. Put the membrane on a 
rocker from this step on. To reuse the primary antibody, add 10-12 mL of 10% 
sodium azide to the primary antibody. The antibody is good for 1 week if in 5% 
nonfat dry milk or 3 weeks if in TBST blocking buffer. 
Probing the Filter 
 
The next day, wash the membrane 3 × 5-10 minutes with 1 × TBST. Add 
10-20 mL Blocking Solution and Secondary Antibody to the dilution of 1:5000 (a 
horseradish peroxidase-conjugated anti-rabbit IgG). Incubate at room 
temperature for 1 hour. Wash filters with two quick rinses, then 3 × 5-10 minutes 
with TBST. The longer wash it takes, the less background signal there is. To 
develop the membrane with electrogenerated chemiluminescent (ECL) Kit 
(Pierce, catalog number 34080) or supersignal ECL kit (Supersignal West Dura 
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Extended Duration Substrate, Pierce, catalog number 34075): mix equal part of 
ECL solutions A and B (~2 ml per fi lter for regular ECL kit; ~1 ml per filter for 
supersignal ECL kit) 
a) Spread ECL Solution Mix onto protein side of filter and incubate for 
3-5 minutes. 
b) Drain filter and wrap in plastic wrap, and expose to ECL developing 
machine. Exposure times range from 30 seconds to 10 min. 
 
If the next target protein on the same membrane has similar molecular 
weight to A1R, or wi ll be detected with a rabbit primary antibody as well, the 
membrane may need to be stripped, reblocked and reprobed. Procedure of 
stripping blot:  
a) Rinse blot off with 1 × TBST. 
b) Put blot into small immunoblot box. 
c) Add about 10 to 20 ml Stripping buffer (Pierce, catalog number 
21059). 
d) Immerse into 37° C shaking water bath and incubate for 20-50 
minutes. 
e) Rinse blot off with 1 × TBST 5-10 minutes for 3 times. 
f) Continue and reblock and reprobe as described previously. 
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B.5. Immunoblot buffers
1% SDS lysis buffer (in autoclaved ddH2O) 
 (Based on recipes in lab of Drs. Gallagher and Herring) 
Component Stock Concentration 50 mL total 
SDS (PH 6.8) 20% 2.5 mL 
NaCl 5 M 1 mL 
Tris (PH 7.4) 1M 2.5 mL 
Water  44 mL 
Note: 20% SDS solution (USB, catalog number BP2436-1). 
 
1 × TBST buffer (in autoclaved ddH2O, for A1R and p-ERK separately) 
Component Stock Concentration A1R: 1 L total p-ERK: 1 L total 
NaCl 5 M 30 mL 100 mL 
Tris (PH 7.4) 1 M 10 mL 20 mL 
Tween 20  1 mL 1 mL 
Water  959 mL 879 mL 
 
2 × Separating gel buffer (in autoclaved ddH2O, PH 8.8) 
Component Stock Concentration 500 mL total Final Concentration 
Tris (Base)  45.4 g 0.75 M 
SDS 20% 5 mL 0.2% 
Water  < 500 mL  
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Note: Dissolve above components in ~ 400 mL ddH2O. Adjust pH to 8.8 
with concentrated (30%) HCl. Ajust final volume to 500 mL with ddH2O. Sterile 
filter into a clean, sterile glass bottle. Store at room temperature indefinitely. 
 
2 × Stacking gel buffer (in autoclaved ddH2O, PH 6.8) 
Component Stock Concentration 500 mL total Final Concentration 
Tris (Base)  15.2 g 0.25 M 
SDS 20% 5 mL 0.2% 
Water  < 500 mL  
Note: Dissolve above components in ~ 400 mL ddH2O. Adjust pH to 6.8 
with concentrated (30%) HCl. Ajust final volume to 500 mL with ddH2O. Sterile 
filter into a clean, sterile glass bottle. Store at room temperature indefinitely. 
 
Polyacrylamide gel electrophoresis (10% separating gel for A1R, p-ERK) 
Component Stock Conc.       Separating gel  Stacking gel  
  1-gel 2-gel 1-gel 2-gel 
Sterile water   1.25 mL 2.5 mL 1.75 mL 3.5 mL 
Separating gel 
buffer 2 × 3.75 mL 7.5 mL N/A N/A 
Acrylamide/Bis 
solution  30% 2.5 mL 5.0 mL 0.75 mL 1.5 mL 
Stacking gel buffer 2 × N/A N/A 2.5 mL 5.0 mL 
Ammonian 
persulfate 10% 38 µL 75 µL 30 µL 60 µL 
TEMED  8 µL 15 µL 5 µL 10 µL 
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Note: Pipet and mix above components well. Use 6-6.5 mL separating gel 
and 4 mL stacking gel each. 30% Acrylamide/Bis solution (Bio-rad, catalog 
number 161-0158); Ammonian persulfate (Sigma, catalog number A3678); 
TEMED (Bio-rad, catalog number 161-0800).  
 
1 × Transfer buffer (in autoclaved ddH2O) 
Component Stock Concentration 1 L total 
Transfer buffer  10 × 100 mL 
Methanol  200 mL 
Water  700 mL 
Note: 10 × Transfer buffer (Bio-rad, catalog number 161-0771); methanol 
(Fisher Scientific, catalog number 67-56-1). 
 
1 × Running buffer (in autoclaved ddH2O) 
Component Stock Concentration 1 L total 
Running buffer  10 × 100 mL 
Water  900 mL 
Note: 10 × Running buffer (Bio-rad, catalog number 161-0772). 
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C. 
Xin Long, Zachary P. Neeb 
Organ Culture 
C.1. 
C.1.1.
Preparation of sterile arterial segments 
Rough / gross dissection of coronary arteries from heart occurs ensues 
immediately after mass of heart is obtained and within 60 seconds following 
removal of heart from chest cavity. 
Sterile dissection of coronary artery from intact heart 
a) Rinse coronary artery area on heart with cold, sterile 2CaNa + 2% 
P/S. 
b) Scissors are run from within 5 mm of coronary ostium into cardiac 
tissue on either side of each artery. Artery is cut away from heart 
with some cardiac tissue still attached. The aim of this step is 
expediency to place in sterile buffer solution. 
c) Rinse dissected arteries again thoroughly with ~20-50 mL of 2CaNa 
+ 2% P/S. 
d) Quickly plunge arteries into 500 mL ice-cold 2CaNa + 2% P/S. 
Container should be kept on ice through entire dissection 
procedure. 
e) Immediately take arteries to dissecting microscope in cell culture 
hood for further dissection. 
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C.1.2.
Each step should be completed with sterile techniques under Class II 
laminar flow culture hood. Utensils, dissecting dish, and gloves should be sterile. 
Solutions should be sterile filtered with 0.2 μm filter (Millipore, catalog number 
SCGPU02RE). Sterilization of tissue is accomplished by quick rinse with 70% 
ethanol followed by thorough rinse with PBS twice if the segments are for RNA 
extraction or immunoblots later. 
Other sterile techniques 
 
C.1.3.
Under magnification, all adventitia and adipose should be carefully 
removed from artery segment dedicated to organ culture. Do not perforate artery 
wall. Dissection of adventitia and adipose along the long axis of the artery avoids 
much perforation. Do not crimp or otherwise disturb the artery wall. Healthy 
looking artery equals healthy cells. Note that coronary artery should be on ice all 
the time to reduce possible RNA or protein degradation and keep cell viability. 
Any coronary artery that needs to be isolated or frozen for later molecular 
analysis should be attended to first. 
Cleaning of coronary artery 
 
C.2. 
RPMI 1640 culture media need to be prepared from powder into sterile 
solution following the protocols described on the package of the RPMI powder 
which is located in the upper shelf of the refrigerator in the entry room to the cell 
culture room. Sterile filter (Pre-sterilized vacuum driven disposable filtration 
Preparation of organ culture media 
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system, Millipore, catalog number SCGPU02RE) the RPMI 1640 solution under 
Class II laminar flow culture hood, add 10 mL of P/S in 1 L RPMI 1640 culture 
media and mix them well. 
 
C.3. 
Cut arterial segment into smaller segments of ~equal length. Put arterial 
segments into 6-well plate supplied with sterile RPMI + 1% P/S, 3-5 mL/well to 
keep arterial segments immersed. Incubate cultures in a 37° C, 5% CO2 / 95% 
air, humidified cell culture incubator. 
Arterial segments in organ culture 
 
C.4. 
RPMI culture media are replenished with every 2 days to keep the arterial 
segments supplied with nutrients until ready for different experiments. We have 
kept arterial segments in organ culture for up to 14 days. Histological analysis is 
underway at the time of writing this appendix. 
Maintenace of arterial segments in organ culture 
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D. 
Xin Long, Pamela G. Lloyd 
Total RNA Isolation 
This is modified from TRIzol® Reagent (Invitrogen, catalog number 15596-
018) manual. 
D.1. 
D.1.1.
Homogenization 
Homogenize tissue samples using a cold tissue pulverizer and pestle 
before into 1 mL of TRIzol® Reagent per 50-100 mg of tissue, or homogenize 
tissue samples already in TRIzol® Reagent with power homogenizer. The sample 
volume should not exceed 10% of the volume of TRIzol® Reagent used for 
homogenization. Centrifuge at 12,000 × g for 10 minutes at 2-8° C. Transfer 
supernatant to a fresh heavy gel phase lock tube (Eppendorf, catalog number 
FP2302830). Discard tubes with pellets in biohazard box. 
Tissues 
 
D.1.2.
Lyse cells directly in a culture dish by adding 1 mL of TRIzol® Reagent to 
a 35 mm diameter dish, and passing the cell lysate several times through a 
pipette. The amount of TRIzol® Reagent added is based on the area of the 
culture dish (1 mL per 10 cm2) and not on the number of cells present. An 
insufficient amount of TRIzol® Reagent may result in contamination of the 
isolated RNA with DNA. 
Cells grown in monolayers 
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D.2. 
Incubate the homogenized samples for 5 minutes at 15 to 30° C to permit 
the complete dissociation of nucleoprotein complexes. Add 0.2 mL of chloroform 
per 1 mL of TRIzol® Reagent. Cap sample tubes securely. Shake tubes 
vigorously by hand for 15 seconds and incubate them at 15 to 30° C for 2 to 3 
minutes. Centrifuge the samples at no more than 12,000 × g for 15 minutes at 2 
to 8° C. Following centrifugation, the mixture separates into a lower red, phenol-
chloroform phase, an interphase, and a colorless upper aqueous phase. RNA 
remains exclusively in the aqueous phase. The volume of the aqueous phase is 
about 60% of the volume of TRIzol® Reagent used for homogenization. We use 
heavy gel phase lock tube for centrifugation, so the red, phenol-chloroform phase 
and interphase will be locked by the gel from the aqueous RNA-containing phase. 
Phase separation 
 
D.3. 
After centrifugation, carefully transfer the aqueous phase to a fresh tube, 
and save the organic phase if isolation of DNA or protein is desired. Discard 
tubes containing phenol phase in biohazard box. Precipitate the RNA from the 
aqueous phase by mixing with isopropyl alcohol (isopropanol). Use 0.5 mL of 
isopropyl alcohol per 1 mL of TRIzol® Reagent used for the initial homogenization. 
Incubate samples at 15 to 30° C for 10 minutes and centrifuge at no more than 
12,000 × g for 10 minutes at 2 to 8° C. The RNA precipitate, often invisible before 
centrifugation, forms a gel-like pellet on the side and bottom of the tube. 
RNA precipitation 
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D.4. 
Remove the supernatant carefully with the suction system on benchtop 
designated for RNA extraction. Be careful not to dislodge the RNA pellet (white). 
Wash the RNA pellet once with 75% ethanol, adding at least 1 mL of 75% 
ethanol per 1 mL of TRIzol® Reagent used for the initial homogenization. Mix the 
sample by vortexing and centrifuge at no more than 7,500 × g for 5 minutes at 2 
to 8° C. 
RNA wash 
 
D.5. 
After centrifugation carefully remove as much ethanol from the tube as 
possible with the suction system described previously. Air-dry the RNA pellet 
until it is almost dry (5-10 minutes, or until semi-transparent). Do not dry the RNA 
by centrifugation under vacuum. It is important not to let the RNA pellet dry 
completely as this will greatly decrease its solubility. Partially dissolved RNA 
samples have an A260/280 < 1.6. Dissolve RNA in certain volume of (depending 
on the original tissue amount and RNA extraction efficiency) RNase-free water or 
0.5% SDS solution by passing the solution a few times through a pipette tip, and 
incubating in heating block for 10 minutes at 55 to 60° C. (Avoid SDS when RNA 
will be used in subsequent enzymatic reactions.) Put on ice and store at -80° C. 
RNA can also be redissolved in 100% deionized formamide and stored at -80° C. 
RNA resuspension 
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D.6. 
For small quantities of tissue (1 to 10 mg) or cell (102 to 104) samples, add 
750 µL of TRIzol® to the tissue or cells. Following sample lysis, add chloroform 
and proceed with the phase separation as described in D.2. Prior to precipitating 
the RNA with isopropyl alcohol, add 5-10 µg RNase-free glycogen (Invitrogen, 
catalog number 10814) as carrier to the aqueous phase. To reduce viscosity, 
shear the genomic DNA with 2 passes through a 26 gauge needle prior to 
chloroform addition. The glycogen remains in the aqueous phase and is co-
precipitated with the RNA. It does not inhibit first-strand synthesis at 
concentrations up to 4 mg/mL and does not inhibit PCR. 
RNA isolation notes 
 
After homogenization and before addition of chloroform, samples can be 
stored at -60 to -70° C for at least one month. The RNA precipitate (D.4, RNA 
Wash) can be stored in 75% ethanol at 2 to 8° C for at least one week, or at least 
one year at -5 to -20° C. 
 
Always wear gloves when working with RNA and change them frequently. 
Keep tissue frozen until it is placed in TRIzol®, or the RNA will degrade. TRIzol® 
contains phenol-toxic-causes burns-use in hood. Always use RNase-, DNase-
free water in every step. Dispose tubes containing phenol in biohazard box. 
 190 
E. 
Xin Long, Pamela G. Lloyd 
DNase Treatment and Spectrophotometric Analysis of RNA 
This protocol is for 50 µL of RNA samples and based on Turbo DNA-free 
kit (Ambion, catalog number 1907) manual. 
E.1. 
Fill a bucket with ice and turn on the heating block. Retrieve RNA samples 
to be treated from the -80° C freezer. Thaw the samples briefly and place on ice. 
Preparation 
 
E.2. 
Add 5 µL 10 × DNase I buffer and 1 µL of DNase I to the RNA sample. For 
multiple samples, prepare a stock mixture of buffer and enzyme, then add 6 µL to 
each tube. Mix gently and spin briefly in the nanofuge to bring all liquid to the 
bottom of the tube. Incubate the tubes at 37° C for 20-30 minutes. 
DNase treatment 
 
E.3. 
Resuspend the DNase Inactivation Reagent (stored in -20° C refrigerator) 
by flicking or vortexing the tube. Add 5 µL to the samples. Watch carefully while 
pipetting to be sure that the aliquot added is mostly white rather than just clear 
fluid. Incubate for 2 minutes at room temperature. Flick 2-3 times during 
incubation to resuspend the inactivation reagent. Centrifuge at 10,000 × g for 90 
seconds to pellet the Inactivation Reagent. Transfer the supernatant to a clean 
0.5 mL tube and place tubes on ice. 
DNase inactivation 
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E.4. 
Analyze RNA by NanoDrop spectrophotometer (ND-1000; locating in MS 
354) to assess purity (A260/280) and concentration. Clean the 
spectrophotometer before usage as indicated on the screen. Choose nucleotides 
and RNA mode. After blanking with nuclease-free water, load 1.5-2.0 µL of RNA 
sample to the spectrophotometer and get A260/280 and concentration readings. 
A260/280 ration should be ~ 2.0. A ratio below 1.7 indicates degration or impurity 
of the RNA sample. 
RNA concentration analysis 
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F. 
Xin Long, Pamela G. Lloyd 
Complementary DNA (cDNA) Synthesis 
This is an example of cDNA synthesis, and the volumes may need to 
change in different conditions. This is based on the iScript cDNA synthesis kit 
(Bio-rad, catalog number 170-8891) manual. 
F.1. 
Component 
Prepare iScript reaction mix 
20 µL reaction Total volume 
5 x iScript reaction mix 4 µL 40 µL 
iScript reverse transcriptase 1 µL 10 µL 
Nuclease-free water (15-X) µL  
RNA template (100 ng to 1 µg) X µL  
Number of samples 10 
Tubes needed 10 
Extra for pipetting error 0 
Total tubes 10 
Note: At least 500 ng of RNA is needed for 20 µL reaction from those 
extracted from 5-10 mm long coronary segments. When using larger amounts of 
input RNA (>1 µg), the reaction should be scaled up, e.g. 40 µL reaction for 2 µg 
RNA, 100 µL reaction for 5 µg RNA. 
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F.2. 
Transfer 5 µL of reaction mix (5 x iScript reaction mix + iScript reverse 
transcriptase) to each flat-top PCR tube (Fisher Scientific, catalog number 14-
230-225). 
Transfer mix to PCR tubes 
 
F.3. 
Add 15 µL RNA template and nuclease-free water to each PCR tube. 
Add RNA samples and nuclease-free water 
 
F.4. 
Use the DNA engine thermocycler in MS 366 for RT reactions. Reaction 
conditions: 5 minutes at 25° C, 30 minutes at 42° C, 5 minutes at 85° C, hold at 4° 
C. Program is saved on the thermocycler as iScript RT. 
Place tubes in thermocycler and perform RT reaction 
 
F.5. 
This cDNA (undiluted) will be used for PCR of target mRNAs (e.g., 
adenosine A1 receptor, A1R). The maximum amount of the cDNA reaction that is 
recommended for downstream PCR is one-tenth of the reaction volume, typically 
2 µL. 
Store cDNA at -20° C 
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G. 
Xin Long, Pamela G. Lloyd 
Real-time RT-PCR of Adenosine Receptors 
This is an example of real-time RT-PCR, and the volumes may need to 
adjust in different conditions. 
G.1. 
Component 
Prepare PCR reaction mix for 18s rRNA (endogenous control) 
Stock Concentration 25 µL reaction Total volume 
TaqMan universal 
PCR master mix  2 × 12.5 µL 750 µL 
18s control reagents 20 × 1.25 µL 75 µL 
DNA sample (variable)  2 µL  
Nuclease-free water  9.25 µL 555 µL 
 
G.2. 
Component 
Prepare PCR reaction mix for adenosine A1 receptor (A1R) 
Stock Concentration 25 µL reaction Total volume 
TaqMan universal 
PCR master mix  2 × 12.5 µL 750 µL 
A1R Forward primer 10 µM 2.25 µL 135 µL 
A1R Reverse primer  10 µM 2.25 µL 135 µL 
TaqMan A1R probe  6.25 µM 1 µL 60 µL 
DNA sample (variable)  2 µL  
Nuclease-free water  5 µL 300 µL 
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G.3. 
Component 
Prepare PCR reaction mix for adenosine A2A and A2B receptors (A2A/BR) 
Stock Concentration 25 µL reaction Total volume 
SYBRGreen PCR 
master mix  2 × 12.5 µL 750 µL 
A2A/BR Forward primer  10 µM 0.75 µL 45 µL 
A2A/BR Reverse primer 10 µM 0.75 µL 45 µL 
DNA sample (variable)  2 µL  
Nuclease-free water  9 µL 540 µL 
 
G.4. 
Component 
Prepare PCR reaction mix for adenosine A3 receptor (A3R) 
Stock Concentration 25 µL reaction Total volume 
SYBRGreen PCR 
master mix  2 × 12.5 µL 750 µL 
A2A/BR Forward primer  10 µM 0.75 µL 45 µL 
A2A/BR Reverse primer 10 µM 0.75 µL 45 µL 
DNA sample (variable)  2 µL  
Nuclease-free water  9 µL 540 µL 
Number of samples 27 
Wells needed 54 
Extra for pipetting error 6 
Total wells per target 60 
Note: TaqMan universal PCR master mix (Applied Biosystems, catalog 
number 4304437); SYBRGreen PCR master mix (Applied Biosystems, catalog 
number 4309155); 18s control reagents (Applied Biosystems, catalog number 
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4319413E); primer powders from Integrated DNA Technology and dissolved in 
nuclease-free water at 10 × stock concentration (100 µM). 
 
G.5. 
Note: 96-well semi-skirt PCR plate (Fisher Scientific, catalog number 14-
230-44). 
Pipet 23 µL of reaction mix into wells according to plate map 
 
G.6. 
Cover the top of PCR plate with an optical adhesive cover (Applied 
Biosystems, catalog number 4311971), and centrifuge at 1000 × RPM for one 
minute. 
Add 2 µL of cDNA to wells according to plate map. 
 
G.7. Perform PCR on ABI 7500 instrument in Room MS 366 
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H. 
Xin Long, Kara Standley 
Genotyping 
H.1. 
Cut the sample into small pieces (2 × 2 mm earpunch), place in a 1.5 mL 
centrifuge tube, add 75 µL lysis buffer (25 mM NaOH, 0.2 mM disodium EDTA, 
and a PH of 12 is prepared by dissolving the salts in water without adjusting the 
PH). If the sample piece is relatively large, increase the amount of lysis buffer 
accordingly. 
DNA extraction: Hot Sodium Hydroxide and Tris (HotSHOT) method 
 
Heat at 95° C for 30 minutes. Cool to 4° C. Add 75 µL neutralizing buffer 
(40 mM Tris-HCl not Tris base and a PH of 5 achieved with adding Tris-HCl 
directly without adjusting the PH) or equal volume to lysis buffer if not 75 µL to 
each sample and mix. Store at 4° C. 1-5 µL of the final preparation are used per 
each 10 µL PCR volume. 
 
Note: Tissue sample must be small (2 × 2 mm). Too large a sample can 
cause the methods to fail. 
  
 198 
H.2. 
This is an example of PCR reaction for AMPK γ 3, and the volumes may 
need to adjust in different conditions. 
PCR reaction 
Component Stock Concentration 20 µL reaction Total volume 
Betaine  6.5 µL 65 µL 
AMPK γ 3 Forward primer  10 µM 1 µL 10 µL 
AMPK γ 3 Reverse primer  10 µM 1 µL 10 µL 
KTLA buffer 10 × 2 µL 20 µL 
Water  4.2 µL 42 µL 
dNTP  0.05 µL 0.5 µL 
Cresol red  0.1 µL 1 µL 
KTLA Taq Polymerase  0.04 µL 0.4 µL 
DNA sample (variable)  5 µL 65 µL 
Number of samples 9 
Number tubes/sample 1 
Extra for pipetting error 1 
Total number of reactions 10 
Note: Betaine (Sigma, catalog number B-0300); cresol red (Sigma, catalog 
number 114480-56); KTLA Taq Polymerase, dNTP, KTLA buffer (DNA 
Polymerase Technology, Klentaq.com, catalog number Klentaq-LA). 
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Mix all the preparation materials except Klentaq and DNA. Then add 
Klentaq to the mixture and mix. Add 15 µL of final mixture solution into each PCR 
tube. Add 5 µL DNA preparation into each tube and mix well. 
 
Use the DNA engine thermocycler in MS 366 for PCR reactions. Reaction 
program: Step 1 - 20 seconds at 95° C, step 2 - 30 seconds at 60° C, step 3 - 45 
seconds at 72° C. (Step 2 and 3 repeat 30 cycles.) Step 4 - hold at 4° C. 
Program is saved on the thermocycler as Xin genotyping. 
 
After the PCR reaction is finished, electrophorese each entire PCR 
sample through a 2% agarose gel at 120 V for approximately an hour. 
 
H.3. 
Component 
Restriction enzyme digestion 
Stock Concentration 40 µL reaction Total volume 
NEBuffer  10 × 4 µL 40 µL 
BSA  100 × 0.5 µL 5 µL 
Water  15 µL 150 µL 
PCR products  20 µL  
BsaHI enzymes  0.5 µL  
Number of samples 9 
Extra for pipetting error 1 
Total number of reactions 10 
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Note: This is an example of enzyme digestion recipe. NEBuffer, BSA, 
BsaHI (New England BioLabs, catalog number R0556S). Mix buffer, BSA, and 
water. Add 19.5 µL of mixture into each 1.5 mL centrifuge tube. Add 0.5 µL 
BsaHI enzyme into each tube. Then add PCR products individually. Incubate at 
37° C for 5 hours or O/N. Then 80° C for 20 minutes for heat inactivation of 
BsaHI if step H.4 does not occur right away. 
 
H.4. 
Mix sample buffer: DNA at 1:3. Load 5 µL ladder and 40 µL DNA sample 
buffer mix into wells. Run at 80 mA for 40-50 minutes or 160 V for 10 minutes. 
Digestion product running on 2% agarose gel 
 
H.5. 
Determine the size of enzyme digestion products. 
Agarose gel development for 2-10 seconds 
 201 
I. 
I.1. 
Immunocytochemistry 
Seed SMC on round coverslips in a 6-well plate and incubate cultures in a 
37° C, 5% CO2 / 95% air, humidified cell culture incubator. Change culture media 
(DMEM + 10% FBS + 1% P/S) every 2 days till SMC reach 70% confluence. 
Cell culture 
 
Switch culture media to DMEM + 1 / 0.5 / 0.1% FBS + 1% P/S, culture for 
2 days to switch SMC to more differentiated phenotype. 
 
I.2. 
Wash each well with PBS 3 times. Fix cells with 1 mL methanol per well at 
-20° C for 5 minutes, wash in PBS 3 times. 
Fixation and incubation 
 
Preincubate cells in 2 mL PBS + 1% BSA for 20 minutes at room 
temperature to block nonspecific binding. Gently remove the PBS with suction 
system. Incubate with pairs of primary antibodies overnight at 4° C and wash in 
PBS 3 times. Incubate with the appropriate combination of secondary antibodies, 
wash in PBS 3 times. 
 
I.3. 
Coverslips are mounted with mounting media. (Note, the surface with cells 
will face toward coverslips and try to avoid air bubbles.) For long term storage, 
add organic mounting media around the edge of the coverslips. 
Coverslip preparation 
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